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ABSTRACT 
3-deoxy-D-arabino-heptulosonate 7-phosphate synthase (DAH7PS) catalyses the first 
committed step in the shikimate pathway, responsible for the biosynthesis of the aromatic 
amino acids as well as other aromatic metabolites. The reaction involves the aldol like 
condensation of erythrose 4-phosphate (E4P) and phosphoenol pyruvate (PEP) to form the 
product DAH7P. The presence of the shikimate pathway in plants, fungi, bacteria and 
apicomplexan parasites as well as its absence from mammalian cells makes enzymes of the 
pathway, in particular, the enzyme responsible for the first committed step, useful targets for 
the design of novel therapeutics. The genome of Neisseria meningitidis expresses a single 
DAH7PS, thus making it a vulnerable target for drug design. An in depth knowledge of the 
workings of this enzyme may provide the platform for its efficacy as a target in the fight 
against bacterial meningitis.  
Chapter 2 reports the characterisation of three different synthetic inhibitors against 
NmeDAH7PS and illustrates which of the intermediates formed during the reaction 
mechanism is the better target. The identification of a single conserved active site water 
molecule in the active site has implications for the mechanism of NmeDAH7PS and the 
potency of the synthetic inhibitor. 
Chapter 3 describes the binding and inhibition of the three aromatic amino acids at the 
enzyme’s allosteric site. It identifies the reason(s) for the variable sensitivity and gives insight 
into the inactive conformation adopted by the NmeDAH7PS active site in the presence of an 
allosteric effector with respect to both substrates. It goes further to identify the effect 
incurred on substrate binding in the presence of allosteric inhibitor. 
Chapter 4 investigates the importance of interactions at the tetramer interface for catalysis, 
regulation, stability and structure of NmeDAH7PS. Two mutations were made, one altering 
the only salt bridge at the Chain A-C interface and the other involving the only hydrophobic 
interaction at the Chain A-D interface. 
Chapter 5 looks into the allosteric binding site and identified two residues that may be crucial 
for the binding of Phe. The substitution of these two residues and their structural and 
 
 
functional characterisation illustrates the necessity for certain interactions within the largely 
hydrophobic binding site for binding. This chapter also carries on from work done in chapter 5 
on the identification of residues important for the allosteric mechanism. Substitution of these 
ionisable residues and the structural and functional analysis of the resulting variant enzymes 
have interesting implications for the electrostatic network responsible for the transfer of 
allosteric signal in NmeDAH7PS. 
This thesis gives a detailed description of the inhibitory and regulatory properties of 
NmeDAH7PS and illustrates the applicability of this work to many other systems in nature.
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1.1 NEISSERIA MENINGITIDIS 
Neisseria meningitidis is the bacterium responsible for meningococcal related illness. It was 
first isolated in 1887, however, reports of meningococcal related illness date back to the 16th 
century.1 Meningococcal disease has the potential to cause major epidemics in the sub-
Saharan African ‘meningitis belt’, and in the United States, it is the leading cause of meningitis 
and sepsis.2–5 While several different bacteria can cause meningitis, N. meningitidis is the one 
with the potential to cause large epidemics. Infection with the bacteria can result in serious 
brain injury, hearing loss and in the absence of treatment, it is fatal in ~50% of cases.6–8 
  
N. meningitidis is a Gram-negative bacterium that is exclusively pathogenic to humans and is 
carried asymptomatically in the human nasopharynx.9,10 Colonisation by the bacterium begins 
with adhesion to epithelial surfaces, enabling invasion of the target cell.11 Once internalised, 
the pathogen’s cytotoxicity is mediated by tumour necrosis factor-α.11 The mechanism of N. 
meningitidis infection begins in the mucosa where it is found dormant in ~10% of the 
population. Isolates of the bacteria in these mucosal surfaces have been found to be 
predominantly polysaccharide capsule deficient.6 This capsule has been suggested to aid in 
the anti-adherent properties of the bacterium, enabling detachment from the mucosal 
surfaces and entry into the bloodstream.9 Isolates of the bacteria from the blood stream and 
cerebrospinal fluid are predominantly polysaccharide encapsulated and because of this 
protective capsule the bacteria is a poor antigen, has serum resistance and can go undetected 
by the immune system.12,13  
 
The septicaemia associated with the disease, only occurs once the disease has traversed the 
mucosal barrier into the host’s blood stream. Upon crossing the blood-brain barrier, it causes 
serious infection of the meninges that line the skull and vertebral canal, which encloses the 
brain and spinal cord.7 
   
The disease itself is categorised into twelve Serogroups, 6 of which have been known to cause 
epidemics (A, B, C, W-135, X and Y).8 Serogroups, A and C are the most predominant 
throughout Asia and Africa while B and C are the most prevalent in countries of the developed 
world including the Americas, Western Europe and Australia.7,14 In New Zealand an outbreak 
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of Serogroup B disease was experienced in 2004 and the resulting campaign involving the 
outer membrane vesicle (OMV) vaccine has since contributed to its decreasing prevalence.15,16  
 
Routine vaccination against the disease remains the most effective strategy for controlling the 
disease. There are several vaccines available to control the disease: a meningococcal A 
conjugate vaccine, C conjugate vaccines, tetravalent A, C, Y and W-135 conjugate vaccines and 
meningococcal polysaccharide vaccines.8 However, polysaccharide vaccines for serogroup B 
are challenging due to antigenic mimicry of components of human neurologic tissues by the 
polysaccharide capsule, thus making the immune response very poor.8,14 The first vaccine 
(4CMenB) against the serogroup B strain (MC58), consisted of 4 components and was 
released for administration in 2014.8 The vaccine was composed of two recombinant fusion 
proteins (Neisseria heparin-binding antigen and factor H-binding protein), recombinant 
Neisserial adhesion A and detergent-treated OMV’s.14  
 
Vaccines remain a preventative measure and upon infection, treatment of the disease with 
broad spectrum antibiotics such as chloramphenicol, ampicillin, penicillin and ceftriaxone is 
the most effective strategy.17 However, this is dangerous, as the ability for the N. meningitidis 
to develop antibiotic resistance is an increasing problem.17 Therefore, the necessity for novel 
antibiotics against particularly the Serogroup B strain (MC58) of N. meningitidis is becoming 
increasingly important.  
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1.2 THE SHIKIMATE PATHWAY 
The presence of the shikimate pathway in plants, fungi, bacteria and apicomplexan parasites 
as well as its absence from mammalian cells makes it a viable target for drug design and 
discovery.18,19 This pathway is responsible for the biosynthesis of the aromatic amino acids, L-
phenylalanine (Phe), L-tyrosine (Tyr) and L-tryptophan (Trp) as well as many other aromatic 
metabolites (Figure 1.2.1). The first committed step of the pathway is catalysed by 3-deoxy-D-
arabino-heptulosonate 7-phosphate synthase (DAH7PS) and involves the aldol-like 
condensation of erythrose 4-phosphate (E4P) and phosphoenol pyruvate (PEP) resulting in the 
seven carbon sugar, 3-deoxy-D-arabino-heptulosonate 7-phosphate (DAH7P). The formation 
of chorismate requires a further six enzymatic steps. At this point the pathway diverges via 
anthranilate synthase to form the precursor for tryptophan (anthranilate) and via chorismate 
mutase to form the precursor for phenylalanine and tyrosine (prephenate), or to generate 
precursors for folate (p-aminobenzoic acid) or vitamin K (isochorismate) biosynthesis.18 Unlike 
plants and bacteria that rely on the shikimate pathway for synthesis of their aromatic amino 
acids, mammals are able to obtain these essential metabolites from their diet. The flux of the 
pathway is regulated at the protein level via DAH7PS, making it, the first committed step in 
the pathway an ideal target for the design and discovery of novel antibiotics.20,21,22. This 
pathway has already been used utilised as a target in herbicides. For instance, Glyphosate, a 
commonly used herbicide is an inhibitor of 5-enol pyruvate shikimate-3-phosphate synthase 
(EPSPS).23 DAH7PS is a curious enzyme, as it uses a variety of complex methods to achieve 
allosteric regulation, whether it be through protein complex formation, gene fusion, insertions 
or extensions to achieve simple feedback inhibition.20,21,24–29 
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Figure 1.2.1 The shikimate pathway illustrating the branch point chorismate and its multiple end-products. 
Highlighted in red is the first committed step catalysed by DAH7PS and the aromatic amino acid end-products; 
L-Phe, L-Tyr and L-Trp. 
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1.3 3-DEOXY-D-ARABINO-HEPTULOSONATE 7-PHOSPHATE SYNTHASE 
(DAH7PS)  
1.3.1 Classification of DAH7PS 
 
DAH7PS can be classified into two distinct families based on sequence identity and molecular 
weight, denoted type I and type II. Type I DAH7PS enzymes can be further divided into two 
subfamilies, denoted type Iα and type Iβ based purely on sequence identity. The classification 
of the DAH7PS subfamilies is centred on these modifications to the core barrel that tend to be 
responsible for allostery (Figure 1.3.1.1).20  
 
DAH7PS from the type Iα subfamily like those from Escherichia coli22,30,31, Saccharomyces 
cerevisiae32–34 and N. meningitidis26 are all below 40 kDa in size, whereas their type II 
orthologues are all larger, like that of Mycobacterium tuberculosis (~54 kDa).35 Type Iβ 
DAH7PSs like those from Pyrococcus furiosus36 and Thermotoga maritima37, are smaller (~30-
38 kDa) and share little sequence identity with their type Iα counterparts. Members of the 
type Iβ subfamily are more closely related to the enzyme 3-deoxy-D-manno-octulosonate 8-
phosphate synthase (KDO8PS), an enzyme involved in the biosynthesis of the cell wall of 
Gram-negative bacteria, which has the ability to accommodate D-arabinose 5-phosphate 
(A5P) as a substrate instead of E4P.38–42 A limited number of organisms have been shown to 
contain both type I and type II DAH7PS, including, Pseudomonas aeruginosa43, Xanthomonas 
campestris44, Stigmatella aurantiaca45 and Amycolatopsis methanolica46. The type II DAH7PS 
from these organisms tends to be involved in secondary metabolism.  
A point of comparison between the different subfamilies of DAH7PS comes about from the 
extensions and modifications to the core (β/α)8 barrel, which is the structural fold for all 
known DAH7PS proteins (Figure 1.3.1.1). Type Iα DAH7PS enzymes typically contain a double 
β-sheet insertion and double α-helix N-terminal extension. Type Iβ enzymes are either not 
regulated (PfuDAH7PS)36, or have a large N-terminal extension that is reminiscent of either a 
chorismate mutase (GspDAH7PS)47 or aspartate kinase, chorismate mutase and tyrA (ACT) 
(TmaDAH7PS)25 domain. Type II enzymes characteristically have a larger insertion of two α-
helices, and a very large N-terminal extension.48 These extensions, insertions and accessory 
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domains are believed to be intrinsically associated with the regulation of these enzymes by 
the pathway end-products.20  
 
Figure 1.3.1.1 Classification of DAH7PS into their appropriate subfamilies. Core (β/α)8 barrel coloured in blue. Β-
sheet or α-helix insertions are coloured in yellow. N-terminal extensions are coloured in red. Type Iα DAH7PS 
represented by N. meningitides (PDB code:4HSN) and E. coli (1KFL). Type Iβ DAH7PS represented by P. furiosus 
(PDB code:1ZCO) and T. maritima (PDB code: 1RZM). Type II DAH7PS represented by M. tuberculosis (PDB code: 
2B7O).  
 
 
1.3.2 Mechanism of DAH7PS 
 
DAH7PS catalyses the aldol-like condensation between E4P and PEP, generating the seven 
carbon sugar DAH7P. Many of the key mechanistic details of the reaction have been 
elucidated via labelling32, alternative substrate,40,49 structural28,31,33,35,50 and inhibitor 
studies.51–54 The enzyme catalysed reaction is believed to proceed in an ordered sequential 
fashion.55–57 The mechanism is stereospecific with respect to both substrates, where the si 
face of PEP nucleophilically attacks the re face of E4P (Figure 1.3.2.1).58–61  
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Figure 1.3.2.1 Diagram illustrating the facial selectivity of the nucleophilic attack of the allylic carbon of PEP on 
the aldehyde moiety of E4P, which is activated by coordination to the divalent active-site metal ion.  
 
The aldol-like reaction begins with the cleavage of the C-O bond to the phosphate group of 
PEP. Activation of the aldehyde functionality of E4P as an electrophile by the essential active-
site divalent metal ion enables the nucleophilic attack of the enol moiety of PEP (Figure 
1.3.2.2). The resulting oxyanion is protonated by an active site Lys residue (part of a conserved 
KPR(T/S) motif). Formation of a bond between C1 of E4P and C3 of PEP yields a transient 7-
carbon oxocarbenium ion intermediate.54 The stereospecific nucleophilic attack of a 
conserved active site water molecule, which is activated via deprotonation by an active site 
residue, results in a phosphohemiketal tetrahedral intermediate. Upon elimination of 
phosphate, the product loses its stereochemistry at C2, giving the acyclic DAH7P. This acyclic 
form of DAH7P is in equilibrium with its pyranose form. 
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Figure 1.3.2.2 Mechanism of the DAH7PS catalysed reaction, illustrating its procession via the oxocarbenium 
and tetrahedral intermediate. 1, phosphoenol-pyruvate; 2, D-erythrose 4-phosphate; 3, Oxocarbenium ion 
intermediate; 4, Tetrahedral intermediate; 5, DAH7PS. 
 
 
1.3.3 The role of the active site water 
 
In the mechanism of the DAH7PS catalysed reaction, the oxocarbenium ion is a transient 
species, which is rapidly attacked by water, resulting in the labile phosphate hemiketal 
intermediate. With the influx of structural information on this enzyme with 
substrates,26,31,33,35,40,50,62,63 substrate mimics63 and intermediate mimics54,64 bound at the 
active site, the water molecule involved in the reaction is hypothesised to sit very close to C2 
of PEP (Figure 1.3.3.1). Previous theories of the enzyme-catalysed reaction mechanism from 
the related KDO8PS enzyme have proposed that nucleophilic attack of water occurs at C2 of 
PEP, which is made possible via coordination to the active site metal ion (carbanion 
mechanism).41,65,66 This mechanism unfortunately does not make any structural or chemical 
sense, as it would require PEP to possess an unprecedented electrophilic character at C2 and 
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upon nucleophilic attack of an active site water molecule, the resulting carbanion would have 
a pKa estimated to be >30. Due to the presence of carbon-hydrogen bonds of greater acidity in 
addition to water molecules, carboxylic acids and ammonium ions in the enzymes active site, 
the carbanion formed would likely be quenched before being able to attack E4P.67 Therefore, 
it is likely that the formation of an oxocarbenium ion intermediate via a Lewis-acid type 
mechanism is the most probable.  
 
Figure 1.3.3.1 Active site of NmeDAH7PS illustrating complex network of waters present during PEP presence. 
Hydrogen bonds involving water molecules indicated by black dashed lines. Proximity of nucleophilic water to 
C2 of PEP is indicated by a maroon dashed line. 
The stereochemistry of the tetrahedral hemiketal intermediate is dictated by the facial 
selectivity of the nucleophilic attack of the water at C2 the oxocarbenium ion. Given the recent 
work on enantiopure tetrahedral intermediate mimics and their relative potency, we can 
hypothesise that this attack occurs on the re face of the oxocarbenium ion.51,54,64 There are 
four conserved water molecules that are present both the PEP-bound NmeDAH7PS structure 
(PDB code 4HSN) and the tetrahedral intermediate mimic-bound MtuDAH7PS structure (PDB 
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code 3PFP).26,54 Three of these are located on the re face of these bound ligands and only one 
is close enough to interact at the C2 position.  
It is has been described that the proficiency of a synthetic inhibitor is due to its ability to 
mimic the most reactive species during the catalytic mechanism.68 Trapping the enzyme in a 
state where it is stabilising the most reactive species has been the best method of obtaining 
irreversible-like dissociation constants.69,70 The ability of a synthetic inhibitor to mimic either 
the tetrahedral or the planar oxocarbenium ion intermediates whilst still appropriately 
accommodating the nucleophilic water molecule, is predicted to result in a highly potent 
inhibitor of DAH7PS.54 
1.3.4 Structure of DAH7PS 
 
DAH7PS enzymes all share the same core barrel structure, despite the low sequence similarity 
between enzymes from different families. The structural characterisation of these enzymes by 
X-ray crystallography has revealed that they share a (β/α)8 barrel fold, which houses the active 
site machinery. The enzymes of different types vary in their extensions and/or insertions to 
the barrel and in their quaternary structure. These modifications have been shown to play an 
important part in the regulation of DAH7PS.20  
 
Type Iα enzymes such as those from E. coli, S. cerevisiae and N. meningitidis contain 
modifications to the core barrel structure that are believed to be involved in the enzymes’ 
allosteric response.22,26,33 A double β-sheet insertion forms the bulk of the allosteric binding 
site and an N-terminal extension closes over the allosteric ligand once bound. These enzymes 
consist of four identical monomeric units that arrange themselves as dimers of dimers forming 
the homotetrameric assembly. The lack of a discrete regulatory domain in these enzymes 
makes their regulatory mechanisms intriguing.  
 
Type Iβ enzymes have acquired allostery through different means. They have recruited large 
domains for their regulation that are attached at either the N or C terminus. The DAH7PSs 
from Geobacillus sp and Listeria monocytogenes have a dimeric chorismate mutase-like 
domain, which binds and catalyses the rearrangement of chorismate to form prephenate.21,71 
It is believed that regulation of DAH7PS activity occurs through adoption of a conformation in 
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the presence of prephenate that limits the activity of DAH7PS.47 TmaDAH7PS contains an N-
terminal extension with structural and sequence homology to the ACT domain. Crystal 
structures and small angle X-ray scattering data have shown that this ACT-like domain 
undergoes a large conformational shift to gate the active site in the presence of tyrosine.25 
The truncated form of this enzyme that lacks the ACT-like regulatory domain loses sensitivity 
to tyrosine, much like that of the unregulated P. furiosus DAH7PS also from the type Iβ 
subfamily.36 Interestingly, fusion of the ACT domain from T. maritima onto the unregulated P. 
furiosus DAH7PS resulted in a chimeric enzyme sensitive to inhibition by tyrosine, illustrating 
that allostery can be transferred between members of the type Iβ subfamily.72 
 
To date the only type II DAH7PS to be structurally characterised is from M. tuberculosis.48,73 
The structure of this enzyme contains the same core catalytic (β/α)8 barrel as the type I 
DAH7PSs, but the primary reason for its ~10% sequence identity with its type I counterparts is 
the extensive modifications to the core structure. These modifications make up three 
different binding sites, enabling regulation by all aromatic amino acids in a synergistic 
manner.24,27,48  
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1.4 ALLOSTERY 
Allostery is an important characteristic of every living cell and because of this it is becoming 
ever more important in drug discovery efforts. Allostery involves the non-covalent binding of 
an effector molecule to a protein, aiding in the regulation, or activation of that protein. This 
process occurs through the binding of an effector molecule at a remote (allosteric) site, 
resulting in a change in, structure, dynamics or electrostatics at the active site.74 Allostery is a 
feature that is present throughout the five kingdoms and its purpose is to regulate the activity 
of important cellular processes.  
Enzymes have a tendency to form multimeric structures and associate as homo-mers, usually 
consisting of even numbers of subunits, generating symmetry related interfaces.75 They also 
have been known to form complexes with other enzymes in the pathway. These two 
phenomena give rise to multiple binding sites and the possibility of cooperativity between 
these sites.76 In these cases, cooperativity (positive and negative) between binding sites can 
enable precise control on cellular demand for metabolites. To date there have been a few 
major models that have contributed to our understanding of allostery.77  
1.4.1 Models for allostery in proteins 
 
The Monod-Wyman-Changeux (MWC) model, states that in the absence of effector molecule, 
the protein exists in equilibrium between two conformational states; relaxed (R) and the 
tense (T) states.78 The binding of an effector molecule shifts this equilibrium to favour the 
state that has a higher affinity for the effector molecule by stabilising a global conformational 
change in the protein’s quaternary structure (Figure 1.4.1A).  
The Koshland-Némethy-Filmer (KNF) model, states that the binding of an effector molecule 
causes a change in the structure of the protein, enabling better accommodation of the 
effector molecule.79 The binding of an effector molecule to a particular subunit of the protein 
induces a change in that subunit, encouraging or discouraging the binding of the second 
effector molecule to that subunit. This model describes a progressive change in conformation 
resulting in an induced fit like mechanism for binding several allosteric effectors.  
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It does however, allow the relative subunits to adopt different conformations, therefore giving 
rise to the notion of positive and negative cooperativity, where the affinity of the protein for 
the same ligand is altered based on the presence or absence of that ligand (Figure 1.4.1B).  
 
Figure 1.4.1 Models for allosteric regulation. A. Monod-Wyman-Changeaux model where the protein adopts 
either the relaxed ‘R’ state or the tense ‘T’ state. B. Koshland-Némethy-Filmer model where ligand binding 
causes a conformational change that facilitates binding of another ligand. C. Allostery without conformational 
change. Binding of a ligand propagates a signal that is registered at the other allosteric site and the active site. 
There are obviously limitations to the aforementioned models of allostery, as they both 
describe conformational change. Recently there have been developments in the modelling of 
allostery in a more broadly applicable manner that incorporates changes to proteins in other 
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ways, elicited by ligand binding.80 Proteins that undergo no conformational change during 
allostery or are intrinsically unstructured are exceptions to the MWC and KNF models.81 Such 
exceptions gave rise to the dynamic energy landscape model and the notion that proteins 
exist as an ensemble of possible conformational states, which are populated according to 
their Boltzmann distribution.82 This ensemble model of protein dynamics, enables sampling of 
a large energy landscape with multiple energy minima, favouring the lowest energy 
conformation across the landscape. The binding of an effector molecule in this model 
restructures the energy landscape, redistributing the protein population, favouring new 
energy minima. Allostery therefore involves far more than the conformational transition from 
‘R’ to ‘T’ state but rather a dynamic equilibrium between sub-states of the energy landscape.83  
The aforementioned traditional views of allostery are governed by a kinetic concept, where 
the contraction and release of strain caused by ligand binding governs the allosteric effect at 
the active site via a single pathway.84 However, more contemporary views are founded on the 
nature of thermodynamic equilibria, which are based on population shift during allostery, 
giving rise to the propagation of multiple signals through complex networks of interactions 
(Figure 1.4.1C).80,82,85–90 Population shifts upon allosteric ligand binding with an accompanied 
conformational change could be dominated by enthalpy or entropy. Variation in free energy 
without conformational change, tend to be governed by changes in entropy. Conversely, in 
enthalpically driven allostery, all propagation pathways effectively culminate in the required 
conformational change.81 In systems that undergo allostery without conformational change, 
treatment of the protein as a dynamic, constantly changing entity that allows the propagation 
of multiple signals from the effector binding site is paramount. These signals form 
communication pathways, which alter the dynamic, structural and electrostatic properties of 
remote sites enabling cooperativity and regulation.87,91  
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1.5 NEISSERIA MENINGITIDIS DAH7PS 
 
1.5.1 Introduction 
 
The genome of N. meningitidis encodes a single DAH7PS, which is primarily regulated by the 
pathway end-product Phe, but is sensitive to inhibition by both Trp and Tyr at high 
concentrations.26 Comparison of the NmeDAH7PS sequence with DAH7PSs from other 
organisms indicates that it belongs to the type Iα subfamily.  
 
1.5.2 Structure 
 
The monomeric subunit of NmeDAH7PS contains a core (β/α)8 barrel fold, which is consistent 
with all other structurally characterised DAH7PS enzymes. There is a single N-terminal α-helix 
and loop extension to the core barrel as well as a double β-sheet insertion (Figure 1.5.2.1A). 
At the N-terminus a tail (residues 1-11) is followed by a β-strand (β0, residues 12-16) and then 
the β0α0 loop (residues 17-20). This loop leads into the α0 helix (residues. 21-28), α0α00 loop 
(residues 29-31) and the large α00 helix (residues 32-50). This N-terminal extension is quite 
large and packs against the outside of the core barrel. The β-hairpin insertion consists of 
residues 209-224, and is positioned on the outside of the monomeric unit. These 
modifications contribute significantly to the inter-subunit interfaces and are similar to that of 
all structurally characterised DAH7PS enzymes in that they play a pivotal role in the creation of 
the allosteric binding site. 
The biological unit of NmeDAH7PS is homotetrameric, consisting of two dimers, one of which 
comprises an extensive interface (denoted tight dimer interface) and the other a far weaker 
interface (termed the tetramer interface) (Figure 1.5.2.1B). The tight dimeric units may 
contribute to the method adopted by NmeDAH7PS to achieve regulation. The β-hairpin 
insertion contributes to the tight dimer interface and the N-terminal extension wraps around 
the base of the tight dimer at the tetramer interface, interacting with adjacent subunits to aid 
in stabilisation of both the dimeric and tetrameric NmeDAH7PS. 
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Figure 1.5.2.1 A) NmeDAH7PS (PDB code 4HSN), coloured by domain extension (red), core catalytic unit (blue), 
insertion (yellow), β2α2 loop (green), active site metal ion Mn
2+
 (purple) and PEP-bound at the active site (green 
sticks)  Top left. Tetrameric assembly of NmeDAH7PS. Top right. Monomeric unit of NmeDAH7PS with labelled 
secondary structural features. B) Schematic of the position of all secondary structural features in chain. 
 
 
1.5.3 Active site of NmeDAH7PS 
 
The active site of NmeDAH7PS resembles that of all other known DAH7PSs. While the 
sequence similarity across different families and sub-families is low, there are several residues 
localised at the active site that remain absolutely conserved, resulting in remarkably similar 
active site architectures. 
1.5.3.1  META L BI NDI NG  SITE  
 
The metal binding site of NmeDAH7PS is similar to all other structurally characterised DAH7PS 
enzymes. From the PEP-bound crystal structure (PDB code: 4HSN) it is evident that there are 
four residues (Cys63, His270, Glu304 and Asp324) that coordinate the preferred Mn2+ metal 
ion in a trigonal bypyrimidal fashion (Figure 1.5.3.1.1).26 This leaves one coordination site 
  β0 α0 α00 β1 α1 β2 α2 β3 α3 β4 α4 β5 α5 
β6a β6b β6c α6 β7 α7 β8 α8 
A 
B 
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available for activation of the aldehyde of E4P upon binding. However, in the PEP-bound 
NmeDAH7PS structure, Mn2+ coordinates a water molecule in the absence of E4P.  
 
Figure 1.5.3.1.1 Metal binding site of NmeDAH7PS coloured in blue (PDB code 4HSN) . Manganese shown as 
purple sphere. Coordinating atoms denoted by black dashed lines 
 
1.5.3.2  PEP  B I NDING SI TE  
 
In the PEP-bound NmeDAH7PS crystal structure (PDB code: 4HSN), the highly negatively 
charged PEP interacts with positively charged side-chains and does not directly coordinate to 
the active site metal ion, which is in agreement with previous investigations.26,92 The 
phosphate group of PEP is held securely in place via salt bridges with Arg167, Lys188, Arg236 
and a hydrogen bond with the backbone peptide amino group of Ala166 (Figure 1.5.3.2.1). 
The linking oxygen of the phosphate group of PEP forms a hydrogen bond with Lys188. The 
carboxylate of PEP is held in place via salt bridges with Arg94 and Lys99. These residues 
(Arg94, Lys99, Arg167 and Arg236), which interact directly with PEP, are conserved across all 
DAH7PS subfamilies. There is a network of water molecules present in the active site, held in 
place by the substrate PEP itself, or by residues Tyr96 and Glu145, which are hypothesised to 
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play a crucial role in the nucleophilic attack of the oxocarbenium ion upon its formation during 
catalysis. 
 
Figure 1.5.3.2.1 The binding site of PEP (PDB code 4HSN). Key interactions between PEP and residues of the 
active site are shown with black dashed lines. 
 
1.5.2.3  E4P  B I NDING SI TE  
 
The binding site for E4P is more difficult to elucidate, as direct crystallographic information of 
E4P binding is difficult to obtain. This is due to the likelihood of catalytic turnover upon 
soaking E4P into the PEP-bound crystal. Interestingly there is a conserved (KPR(T/S)) motif 
that is found across all DAH7PS enzymes. This motif is believed to responsible for the binding 
and orientation of E4P in the active site for reaction with PEP. This motif is positioned on the 
highly flexible β2α2 loop of NmeDAH7PS.  
There have been two occasions where the binding of E4P has been identified experimentally. 
The first involved the soak of E4P into a crystal of thermophilic type Iβ TmaDAH7PS at 4°C. 
This cold soak of a thermophilic enzyme enabled identification of both substrates in the 
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crystal structure due to the limited turnover at this temperature (PDB code 1RZM).31 
Unfortunately, E4P adopted an unlikely binding mode in this crystal structure. However, in 
conjunction with the information obtained from the crystal structure of S. cerevisiae DAH7PS 
(PDB code 1OF8), which was soaked with an analogue of E4P, glyceraldehyde 3-phosphate 
(G3P), the binding mode of E4P could be properly modelled.33 The valuable information 
obtained from the positioning of the phosphate and hydroxyl groups in these structures 
helped guide the modelling, design and synthesis of several potent tetrahedral intermediate 
mimics as inhibitors of MtuDAH7PS.54 The inability for the active site of MtuDAH7PS to bind 
smaller or larger intermediate mimics with the same affinity, illustrates the selectivity of the 
site for a seven carbon mimic.64 From the computational modelling experiments and the 
conservation of residues in the active site of DAH7PS, it is likely that in NmeDAH7PS a hydroxyl 
group of E4P interacts with the proline backbone carbonyl group of the KPR(T/S) motif. Lys99 
is proposed to be involved in the protonation of the aldehyde of E4P during reaction with PEP. 
Arg101 is predicted to be involved in binding the phosphate group of E4P. All of these residues 
are part of the highly conserved KPR(T/S) motif and therefore give credence to the proposed 
binding mode of the natural substrate E4P. 
 - 21 - 
 
 
Figure 1.5.3.3.1 Comparison of E4P binding sites from S. cerevisiae, M. tuberculosis and N. meningitidis. 
Important interactions are illustrated with black dashed lines. A. SceDAH7PS E4P binding site showing 
important residues and ligands bound to enzyme (PDB code 1OF8). B. MtuDAH7PS E4P binding site illustrating 
important residues for tetrahedral intermediate binding (PDB code 3PFP). C. NmeDAH7PS E4P binding site with 
only PEP-bound (PDB code 4HSN). D. Overlay of all three structures indicating both sequence and structural 
conservation of PEP and E4P binding site. 
Comparison of these different structures (PDB codes: 3PFP, 1OF8 and 4HSN) reveal some 
interesting features of the E4P binding site in DAH7PS (Figure 1.5.3.3.1). Firstly, there is a high 
degree of sequence conservation in this binding site, however, in EcoDAH7PS and 
NmeDAH7PS, a tyrosine residue is responsible for positioning of the nucleophilic water 
molecule, whereas in Mtu, this is replaced with a tryptophan.54 The backbone peptide amino 
group of the alanine found in SceDAH7PS and NmeDAH7PS forms a hydrogen bond with the 
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phosphate of PEP, however in MtuDAH7PS, this residue is replaced with a glutamate. This 
glutamate residue in MtuDAH7PS, may play important roles in mediating an allosteric signal 
from one of its three functionally distinct binding sites.24 The only other variation is in the 
KPR(T/S) motif, where, for MtuDAH7PS, the threonine is replaced with a serine. This residue is 
functionally the same across these organisms. Overall, the binding site for type I and type II 
DAH7PS is structurally similar and functionally identical. This enables confident translation of 
active site characteristics between different organisms.  
1.5.4 Allostery in NmeDAH7PS 
 
NmeDAH7PS does not require complex formation like that seen in the type II MtuDAH7PS93, 
nor does it have a  large discrete domains for regulation, like that seen in type Iβ DAH7PS.21,25 
All structures of type Iα DAH7PS with an allosteric ligand bound show no major 
conformational change upon ligand binding, therefore the mechanism of allostery in this 
enzyme is intriguing. 
Kinetic analysis of the inhibitory properties of the pathway end-products (Phe, Tyr and Trp) 
has revealed that NmeDAH7PS is sensitive to all three aromatic amino acids at high 
concentrations, but is most sensitive to inhibition by Phe.26 Isothermal titration calorimetry 
(ITC) experiments have shown that there is cooperativity between allosteric sites, obtained 
from the binding isotherm fit to a sequential two-site binding model.26  
The allosteric binding site in NmeDAH7PS is formed by the modifications to the core catalytic 
barrel (PDB code: 4HSO). The N-terminal extension closes over the site and provides a scaffold 
to aid in closure of the site (α00-helix). The double β-strand insertion forms a large part of the 
binding site and plays a large role in ligand binding (Figure 1.5.4.1). 
Inspection of the binding site of the Phe- and Tyr-bound structures from EcoDAH7PS 
SceDAH7PS and NmeDAH7PS (PDB codes: 1KFL, 1OF6 and 4HSO), indicate that the binding site 
itself has a very strong hydrophobic character, enabling binding of aromatic amino acids. The 
residue Ser213 has been shown to aid in selectivity of this enzyme towards feedback 
inhibition by Phe. Upon mutation to glycine, the enzyme becomes sensitive to inhibition by 
Tyr and no longer by Phe.26 Tyr was shown to be able to bind to this Ser213Gly variant by ITC 
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and approximates the KD seen for Phe binding to the second site in the NmeDAH7PS
WT (21.1 ± 
0.4 µM vs 22 ± 2 µM).26  
  
 
Figure 1.5.4.1 Allosteric binding site in NmeDAH7PS (PDB code 4HSN), illustrating the contribution of the N-
terminal extension (red), insertion (yellow) and core barrel (blue) 
Comparison of the Tyr-bound NmeDAH7PSS213G and the Phe-bound DAH7PS from E.coli 
illustrates some important features of the binding site. Firstly, there is absolute conservation 
of all residues that interact with the bound ligand. Secondly, the amino acid moiety of the 
allosteric ligands as well as the residues with which they form hydrogen bonds adopt the 
same conformation, however, the position of Phe209/211 on the β6a strand is different (PDB 
codes: 1KFL and 4HSO). In EcoDAH7PS, this residue is shifted and forms an end-on π-π 
stacking interaction with the bound Phe. This interaction is not observed in the Tyr-bound 
NmeDAH7PSS213G variant, which may explain the reduced sensitivity to Tyr observed for this 
variant compared to the sensitivity of NmeDAH7PSWT to Phe (Figure 1.5.4.2). The loss of this 
interaction may be due to the increased conformational flexibility allowed by Gly in the 
NmeDAH7PSS213G variant. 
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The Phe-bound EcoDAH7PS structure showed that upon Phe binding, subtle conformational 
changes are propagated across the tight dimer. These changes extend all the way to the 
catalytic β2α2 loop, which is responsible for the binding of both substrates.
28 In this structure, 
PEP adopted a flipped conformation. An important structural change noted was the loss of 
interaction between the β3α3 and β2α2 loops in this structure, hypothesised to contribute to 
the partial disorder of the loop. Interestingly, the Tyr-bound structure from SceDAH7PS 
showed similar features, however in this structure, PEP was absent.20 Both of these structures 
illustrate the importance of the interaction between the β-hairpin insertion, which makes up a 
large portion of the allosteric binding site and the catalytic β2α2 loop. The lack of large 
conformational change observed in the structurally characterised enzymes from the type Iα 
sub-family in the presence of allosteric ligand implies that subtle variations at the allosteric 
site may have large effects on possible communication pathways that link the remote 
allosteric and active sites. 
 
Figure 1.5.4.2 Overlay of the allosteric binding sites of the Tyr bound NmeDAH7PS S213G variant (orange, PDB 
code 4HSO), the Phe-bound EcoDAH7PS (white, PDB code 1KFL)and the Tyr bound SceDAH7PS(PDB code 1OF6) 
illustrating hydrogen bonds (black dashed lines) and the single amino acid change that changes selectivity from 
Phe to Tyr. 
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1.6 AIMS OF THIS THESIS 
The primary aim of this thesis is to better understand how NmeDAH7PS is inhibited and 
regulated. An understanding of inhibition at the active site as well as the allosteric site can aid 
in future antibiotic development. These studies will disentangle how this enzyme achieves 
regulation through a dynamic allosteric mechanism involving minimal conformational change. 
The specific research objectives of this thesis are: 
 To gain a critical understanding of the structure-activity relationships (SAR) between 
small molecule active site inhibitors of NmeDAH7PS 
 To understand the reasons why NmeDAH7PS is primarily inhibited by Phe. 
 To understand how substrates bind at the active site in the presence of allosteric 
effector. 
 To explore the necessity for interactions between the tight dimers at the tetramer 
interface in NmeDAH7PS. 
 To identify the roles of hydrophobic residues in the allosteric site and their relative 
contributions to binding of Phe.  
  To gain an in depth understanding for how allostery is communicated between 
allosteric and active sites of NmeDAH7PS without conformational change, accessory 
domains or complex formation. 
 To identify the relative contributions of ionisable residues believed to be responsible 
for communication of the allosteric signal. 
The Phe-sensitive DAH7PS from E.coli is the most extensively characterised type Iα DAH7PS to 
date and shares high sequence identity with NmeDAH7PS. For this reason, comparisons 
between the DAH7PS from these organisms will be referenced throughout this thesis. 
Comparisons to the Tyr sensitive DAH7PS from S. cerevisiae, which has also been well 
characterised will also be made, to give context to the aforementioned enzymes. This thesis 
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entails a comprehensive structural and functional characterisation of NmeDAH7PS with a view 
to be able to apply the findings and methods to other systems in nature. 
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CHAPTER 2- STRUCTURAL ANALYSIS OF SUBSTRATE-
MIMICKING INHIBITORS IN COMPLEX WITH NEISSERIA 
MENINGITIDIS 3-DEOXY-D-ARABINO-HEPTULOSONATE 7-
PHOSPHATE SYNTHASE - THE IMPORTANCE OF 
ACCOMMODATING THE ACTIVE SITE WATER 
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2.1 INTRODUCTION 
Inhibitors of DAH7PS have previously been focussed on the mimicry of substrates or 
intermediates of the DAH7PS catalysed reaction. Recently published work has involved the 
design and synthesis of small three-carbon PEP/intermediate mimics of the planarity and 
stereochemistry of the postulated oxocarbenium and tetrahedral phosphohemiketal 
intermediate.53 This work has been developed into the design and synthesis of tetrahedral 
intermediate mimics with 6-8 carbon atoms, which were shown to inhibit MtuDAH7PS in the 
nano-molar range.54 
The previous work on the type Iα DAH7PS from E. coli showed that the three-carbon mimics 
showed variable potency, dictated by their stereochemical makeup. It was found that the 
planar E-vinyl phosphonate was the most potent, followed by the R-phospholactate and then 
the S-phospholactate, which exhibited the weakest potency.51 However, there was no 
structural investigation into the binding modes of these inhibitors and therefore, an 
understanding of their relative potencies was theoretical and speculative. The less labile 
character of the E-vinyl phosphonate, which was the most potent inhibitor of E.coli, may be 
highly beneficial as the instability of the phosphate moiety, present in all other designed 
inhibitors may be unfavourable due to the presence of phosphatases in most biological 
fluids.94 Therefore, inhibitors containing such labile functionalities are likely to be problematic 
during administration of the drug.  
This study involved the kinetic and structural characterisation of these three substrate mimics 
against a type Iα DAH7PS from a pathogenic Neisseria meningitidis bacterium in order to 
provide some insight as to why a planar mimic may have greater affinity for the site. A critical 
examination of their binding modes and important interactions within the active site will 
hopefully aid in further modification and extension into inhibitors with greater potency. 
This chapter comprises a single publication detailing the inhibition of N. meningitidis 
DAH7PS by three different, three-carbon substrate and intermediate mimics: 
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Figure 2.1.1. Rationale for inhibitors to be tested. Phospholactates based on tetrahedral intermediate and 
vinyl phosphonate based in planar oxocarbenium ion intermediate. 
 
The studies were published in Bioorganic Chemistry: 
 
Heyes, L. C., Reichau, S., Cross, P. J., Jameson, G. B. & Parker, E. J. Structural analysis of 
substrate-mimicking inhibitors in complex with Neisseria meningitidis 3-deoxy-D-arabino-
heptulosonate 7-phosphate synthase - The importance of accommodating the active site 
water. Bioorg. Chem. 57, 242–50 (2014). 
 
Dr S. Reichau aided in the synthesis of the three-carbon compounds. Dr P. J. Cross cloned 
and expressed NmeDAH7PS. Prof G. B. Jameson contributed to the crystallographic analysis 
of the three co-crystallised inhibitors. Prof E.J. Parker designed experiments and contributed 
to the writing of the manuscript. The author of this thesis wrote the publication manuscript 
and all co-authors contributed to the writing and/or revision of the manuscript. The author 
of this thesis carried out the synthesis, characterisation and testing of the three inhibitors 
and the growth of crystals, refinement and deposition of the crystal structures reported in 
the manuscript was also carried out by the author of this thesis. 
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Meningitis3-Deoxy-D-arabino-heptulosonate 7-phosphate synthase (DAH7PS) catalyses the first committed step of
the shikimate pathway, which produces the aromatic amino acids as well as many other aromatic
metabolites. DAH7PS catalyses an aldol-like reaction between phosphoenolpyruvate and erythrose
4-phosphate. Three phosphoenolpyruvate mimics, (R)-phospholactate, (S)-phospholactate and vinyl
phosphonate [(E)-2-methyl-3-phosphonoacrylate], were found to competitively inhibit DAH7PS from
Neisseria meningitidis, which is the pathogen responsible for bacterial meningitis. The most potent
inhibitor was the vinyl phosphonate with a Ki value of 3.9 ± 0.4 lM. We report for the first time crystal
structures of these compounds bound in the active site of a DAH7PS enzyme which reveals that the
inhibitors bind to the active site of the enzyme in binding modes that mimic those of the predicted
oxocarbenium and tetrahedral intermediates of the enzyme-catalysed reaction. Furthermore, the
inhibitors accommodate the binding of a key active site water molecule. Together, these observations
provide strong evidence that this active site water participates directly in the DAH7PS reaction, enabling
the facial selectivity of the enzyme-catalysed reaction sequence to be delineated.
 2014 Elsevier Inc. All rights reserved.1. Introduction
3-Deoxy-D-arabino-heptulosonate 7-phosphate synthase (DAH7PS)
catalyses the first committed step of the shikimate pathway, which
is responsible for the biosynthesis of the aromatic amino acids and
other important aromatic metabolites in plants and microorgan-
isms [1,2]. In mammals these essential metabolites are obtained
from dietary sources, and the enzymes of the shikimate pathway
are absent. Therefore, the enzymes of this pathway have beenidentified as promising targets for the development of new anti-
bacterial therapeutics [3–5].
DAH7PS catalyses the condensation between D-erythrose 4-
phosphate (E4P, 2) and phosphoenol-pyruvate (PEP, 1) to generate
DAH7P (3, Fig. 1). Many of the key mechanistic details of the reac-
tion have been elucidated through various labelling, structural and
alternative-substrate studies [3,6–12]. The ordered sequential
reaction proceeds stereospecifically with respect to both sub-
strates, with the si face of PEP attacking the re face of E4P. The
aldol-like reaction takes place with cleavage of the C–O bond of
the phosphate group of PEP, requiring water to act as a co-sub-
strate. The initial nucleophilic attack of PEP on E4P is predicted
to be promoted by coordination of the E4P aldehydic oxygen to
the essential divalent metal ion, giving an oxocarbenium ion inter-
mediate 4 (Fig. 1) [3,6]. The addition of an active site nucleophilic
water results in a phosphohemiketal tetrahedral intermediate 5,
which forms acyclic DAH7P on the elimination of phosphate. The
stereochemistry of the tetrahedral intermediate 5, which is lost
on the elimination of phosphate, is determined by the face of the
oxocarbenium ion 4 that is attacked by the nucleophilic water.
Therefore, the ability of the active site to accommodate and
Fig. 1. The overall DAH7PS catalysed reaction showing the likely mechanism via oxocarbenium ion and tetrahedral intermediates (in blue). Compounds 6–10 have been
shown to act as inhibitors of the DAH7PS enzymes from Escherichia coli or Mycobacterium tuberculosis.
L.C. Heyes et al. / Bioorganic Chemistry 57 (2014) 242–250 243activate a water molecule is an important aspect of DAH7PS catal-
ysis and, furthermore, may have implications for inhibitor design
[3,13].
DAH7PS enzymes have been structurally and functionally char-
acterised from a variety of sources [6,13–19]. While all known
enzymes have similar active site architectures supporting a com-
mon catalytic mechanism and share a common (b/a)8-barrel core,
there is considerable sequence divergence between enzymes from
different sources leading to the classification of DAH7PS enzymes
into two types [20]. Type I enzymes are further divided into type
Ia and type Ib subfamilies, which differ in sequence and their allo-
steric regulatory machinery. The only structurally characterised
type II enzyme is from Mycobacterium tuberculosis [16,21].
Active site inhibitors have been previously reported for the
phenylalanine-sensitive type Ia DAH7PS from Escherichia coli (Eco-
DAH7PS) and the type II enzyme fromM. tuberculosis (MtuDAH7PS)
[3,12,22–24]. PEP-like analogues were found to inhibit EcoDAH7PS,
with the most potent inhibitor being the vinyl phosphonate, (E)-2-
methyl-3-phosphonoacrylate 6, followed by the (R)-phospholac-
tate 7 [23]. (S)-Phospholactate 8 was the poorest inhibitor. The
rationale for a ten-fold difference in potency of the two phospholactatestereoisomers is not clear, as no structures of the inhibited
enzymes were determined, but may relate to the stereochemistry
of the transient phosphohemiketal tetrahedral intermediate 5.
The vinyl phosphonate 6 was found to have a Ki of 4.7 ± 0.7 lM,
which approaches the Km for PEP of 2 lM for this enzyme [23].
Inhibition studies on the type IIMtuDAH7PS were carried out using
extended (R)- and (S)-phospholactates of variable chain length
bearing an additional phosphate moiety in order to better
mimic the key functionality of the tetrahedral intermediate
(bisphosphates 9 and 10) [3,24]. In each case the compounds
bearing (R)-configuration were found to inhibit enzymatic activity
more potently than the respective (S)-enantiomers. The seven-car-
bon containing (R)-bisphosphate 9 had a Ki value of 0.36 ± 0.05 lM,
consistent with this compound significantly out-competing the
natural substrate PEP (KmPEP of 37 lM) [3,24].
The genome of Neisseria meningitidis, the causative agent of
pyogenic meningitis and meningococcal septicaemia, encodes a
single type Ia DAH7PS (NmeDAH7PS) [17,25]. The crystal structure
of NmeDAH7PS, which was recently determined in our laboratory,
revealed that the active site of NmeDAH7PS shares many
similarities to the DAH7PS from E. coli [33]. The active site Mn2+
244 L.C. Heyes et al. / Bioorganic Chemistry 57 (2014) 242–250is coordinated in a trigonal–bipyramidal fashion by four conserved
protein residues, Cys63, His270, Asp304 and Asp324 [17], leaving
one coordination site available for the aldehyde moiety of E4P.
PEP binding occurs through interaction with the highly conserved
residues Arg167, Arg236, Lys188, Arg94 and Lys99. The predicted
E4P binding site consists of a highly conserved motif involving
the residues Lys99, Pro100, Arg101 and Thr102.
Here we examine the inhibition of NmeDAH7PS by the active
site directed PEP-mimicking inhibitors 6, 7 and 8 in order to assess
their efficacies against a DAH7PS enzyme from an important path-
ogen. Furthermore, we report for the first time crystal structures of
a DAH7PS, here NmeDAH7PS, in complex with each of these inhib-
itors, revealing that these inhibitors do accurately mimic the bind-
ing modes predicted for the oxocarbenium ion 4 and tetrahedral
intermediates 5, along with the co-coordination of a water mole-
cule. Our findings allow refinement of the DAH7PS mechanism,
aid the identification of the nucleophilic water in this type Ia
enzyme and guide further structure-based inhibitor design of this
enzyme.2. Experimental
2.1. Inhibitor synthesis
(R)-Phospholactate 7, (S)-phospholactate 8 and the vinyl phos-
phonate 6 were synthesised according to the previously reported
methods [23]. Concentration determination of the vinyl phospho-
nate 6 was achieved by comparison of signal integrals from 31P
NMR spectroscopy using 85% phosphoric acid as a standard at suf-
ficiently long relaxation times. Phospholactate concentrations
were determined via Lanzetta assay for phosphate detection as
previously described [3,26].
2.2. Inhibition assays
Enzyme activity was measured by monitoring the loss of absor-
bance at 232 nm indicating the consumption of PEP (Sigma–
Aldrich). Assays were carried out in 50 mM bis(tris(hydroxy-
methyl) methylamino)propane (BTP) buffer at pH 6.8 with 10 lM
ethylenediaminetetraacetic acid (EDTA). The buffer was made up
in ultrapure water that had been treated with Chelex resin. E4P
was synthesised as reported previously from glucose 6-phosphate
[27]. Accurate substrate concentrations were determined by
the measurement of absorbance changes that corresponded to
the total consumption of substrates in triplicate. The reaction com-
ponents BTP buffer, MnSO4, PEP, E4P and inhibitor were incubated
for two minutes at 25 C to ensure equilibration before the addi-
tion of 2 lL of 0.9 mg mL1 NmeDAH7PS. Final assay conditions
were 100 lMMnSO4, 115 lM E4P, 19.9–79.6 lM PEP, and variable
concentrations of the inhibitors (18.9–151.2 lM vinyl phospho-
nate 6 inhibitor, 202–1616 lM (R)-phospholactate 7 and 268–
2144 lM (S)-phospholactate 8). BTP buffer was added to each
cuvette to bring the final volume to 1 mL. The values of Ki and
Km were determined by fitting all the initial-rate data points using
non-linear regression to the Michaelis–Menten equation modified
for the presence of a competitive inhibitor (Eq. (1) below) using
Grafit (Erithicus software).v ¼ Vmax½PEP
Kmð1þ ½I=K iÞ þ ½PEP ð1Þ2.3. Co-crystallisation of inhibitors with NmeDAH7PS
NmeDAH7PS was overexpressed and purified as previously
described [17]. Co-crystallisation of the protein and inhibitor wasachieved by preparing a solution containing approximately 5 mM
inhibitor dissolved in 10 mM BTP (pH 7.3). 400 lL of this solution
was added to the stock solution containing 50 lL of 10 mg mL1
enzyme and was concentrated to 50 lL using a 10 kDa molecular
weight cut-off membrane (Vivaspin). The resulting solution was
diluted again with 400 lL of inhibitor solution and concentrated
by centrifugation. This process was repeated four times. The
resulting protein solution was concentrated to approximately
10 mg mL1. 1 lL of the buffer-exchanged enzyme solution
(9–11 mg mL1) was mixed with 1 lL of crystallisation buffer con-
taining 0.1 M Tris HCl (pH 7.3), 0.2 M trimethyl-amino-N-oxide
(TMAO), 0.4 mMMnSO4 and 15–20% (w/v) PEG 2000MME. Crystals
were grown by hanging-drop vapour diffusion over 500 lL of
crystallisation buffer and the crystallisation trays were incubated
at 20 C. Crystals began to form in 24 h and were fully formed
within three days. Crystals were flash frozen using liquid nitrogen
in a cryoprotectant solution containing reservoir solution and 20%
(v/v) PEG400.
2.4. Crystallography and structure determination
X-ray diffraction datasets were collected at the Australian syn-
chrotron using the MX1 and MX2 beamlines [28]. The datasets
were integrated and processed using XDS and aimless (CCP4 pro-
gram suite) [29,30]. The appropriate cut-off resolution was deter-
mined via CC1/2P 0.5 while ensuring the data set was complete
in the highest resolution shell [31]. For the co-crystal structures
with the vinyl phosphonate and (S)-phospholactate ligands, the
space group (P1211) and unit cell parameters were the same as
those previously identified for NmeDAH7PS (PDB code 4HSN
[17]). To minimise bias, all ligands and waters were removed from
the search model (PDB code 4HSN) before molecular replacement
(Phaser MR (CCP4) [32]) was carried out. When co-crystallised
with (R)-phospholactate, NmeDAH7PS crystallised, non-isomor-
phously, in the orthorhombic space group, P212121. Although struc-
ture solution and refinement proceeded normally, the data
collected were affected by anisotropy. Refmac5 was used to gener-
ate the electron density maps for all three structures and these
were manually analysed to develop the structural model by means
of COOT [33–35]. The quality of the model was optimised by con-
secutive model building in COOT and refinement with Refmac5.
Water molecules were added manually via interpretation of the
(2|Fo|  |Fc|) and (|Fo|  |Fc|) maps, with the requirement that
putative water molecules had at least one hydrogen-bonding part-
ner. In all structures, no electron density for the 14 amino acids at
the N-terminus of each NmeDAH7PS chain could be found, which is
attributed to these residues being part of a conformationally highly
flexible allosteric binding loop [17]. Residues Met1-Asp9 were also
absent from the model (PDB code 4HSN) used for molecular
replacement. Molprobity [36] and the validation tools of COOT
were used to assess structure quality during refinement cycles
and before deposition [36]. After refinement of all protein and
non-active-site water molecules had been completed, electron
density that could be interpreted as the respective inhibitors could
be observed in the active site. CIF files for all three inhibitors were
built using the Dundee PRODRG2 server [37]. The inhibitors were
positioned manually into this electron density using COOT and
then refined. In all three structures, model elaboration and refine-
ment continued until no further improvement in Rfree could be
gained and for final refinements NCS restraints were dropped.
The (R)-phospholactate 7 structure crystallised in the
orthorhombic space group P212121 as confirmed by the presence of
systematic absences for this space group, and the subsequent suc-
cessful structure solution and refinement. The data are noticeably
anisotropic such that diffraction in the b⁄ direction is relatively very
much weaker than in the other directions, especially at higher
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Wilson B value of 19.65 Å2 vis-à-vis resolution of this dataset is
biased by strong diffraction in the other two directions; it is not
the result of overlooked twinning, for which no evidence could be
found from intensity statistics nor from metrical relationships
among unit cell parameters. Notwithstanding anisotropy in the
diffraction data, electron-density maps were of noticeably higher
quality upon inclusion of the high-resolution data. In this (and the
other two structures) the refined average B value was similar to
the respective Wilson B value. The final value for Rfree (0.227) and
the small differencebetweenRfree andRwork (0.026) indicate that this
structure (and also the other two structures, which had similarly
favourable values) had not been over-refined.
Distances given in the structural analysis of inhibitor binding
are defined as a range in Å across all subunits of the tetramer, to
ensure consistency during comparison. Only distance differences
that remain consistent throughout all subunits during comparison
of respective structures are included.
3. Results and discussion
3.1. NmeDAH7PS is inhibited by PEP analogues
Previous studies have shown that both EcoDAH7PS and Mtu-
DAH7PS were inhibited by compounds that possess either a planar
trigonal or a tetrahedral geometry at C2 [3,22,23]. Both phospho-
lactate stereoisomers 7 and 8 and the vinyl phosphonate 6 were
synthesised and tested as inhibitors of NmeDAH7PS. All three com-
pounds were found to inhibit NmeDAH7PS competitively with
respect to substrate PEP. The most potent inhibitor was the vinyl
phosphonate 6, with an observed Ki value of 3.9 ± 0.4 lM. This
value is significantly lower than the measured Km for PEP
(12 lM). While both enantiomers of the phospholactate were also
inhibitory, inhibition by the (R)-phospholactate 7 was 3.5 times
greater than that observed for the (S)-phospholactate 8 (Table 2).
The order of inhibitory potency observed for these compounds
with NmeDAH7PS parallels the observations made for the type Ia
EcoDAH7PS. For EcoDAH7PS, the (R)-phospholactate 7 was shown
to be more than 10-fold more potent than the (S)-stereoisomer
[23]. TheMtuDAH7PS enzyme also demonstrated this same stereo-
chemicalpreference for the configurationatC2when testedwith the
extended bisphosphate inhibitors 9 and 10 [3,24]. The most potent
of these bisphosphate inhibitors was the (R)-bisphosphate 9, which
exhibited a Ki value of 0.36 ± 0.05 lM (in comparison to the (S)-bis-
phosphate 10 with a Ki of 0.6 ± 0.1 lM) [3]. Thus, stereochemical
influences on inhibitor-binding affinity appear to be intrinsic to
the active sites of DAH7PS and are independent of the class of
DAH7PS and the species from which the enzyme is derived.
The increase in potency upon introduction of a phosphonate
with a planar geometry at C2, observed for vinyl phosphonate 6,
is consistent with what has been reported previously for
EcoDAH7PS [23]. It should be noted that all these inhibitors are
particularly potent with respect to their size, showing very high
ligand efficiencies (ligand efficiency (LE) =DG/N; where DG=
RTlnKi and N = number of non-hydrogen atoms per ligand)
[38,39]. When comparing the relative ligand efficiencies of the
vinyl phosphonate measured here for NmeDAH7PS, and the
extended (R)-bisphosphate 9 (as an inhibitor of MtuDAH7PS), it is
evident that the vinyl phosphonate 6 is 1.6-fold more efficient than
the longer inhibitor. The (R)-bisphosphate 9 is the most potent
inhibitor reported for any DAH7PS enzyme to date [3].
3.2. Structural analysis of inhibitor binding
Structures of NmeDAH7PS co-crystallised with each of the
inhibitors were determined by X-ray diffraction. The threestructures containing the ligands vinyl phosphonate 6, (R)-phos-
pholactate 7 and (S)-phospholactate 8 were refined to resolutions
of 1.76 Å, 2.17 Å and 2.35 Å respectively (Table 1). The vinyl phos-
phonate and (S)-phospholactate-bound proteins crystallised in the
same space group (monoclinic P1211) as the wild-type protein,
whereas the (R)-phospholactate-bound enzyme crystallised in
the orthorhombic space group P212121. The asymmetric unit for
all three inhibitor-bound structures contained a homotetramer.
Continuous electron density for the three ligands was observed
in all active sites after complete refinement of the protein and non-
active-site water molecules (Fig. 2). Judging from B values of
ligands and ligand-binding side chains, the ligands are present in
full, or close to full, occupancy. The binding of inhibitors does not
affect the secondary or tertiary structure of the enzyme. Individual
subunits within a tetramer superimpose on each other with a root-
means-square displacement (RMSD) of between 0.05 and 0.09 Å,
whereas superposition of subunits from different tetramers super-
impose with RMSD values in the range 0.10 to 0.18 Å.
The inhibitors show similar placement within the active site
and binding modes to that observed for the natural substrate PEP
1 (Fig. S4, Supplementary material). The side chains of residues
Lys188, Arg167 and Arg236 and the main-chain peptide N of
Ala166 that interact with the phosphate moiety of PEP form similar
interactions with the phosphate or phosphonate functionalities of
the three ligands, consistent with this portion of each inhibitor
being able to mimic the PEP binding characteristics well. Mn2+ is
found in the metal-binding site of all the structures in full occu-
pancy. As well as coordinating to the Mn2+ in the active site, the
carboxylate group of each ligand forms salt bridges with the side
chain of Arg94 and with the side chain of Lys99 of the conserved
LysProArgThr motif, which extends into the E4P binding site. In
the structure of the PEP-bound enzyme, Mn2+ also coordinates
the PEP carboxylate functionality and a water molecule. The lack
of this coordinating water molecule in any of the inhibitor-bound
structures is associated with a closer positioning of the carboxylate
group of the respective PEP-mimic to the metal ion (Fig. S2).
There are five waters in the active site of each subunit occupy-
ing similar positions in the vicinity of both the vinyl phosphonate 6
and (R)-phospholactate 7 inhibitors (labelled WAT1-5, Fig. 2).
WAT1 is found in a position corresponding to the re face of PEP
and establishes hydrogen bonds with the bridging oxygen of the
phosphate group and with a terminal oxygen of the phosphate or
phosphonate functionalities. Additionally, WAT1 hydrogen-bonds
to WAT2 and Glu145. WAT2 also forms hydrogen-bonding interac-
tions with Lys188 and Tyr96. WAT3 is also hydrogen-bonded to the
phosphate or phosphonate moieties and interacts with the back-
bone amino group and the g1 nitrogen of Arg167. WAT4 forms
hydrogen-bonding interactions with both g1 and g2 of Arg167
and to an oxygen of the phosphate or phosphonate functionalities.
WAT5 makes no direct interactions with the inhibitors, but pro-
vides a hydrogen-bonding bridge between Glu145 and Lys99.
WAT1, WAT2, WAT3 and WAT5 are also found occupying similar
positions in the (S)-phospholactate 8 inhibitor-bound structure.
No evidence for a WAT4 was observed for this structure, although
it is noted that this structure has the lowest resolution of this set.
All five of these water molecules were also present in the PEP-
bound structure, although WAT4 is only modelled into chain A of
this structure [17]. In addition, as noted earlier, a Mn2+-coordi-
nated water is observed in the PEP-bound structure.
Tertiary structures, as noted above, are unaffected by inhibitor
binding and the tetrameric quaternary structures of NmeDAH7PS
bound with (S)-phospholactate and vinyl phosphonate are identi-
cal to that of the isomorphous PEP-bound parent structure (PDB
code 4HSN) (RMSDs for superposition onto 4HSN of 0.17 and
0.23 Å for 1328 and 1327 Ca atoms, respectively). However, there
are small but significant changes in the arrangement of subunits
Table 1
Data collection and refinement.
NmeDAH7PS complex
Vinyl phosphonate 6 (R)-phospholactate 7 (S)-phospholactate 8
Data Collection
Crystal system; space group Monoclinic, P1211 Orthorhombic, P212121 Monoclinic, P1211
Unit cell parameters
a, b, c (Å) 73.49, 136.50, 76.16 79.44, 133.7, 147.2 73.42, 137, 76.48
a, b, c () 90, 96.41, 90 90, 90, 90 90, 96.48, 90
Resolution range (Å) 46.82–1.76 (1.79–1.76) 48.31–2.17 (2.21–2.17) 46.88–2.34 (2.40–2.34)
Measurements 1,113,629 617,846 242,429
Unique reflections 147,006 83,610 63,250
Redundancy 7.6 7.4 3.8
Completeness (%) 99.8 (99.2) 99.9 (98.7) 99.9 (99.8)
I/r (I) 16.9 (1.9) 6.5 (1.2) 8.0 (1.1)
Rmerge 0.070 0.298 0.148
CC1/2 0.88 0.52 0.50
Wilson B value (Å)2 24.52 19.65 30.63
Matthews coefficient 2.50 2.57 2.51
Refinement
Rwork 0.1918 0.2007 0.2040
Rfree 0.2144 0.2267 0.2304
Chain length 351 351 351
Observed number of residues 333 (Chain C & D) 332 (Chain A & B) 333 (Chain A), 332 (Chain B, C &D) 333 (Chain A & B), 334 (Chain C), 332 (Chain D)
Water molecules 779 634 263
Other 4 8 8
Ligand 4 4 4
Mean B (Å)2
Protein 32.87 24.90 38.37
Water 34.50 24.42 30.42
Other 23.66 33.12 57.93
Ligand 24.35 22.54 40.23
R.m.s.d from target values
Bond lengths (Å) 0.0104 0.0106 0.0117
Bond angles 1.3822 1.3951 1.4594
Dihedral angles 0.0800 0.0745 0.0761
Ramachandran
Preferred (%) 97.71 97.54 98.36
Allowed (%) 1.68 1.84 1.22
Outliers (%) 0.61 0.61 0.61
PDB Entry 4UMA 4UMB 4UMC
Table 2
Inhibition constants of compounds tested against NmeDAH7PS.
Inhibitor Ki (lM)a
3.9 ± 0.4
99 ± 16
360 ± 30
a Assay conditions used were 100 lM MnSO4, 115 lM E4P, 19.9–79.6 lM PEP,
18.9–151.2 lM vinyl phosphonate inhibitor 6, 202–1616 lM (R)-phospholactate 7,
and 268–2144 lM (S)-phospholactate 8. A graphical representation of the data is
provided in the supplementary material (Fig. S1 and Table S1).
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the PEP-bound parent (RMSD of 0.60 Å for superposition of 1325
Ca atoms). The tetramer is made up of two dimers, one comprising
an extensive interface with mutual proximity of the E4P binding
loops (b2a2), often referred to as the tight dimer interface, theother dimer, often referred to as the loose dimer interface, being
formed largely by antiparallel association of helix a0. The quater-
nary structural changes are concentrated at the weak dimer inter-
face, the tight dimers superimposing on PEP-bound enzyme with
RMSDs in the range 0.13–0.27 Å. Thus, these differences between
the (R)-phospholactate-bound structure and the PEP-, (S)-phospho-
lactate- and vinyl phosphonate-bound structures can be attributed
to crystal packing effects (sampling different conformations of
the ensemble of quaternary structures freely sampled in solution).
3.3. Small differences in inhibitor binding modes are observed
While the binding modes of the two phospholactate enantio-
mers are very similar, a comparison of the (R)- and (S)-phospholac-
tate inhibitor-bound structures and the different way in which the
two stereoisomers can be accommodated in the active site
highlights some small differences in the relative positions of the
key functional groups which may account for their inhibitory dif-
ferences (Fig. 3). These differences are shared when any subunit
of one tetramer is compared to any subunit of another tetramer,
consistent with the very high similarity of all individual subunits
described above. This allows small differences of marginal signifi-
cance in a single pairwise comparison to become highly significant
when all subunits are compared. The phosphate groups of the two
molecules are similarly positioned and a slight displacement of the
carboxylate functionality of (R)-phospholactate away from Lys99
towards Arg94 is observed. WAT1 is found in closer proximity to
Mn2+ 
Mn2+ 
Mn2+ 
Mn2+ 
Mn2+ 
Mn2+ 
A B
C D
E F
Fig. 2. Structure of NmeDAH7PS in complex with inhibitors. Panels A and B: vinyl phosphonate 6 bound structure (chain A). Panels C and D: (R)-phospholactate 7 bound
structure (chain A). Panels E and F: (S)-phospholactate 8 bound structure (chain A). Panels B, D and F show interatomic distances (in Å). Panels A, C and E display the |2Fo  Fc|
map to indicate the observed electron density for the bound ligand and WAT1 contoured at 1r. The interatomic distances for each chain and the omit maps are provided in
the supplementary material (Figs. S3–S7). Mn2+ is shown as a purple sphere in all panels.
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0.2–0.7 Å by comparison across all chains), bringing this separation
to less than van der Waals distance. This is likely to be a direct
result of the configurational difference between the two phospho-
lactate inhibitors. The stereochemical difference will necessarily
result in the C2 hydrogen of the inhibitor pointing directly towards
WAT1 when (S)-phospholactate is bound, whereas for the (R)-
enantiomer, this hydrogen will be positioned away from WAT1
(Fig. 4). In addition, the positioning of the (R)-phospholactate
allows for more optimal hydrogen-bonding interactions to WAT1,as can be seen when the angles (C2 phospholactate-bridging phos-
phate oxygen-WAT1) are compared between the (R)- and (S)-phos-
pholactate inhibitor-bound structures: for (S)-phospholactate, this
angle is close to 90, leading to poor hydrogen-bonding interac-
tions when the direction of the lone pair electrons of the bridging
oxygen is considered. In contrast, the angle (C2 phospholactate-
bridging phosphate oxygen-WAT1) is close to 109 in the (R)-phos-
pholactate bound structure, which leads to a close to optimal
angular geometry for a hydrogen bond between WAT1 and the
bridging phosphate oxygen in the (R)-phospholactate ligand. In
Fig. 3. Comparison of binding modes of (R)- and (S)-phospholactate in stereo view. (R)-Phospholactate is shown in cyan and (S)-phospholactate is shown in magenta.
Interatomic distances are shown as pale cyan dashes for the (R)-phospholactate interactions and pink dashes for the (S)-phospholactate interactions. Distances between
WAT1 and C2 of the ligand are 3.8 Å for (R)-phospholactate and 3.3 Å for the (S)-phospholactate (shown as grey dashes). Mn2+ is shown as a purple sphere. The carboxylate
and phosphate moieties of both inhibitors are in very similar positions, which correspond well to the placement of these moieties when the substrate PEP is bound; the
positions of ligand-binding side chains do not change significantly on ligand binding. However, a slight displacement of the bridging phosphate oxygen is apparent, along
with the methyl substituent, which results in an altered hydrogen-bonding geometry between WAT1 and the bridging phosphate oxygen.
O
O OH
P
OO
O
2-
HWAT2
WAT1
Lys188
WAT3
WAT4
Tyr96
O
O O
P
OO
O
2-
HWAT2
WAT1
Lys188
WAT3
WAT4
Tyr96
O O
P
OO
O
2-
WAT2
WAT1
Lys188
WAT3
WAT4
Tyr96
Fig. 4. Schematic representation of subtle differences in the water-mediated hydrogen-bonding network in the inhibitor bound crystal structures. For (R)-phospholactate
(left), the C2–hydrogen (bold) points away from WAT1. For (S)-phospholactate (centre), the C2–hydrogen (bold and red) points towards WAT1, potentially resulting in steric
hindrance (indicated by red wavy line). Both phospholactate enantiomers establish hydrogen-bonding interactions with WAT1 and WAT2 through the bridging phosphate
oxygen (dotted lines). These interactions are not observed in the binding mode of E-vinyl phosphonate (right), which has a bridging methylene group instead of an oxygen.
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NmeDAH7PS in complex with the two enantiomers of phospholac-
tate, improved accommodation of WAT1 and a more optimal
hydrogen-bonding network between the inhibitor and the active-
site waters may serve to explain the difference in potency of the
enantiomeric phospholactates. Our study reveals that the small
differences in inhibitory potency correlate with subtly different
binding modes of the inhibitors as could have been predicted;
however, the precise structural information obtained here on
the enzyme-inhibitor co-crystal structures will help inform future
inhibitor design.
The increased inhibitor potency observed for the vinyl phospho-
nate 6 over the (R)-phospholactate 7 suggests that the active site is
better prepared to accommodate a planar rather than tetrahedral
intermediate. This occurs despite the lack of a hydrogen bond
acceptor in the vinyl phosphonate, which results in one less hydro-
gen bond being established between the vinyl phosphonate and
WAT1. Although a similar binding mode is adopted by both inhib-
itors and the distances between the phosphonate or phosphate
moieties of these inhibitors and the residues with which they
interact are very similar, there are small structural differences that
may be relevant to this change in functionality and potency. The
bridging oxygen of the phosphate in the (R)-phospholactate is
0.1–0.4 Å closer to Lys188 than the bridging carbon of the phos-
phonate functionality in the vinyl phosphonate. A small relativedisplacement (0.1–0.3 Å) of the carboxylate functionality of the
vinyl phosphonate towards to the amino group of Lys99 is also
apparent. This shift in the binding mode of the vinyl phosphonate
towards Lys99 compromises the interaction between the carboxyl-
ate functionality and WAT2, which are further apart (0.2–0.5 Å) in
the vinyl phosphonate bound structure. However, the planar and
more compact geometry of the vinyl phosphonate compared to
(R)-phospholactate enables closer proximity and thus a stronger
Coulomb interaction to develop between the negative charge of
the vinyl phosphonate carboxylate and the potentially positively
charged Lys99 amino group. Another key factor in the stronger
binding of the vinyl phosphonate compared to the phospholactate
moieties is that the rotational/torsional degrees of freedom around
the C1–C2 and the C2–C3 bond are surrendered upon binding to
the enzyme for the phospholactate species, in contrast to minimal
loss of such degrees of freedom when the more rigid vinyl phos-
phonate binds. This can be estimated to contribute a free-energy
stabilisation as 2RTln3 (allowing three torsional conformations),
that is 5.4 kJ mol1 at 25 C, or a factor of 9 in terms of
equilibrium constant, a number remarkably similar to the relative
affinities of binding of the vinyl phosphonate compared to the
more easily accommodated (R)-enantiomer of the phospholactate
species.
The accommodation of WAT1 appears to be an important
feature of all the inhibitor-NmeDAH7PS structures. The distance
Fig. 5. Proposed mechanism of catalysis of NmeDAH7PS showing key nucleophilic role for active site WAT1.
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than is that observed for the (R)-phospholactate-bound structure.
This difference appears to be a direct result of the planarity result-
ing from the double bond of the vinyl phosphonate concomitant
with the fixing of the carboxylate and phosphate moieties into
their binding pockets. Taken together with the inhibition con-
stants, this analysis suggests that the geometry of the NmeDAH7PS
active site is better optimised to accommodate a planar reaction
intermediate or mimic (vinyl phosphonate) thereof, in combina-
tion with the nucleophilic WAT1. The loss of a hydrogen bonding
contact when moving from the phospholactates to vinyl phospho-
nate appears to be outweighed by WAT1 being able to be accom-
modated at a slightly better van der Waals separation than the
(R)-phospholactate, which at 3.8–3.9 Å is slightly longer (and
(S)-phospholactate which is noticeably shorter) than ideal van
der Waals contact, even after allowing for different hybridisation
of carbon atom C2.
3.4. Implications for the mechanism of the DAH7PS-catalysed reaction
The cleavage of the C–O bond to release phosphate in the reac-
tion catalysed by DAH7PS demands that water acts as a co-sub-
strate in the reaction (Fig. 1). Coordination of the aldehydic
group of E4P to the divalent active site metal ion both assists in
presenting the re face of the aldehyde group to the si face of PEP
and thus pre-organises the substrates for nucleophilic attack by
PEP through its C3. It is likely that an oxocarbenium-like transition
state or transient intermediate is then quenched by water to gen-
erate a tetrahedral intermediate. The direction of attack of this
water determines the stereochemistry of this intermediate. From
the structural information gathered in these ligand-bound struc-
tures, it is evident that the most likely candidate for the nucleo-
philic water is indeed WAT1 based on its proximity to C2 of PEP,
supporting the attack by water on the re face of PEP, overall anti
addition across the PEP-double bond, and the generation of a
transient stereogenic centre in the intermediate with an (S) abso-
lute configuration. In support of this, water has been observed tooccupy similar positions in the DAH7PS structures from Saccharo-
myces cerevisiae, E. coli, M. tuberculosis and Thermotoga maritima
[3,6,13,14].
The preference for the binding of the (R)-phospholactate over
the (S)-phospholactate and the structural observations from these
ligand-bound structures are also consistent with re face water
attack and the generation of (S)-configuration at C2 of the tetrahe-
dral intermediate. A greater than 3-fold difference in potency
between the (R)- and (S)-phospholactate inhibitors results from
change in absolute configuration at C2. Although an (S)-configura-
tion of the phosphohemiketal tetrahedral intermediate 5 will
arise from re face water attack, the closer placement of C2 of the
(S)-phospholactate and the corresponding requirement to accom-
modate a hydrogen on C2 of the phospholactate likely hinders
co-occupation of the active site with this water molecule, account-
ing for the reduced potency observed for the (S)-phospholactate.
Conversely, (R)-phospholactate, with the hydrogen at C2 pointing
away from the active site water more readily accommodates
WAT1. A similar stereochemical preference was also observed for
the extended (R)- and (S)-bisphosphate inhibitors 9 and 10 for
MtuDAH7PS. While the preference for the (R)-configuration was
only twofold, the differences in potency were also attributed to
better accommodation of a water molecule in an equivalent posi-
tion to WAT1 from this study [3].
The planar geometry of the vinyl phosphonate is accompanied
by a significant increase in potency over either of the phospholac-
tate stereoisomers. The double bond introduced at C2 is able to
mimic the prochirality seen in the oxocarbenium ion intermediate,
which further suggests that the planar ligand geometry is best sui-
ted to accommodate the binding of the nucleophilic water mole-
cule (WAT1). Therefore, among the three ligands examined in
this study, the ability for the inhibitor to adequately accommodate
WAT1 upon binding and the lessened changes in conformational
flexibility on binding with respect to the free ligand are the defin-
ing criteria for inhibitor potency. From our structural analysis, we
propose that (R)-phospholactate is a stronger inhibitor than
(S)-phospholactate, in part due to improved hydrogen-bond
250 L.C. Heyes et al. / Bioorganic Chemistry 57 (2014) 242–250geometry between WAT1 and the bridging phosphate oxygen in
(R)-phospholactate and in part due to lesser stereochemical clash
of WAT1 with C2. We further suggest that the highest potency of
the planar vinyl phosphonate inhibitor is due in part to lowered
loss of conformational flexibility of this more rigid ligand on bind-
ing to the enzyme and in part on WAT1 being placed in ideal prox-
imity to C2 of the ligand. This position may most resemble that
whichWAT1 would assume during the course of regular enzymatic
turnover, acting as the nucleophilic water which attacks C2 of the
oxocarbenium ion 4 (Fig. 1).
With the identification of the nucleophilic water, the details of
the NmeDAH7PS-catalysed reaction mechanism can be elucidated
from the kinetic and structural data presented here in combination
with previous mechanistic and structural studies on DAH7PS from
other sources (Fig. 5) [3,10]. Nucleophilic attack of PEP at the E4P
aldehyde moiety is facilitated by activation of the carbonyl moiety
by coordination to the active-site metal ion and subsequent pro-
tonation of the nascent alkoxo group by Lys99. The transient
oxocarbenium ion species 4 is then rapidly attacked by WAT1,
which is deprotonated by Glu145, resulting in the formation of
the tetrahedral intermediate 5. This nucleophilic water is held in
position on the re face of PEP by hydrogen bonds to Glu145 and
WAT2. Glu145 is conserved in both sequence and structure in all
known DAH7PS enzymes [3,13]. Lys99 residue is protonated via
an active site water molecule by Glu145. Lys188, which is posi-
tioned within proximity for hydrogen bonding interactions with
the phosphate of PEP, is predicted to aid in the elimination of phos-
phate from the tetrahedral intermediate 5 via protonation of the
leaving group. Elimination of phosphate results in the linear
DAH7P product, which is protonated at the 2-keto moiety. Depro-
tonation of this species by Lys188 subsequently results in the for-
mation of the product, DAH7P, which is in equilibrium with its
pyranose form 3, and restores the enzyme for a subsequent cata-
lytic cycle (Fig. 5).4. Conclusion
Three PEP mimics were found to be inhibitors of NmeDAH7PS
and to occupy the PEP binding pocket of the active site of this
enzyme. Analysis of the first co-crystal structures of these small
but highly atom-efficient inhibitors with their target enzyme high-
light the importance of the accommodation of the nucleophilic
water molecule in the active site for potent inhibition. From our
studies we conclude that planar rather than tetrahedral PEP-mim-
ics are more promising candidates for inhibition of NmeDAH7PS,
and the ability of inhibitors to accommodate the key nucleophilic
water molecule needs to be considered in future inhibitor design.
Extension of a planar ligand based on the rigid vinyl phosphonate
scaffold facilitated by the first structural information on enzyme-
inhibitor complexes presented here would likely be a highly potent
inhibitor of NmeDAH7PS.
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CHAPTER 3- INVESTIGATIONS INTO THE SPECIFICITY OF THE 
ALLOSTERIC BINDING SITE AND THE STRUCTURAL 
REORGANISATION OF THE ACTIVE SITE  
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3.1 INTRODUCTION 
N. meningitidis expresses a single DAH7PS that is primarily inhibited by phenylalanine (Phe).26 
However, two other aromatic amino acids, tyrosine (Tyr) and tryptophan (Trp) also inhibit the 
enzyme to a lesser extent.26 This promiscuity at a single binding site of NmeDAH7PS has 
interesting implications for drug design and discovery. Traditionally, drug discovery attempts 
have been focused on targeting enzyme active sites, through substrate, transition-state and 
even product analogues.53,54,69,70 It has been hypothesised that drugs, which target allosteric 
sites lead to higher specificity than orthosteric drugs, which target an enzyme’s functional site, 
as regions outside the active site tend to be less conserved among enzyme families. Allosteric 
drugs can act to modulate activity in a pathway, rather than eliminating activity altogether, 
and generally work when the enzyme is in its active state, which may be desirable in certain 
cases (i.e. when enzymatic activity is required by the cell).85,95  
It remains unclear what features of the aromatic amino acids are required to achieve the 
allosteric response in this enzyme. Therefore, a detailed investigation into the binding of these 
aromatic amino acids and their ability to propagate allosteric signals to the active site, may aid 
future work into the targeting of this site for drug discovery. 
An enzyme selects specific conformations of substrate that support the appropriate charge 
and the relative orientation of substrates to facilitate the desired reaction.68,96 Active site 
reorganisation produced by binding of an allosteric effector can produce a response in 
catalytic rate. Type Iα DAH7PSs have been shown to undergo reorganisation of the active site 
in the presence of allosteric effector. In the Phe-sensitive isozyme from E. coli, the substrate, 
PEP was shown to adopt an alternative  binding mode in the presence of Phe, which may be 
correlated to the reorganisation of crucial active site residues (PDB code: 1KFL).22 It is 
hypothesised that NmeDAH7PS will undergo a similar structural reorganisation at the active 
site, as the active site reorganisation was also observed in the Tyr sensitive SceDAH7PS (PDB 
code: 1OF6).  
This chapter entails a detailed account of the binding and inhibition of NmeDAH7PS by the 
three aromatic amino acids, Phe, Tyr and Trp. The crystallisation of these ligands in the 
allosteric site of NmeDAH7PS depicts the reasons for selectivity between the three aromatic 
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amino acids, as well as similar structural reorganisation of the active site residues. These 
studies reveal that in the presence of allosteric ligand, the active site becomes pre-organised 
for the binding of the substrate PEP, which adopts an alternative binding mode and is less 
likely to react with E4P due to the reorganisation of active site residues. These insights into 
the allosteric mechanism pose an interesting avenue for future drug discovery efforts and our 
understanding of allostery in the enzyme, NmeDAH7PS. 
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3.2 RESULTS 
3.2.1 The effect of Phe, Trp and Tyr on NmeDAH7PS activity. 
 
The allosteric response of NmeDAH7PS to the three aromatic amino acids (Phe, Tyr and Trp) 
was tested using standard assay conditions (section 7.1.27). The results presented are similar 
to those of previously published work on this enzyme and illustrate that NmeDAH7PS is most 
sensitive to inhibition by Phe, is somewhat inhibited by Trp and least inhibited by Tyr (Figure 
3.2.1.1).26 The concentrations of metabolites in E. coli indicate the Tyr is the most abundant, 
followed by Phe and then Trp.97 The heightened sensitivity of NmeDAH7PS to inhibition by 
Phe, suggests that regulation by Phe is sufficient to regulate the pathway in this organism, or 
that cellular levels of Tyr are regulated by other means.  
 
Figure 3.2.1.1 Allosteric effect of all three aromatic amino acids on the activity of NmeDAH7PS (2µL, 0.6 
mg/mL) as a function of aromatic amino acid concentration, Tyrosine (green), Tryptophan (red) and 
Phenylalanine (blue). Concentrations of substrates were kept constant (PEP - 100 µM and E4P - 250 µM), while 
the concentration of the three aromatic amino acids was varied (50-1000 µM). 
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3.2.2 Binding of Phe, Trp and Tyr 
 
Isothermal titration calorimetry (ITC) experiments were employed to determine the binding 
constants for the three aromatic amino acids. It was reported in the original published 
NmeDAH7PS data that binding of Tyr to NmeDAH7PS was not detected in the binding 
isotherm and therefore this titration was not attempted in this study.26 Unfortunately, binding 
of Trp to NmeDAH7PS was too weak to fit an appropriate model to the binding isotherm after 
titration (Figure A.3.1). The binding of Phe to NmeDAH7PS was determined by titrating Phe 
into the enzyme and the binding isotherm was consistent with a two-site sequential binding 
model (Figure 4.2.2.1A).   
 
Figure 3.2.2.1 A) Raw data from ITC experiment involving the titration of 1.2 mM Phe into the cell containing 16 
µM NmeDAH7PS corrected for heat of dilution. B) Comparison of the thermodynamic parameters (-TΔS-blue; 
ΔG-green and ΔH-red) for binding at both sites NmeDAH7PS. C) Comparison of dissociation constant (KD) at 
both sites of the sequential binding model. 
The binding of Phe to NmeDAH7PS had a KD of 3 ± 1 µM at the first binding site and a KD of 11 
± 1 µM for the second site. This indicates that binding occurs in an un-cooperative manner, 
where binding at the first available site decreases binding affinity at the second allosteric site. 
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The thermodynamic parameters obtained from the binding isotherm indicate that the large 
TΔS contribution to binding at the first site is due to the accessibility to two sites. The binding 
at this first site appears to be entropically driven whereas binding at the second site also has a 
large enthalpic contribution (Figure 3.2.2.1). Taken together, it is evident that binding of Phe 
to NmeDAH7PS is predominantly an entropically driven process.  
3.2.3 Crystallographic characterisation of aromatic amino acid binding 
 
In order to elucidate the binding mode of the aromatic amino acids, crystal structures of these 
ligands in complex with NmeDAH7PS were determined by X-ray diffraction methods. Crystals 
of NmeDAH7PS were grown in the absence of allosteric ligand using methods outlined in 
(section 7.1.30). Crystals were either transferred to droplets containing the crystallisation 
condition and the corresponding aromatic amino acid, or the crystallisation condition with 
aromatic amino acids was added directly to the drop containing the crystal in order to 
preserve crystal quality during soaking (section 7.1.33). Crystals were left to soak for 2-6 
hours, where they were cryo-protected and flash frozen in liquid nitrogen prior to analysis 
(Data collection and refinement statistics are shown in Table 3.2.3.1). 
 
Concentrations of amino acids used to obtain crystal structures containing these ligands 
varied considerably due to their vastly different affinity for the allosteric binding site of 
NmeDAH7PS. The final concentration of Phe, Trp and Tyr in the crystallisation drop used for 
soaking was 1 mM, 10 mM and 20 mM respectively.  
 
It was apparent that none of the crystal structures contained electron density from the |Fo-Fc| 
maps to indicate that the active site ligand, PEP was bound, even at low occupancy. This may 
have been lost during soaking experiments as PEP was in the purification buffer, but not in the 
crystallisation condition used for soaking. This remained an anomaly as previous structures of 
other type Iα DAH7PSs indicated a flipped binding mode for PEP.28  
 
Instead of using soaking to diffuse the ligand into the crystal, attempts were made to co-
crystallise the enzyme in the presence of (1 mM PEP and 1.5 mM Phe). Co-crystallisation of 
this protein in the presence of Phe is problematic in NmeDAH7PS due to the altered 
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conformation of the allosteric binding loop as it becomes ordered upon binding of the 
allosteric ligand. However, the use of several rounds of micro-seeding, generated crystals, that 
were of appropriate quality for analysis. Fortunately the structure was refined, and both 
ligands (Phe and PEP) were present at full occupancy (data collection and refinement statistics 
are given in Table 3.2.3.1).  
 
NmeDAH7PS     
 L-Phenylalanine L-Phenylalanine, PEP L-Tyrosine L-Tryptophan 
Data Collection     
Crystal system; space group Monoclinic, P1211 Monoclinic, P1211 Monoclinic, P1211 Monoclinic, P1211 
Unit cell parameters      
a, b, c (Å) 73.61, 143.50, 75.18 75.46, 140.31, 75.50 72.94, 141.30, 74.68 73.43, 138.04, 75.87 
α, β, γ (º) 90, 96.18, 90 90, 96.89, 90 90, 96.28, 90 90, 96.58, 90 
Resolution range (Å) 47.82-2.19 (2.23-2.19) 74.96-2.05 (2.09-2.05) 74.23-2.31 (2.37-2.31) 75.37-2.23 (2.28-2.23) 
Measurements 301997 364904 492196 546860 
Unique reflections 79522 97425 65792 72956 
Redundancy 3.8 (3.8) 3.7 (3.7) 7.5 (7.7) 7.5 (7.5) 
Completeness (%) 99.9 (100.0) 99.9 (99.9) 100.0 (99.9) 99.9 (100.0) 
I/σ (I) 9.3 (1.2) 8.3 (1.82) 18.1 (3.75) 14.6 (2.26) 
Rmerge 0.084 (1.05) 0.109 (0.686) 0.072 (0.499) 0.086 (1.10) 
CC1/2 0.50 0.50 0.92 0.66 
Wilson B value (Å)2 39.81 23.9 37.4 43.2 
Matthews coefficient 2.60 (52.65) 2.61 (52.91) 2.52 (51.15) 2.51 (51.09) 
 
Refinement 
    
Rwork 0.1890 0.1687 0.1938 0.1915 
Rfree 0.2357 0.2120 0.2387 0.2378 
Chain length 351 351 351 351 
Observed number of residues 345 (Chain A&B), 345 
(Chain C&D) 
345 ( Chain A &B), 347 
(Chain C), 344 (chain D) 
346 (In all chains) 345 (Chain C), 348 (Chain 
D), 344 (Chain A), 342 
(Chain B) 
Water molecules 330 778 290 216 
Other  9 (Mn2+, SO4
2-, PEG) 11 (Mn2+, SO4
2-, PEG) 9 (Mn2+, SO4
2-, TMO) 4 (Mn2+) 
Ligand 4 8 4 4 
Mean B (Å)2     
Protein 36.47 28.34 38.37 34.10 
Water 43.82 30.05 38.05 49.51 
Other 67.46 48.77 48.41 60.35 
Ligand 37.13 30.97 (PEP), 20.92 (Phe) 38.11 57.92 
R.m.s.d from target values     
Bond lengths (Å) 0.0095 0.0094 0.0102 0.0092 
Bond angles  1.2712 1.3263 1.3477 1.2624 
Dihedral angles 0.0690 0.0768 0.0758 0.0718 
Ramachandran     
Preferred (%) 97.69 97.25 97.45 97.51 
Allowed (%) 1.73 2.61 1.97 1.90 
Outliers (%)  0.58 0.14 0.58 0.59 
PDB Entry 4UC5 5DCB 5DCD 5DCE 
Table 3.2.3.1 Data collection and refinement statistics for the four ligand-bound structures of NmeDAH7PS.  
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3.2.3.1 Binding modes of Phe, Trp and Tyr at NmeDAH7PS allosteric site 
 
All liganded structures crystallised in a monoclinic space group (P1211), as that of the PEP-
bound NmeDAH7PSWT (PDB code: 4HSN). The Phe, Phe + PEP, Tyr and Trp bound structures 
were refined to resolutions of 2.19, 2.05, 2.31 and 2.23 Å respectively, and all ligands have 
been modelled into their respective structures at full occupancy. 
 
The refined structures all exhibit similar structural characteristics. The RMSD for the alignment 
of all Cα atoms of the tight dimers of the Phe-bound structure (PDB code: 4UC5) with the PEP-
bound structure (PDB code: 4HSN) was 0.583-0.752 Å. This is indicative of very little 
conformational change upon binding of the most potent allosteric effector. The most severely 
affected regions of the enzyme in the presence of Phe are localised to the β2α2 loop, the β3α3 
loop, α3 helix and the β-hairpin insertion (Figure 3.2.3.1.1). The variation seen in these regions 
is consistent throughout all liganded structures.  
 
Figure 3.2.3.1.1. Root mean squared deviation plot of all Cα-atoms per residue of ligand-bound structures of 
NmeDAH7PS illustrating important regions of variation are highlighted by a black double dashed box. Liganded 
structures against PEP-bound structure (PDB code: 4HSN). Trp (red), Tyr (gold), Phe (blue) and Phe + PEP (black) 
 
β2α2 
loop 
β-hairpin 
insertion 
β3α3 
loop & 
α3-helix 
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The Trp- and Tyr-bound structures (PDB code: 5DCD and 5DCE) have very similar structural 
characteristics to the Phe-bound structure. They both show significant variation from the PEP-
bound structure in the same regions (β2α2 loop, the β3α3 loop and the β-hairpin insertion) 
(Figure 3.2.3.1.1). Alignment of the tight dimers of the Tyr-bound structure (PDB code: 5DCD) 
with that of the Phe-bound structure (PDB code 4UC5) yielded an RMSD of 0.220-0.399 Å. This 
result is indicative of very small variation in the presence of Tyr and implies a very similar 
structural reorganisation upon ligand binding to NmeDAH7PS. The Trp bound structure (PDB 
code: 5DCE) shows a slightly greater degree of variation from the Phe-bound structure and 
has an RMSD for the alignment of the tight dimers of 0.460-0.572 Å. This structural variation is 
localised to the aforementioned regions that are most affected in the presence of allosteric 
effector (Figure 3.2.3.1.1 and 3.2.3.1.2). 
 
Figure 3.2.3.1.2. Root mean squared deviation plot all Cα-atoms per residue of ligand-bound structures of 
NmeDAH7PS illustrating important regions of variation are highlighted by a black double dashed box. Liganded 
structures against Phe-bound structure (PDB code: 4UC5). Trp (red), Tyr (gold), and Phe + PEP (black).  
 
Unsurprisingly, the Phe+PEP-bound structure (PDB code: 5DCB) was very similar to the Phe-
bound structure (PDB code: 4UC5) with an RMSD for the alignment of the tight dimers of 
β2α2 
loop 
β3α3 
loop & 
α3-helix 
β-hairpin 
insertion 
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0.237-0.326 Å. However, there are small differences in the positioning of the β7α7, β8α8 loops 
and the α8 helix located towards the C-terminus of the enzyme (res. 260-350). 
    
All three aromatic amino acids adopt a very similar binding mode at the allosteric site of 
NmeDAH7PS. Tyr and Phe are present at full occupancy in the allosteric site of NmeDAH7PS, 
whereas, Trp is present at less than full occupancy. The lower occupancy of Trp is evidenced 
by slightly higher temperature factors for this ligand and N-terminal tail residues compared to 
central residues. The conformations of the side-chains of surrounding residues are nearly 
identical when all ligands are superimposed. The amino-carboxylate moiety of Phe, Trp and 
Tyr are almost identically positioned within the binding pocket, however, the side-chains of 
these ligands interact in a slightly different manner with residues of the binding site. It is likely 
that favourable and unfavourable interactions within the pocket are the driving force behind 
selectivity in NmeDAH7PS (Figure 3.2.3.1.3). 
 
 
The selectivity for aromatic amino acids in NmeDAH7PS likely arises from the largely 
hydrophobic pocket as well as a highly specific and conserved N-terminal extension (allosteric 
binding loop). The residues deep within the pocket interact with the aromatic rings of the 
bound ligands, whereas the residues of the loop and other polar residues interact with the 
amine and carboxylate moiety of the aromatic amino acid (Table 3.2.3.1.1 and Figure 
3.2.3.1.3). 
 
 
Liganded 
structure 
Lig-COO
-
 
Asp9 
backbone 
(NH2) 
Lig-COO
-
 
Ser182 
backbone 
(NH2) 
Lig-NH3
+
 
Asp8 side-
chain 
(C=O) 
Lig-NH3
+ 
Asp9 side-
chain 
(C=O) 
Lig- NH3
+ 
Gln153 
side-chain 
(C=O) 
Lig- π 
Phe211 
side-chain 
(π) 
Lig-Ser213 
side-chain 
(OH)  
Lig-NH3
+
 
to HOH 
Phe 2.9 Å 2.8 Å 3.5 Å 2.8 Å 2.9 Å 3.9 Å 3.2 Å 2.9 Å 
Phe+PEP 2.8 Å 2.8 Å 3.5 Å 2.8 Å 2.9 Å 3.8 Å 3.4 Å 2.7 Å 
Tyr 2.9 Å 2.7 Å 3.7 Å 2.8 Å 2.9 Å 4.1 Å 2.4 Å 2.7 Å 
Trp 2.9 Å 2.8 Å 3.7 Å 2.9 Å 2.8 Å 4.4 Å 3.5 Å N/A 
Table 3.2.3.1.1 Key protein-ligand interactions in the Phe, Tyr, Trp and Phe+PEP-bound structures. Green-more 
favourable interactions between structures. Red- unfavourable interactions. 
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Figure 3.2.3.1.3 Binding modes of the three aromatic amino acids (Phe, Trp and Tyr). Hydrogen bonds are 
indicated in black. Distance of π-interaction with Phe211 indicated in green and an unfavourable interaction 
with Ser213 indicated in red. A) |Fo-Fc| map of the Tyr binding site from chain A of Tyr-bound structure (PDB 
code: 5DCD) contoured at 3σ. B) The Tyr binding site with average interaction distances from all chains 
depicted. C) |Fo-Fc| map of the Phe binding site from chain A of Phe-bound structure (PDB code: 4UC5) 
contoured at 3σ. D) The Phe binding site with average interaction distances from all chains depicted. E) |Fo-Fc|  
map of the Trp binding site from chain A of Phe-bound structure (PDB code: 5DCE) contoured at 3σ. F) The Trp 
binding site with average interaction distances from all chains depicted.  
A 
F E 
D C 
B 
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Residues (4-10) of the N-terminal allosteric binding loop become ordered upon binding of the 
aromatic amino acid. The side-chain of Asp9 forms a hydrogen bond with the amine of the 
bound ligands and the backbone peptide amino group of Asp9 forms a hydrogen bond with 
the carboxylate of the bound ligands. Interestingly, the distance between the amine of the 
bound ligand and the side-chain carboxylate of Asp8 is closer (~0.2 Å) in the Phe-bound 
structure than the Trp and Tyr bound structures and may reflect a tighter interaction of Phe 
with this loop.  
 
Inspection of the interactions of the ligand with residues Phe211 and Ser213, located deep 
within the site, reveals some interesting and noteworthy differences. The recruitment of 
Phe211 and repulsion of Ser213 are believed to be very important for ligand binding and 
allosteric communication.22,26 Comparison of the distance for the edge to face π-interaction 
between Phe211 and the bound ligand reveal some subtle differences between the binding 
modes of the aromatic amino acids at the allosteric site. In the Phe-bound structures, this 
distance is as close as 3.8 Å, whereas, in the Tyr bound structure the distance is 4.2 Å and in 
the Trp bound structure the distance gets as large as 4.5 Å.  
 
Ser213 does not form a hydrogen bond with any of the bound ligands. In the Phe and Trp 
bound structures, the distance between the side-chain hydroxyl group of Ser213 and the 
bound ligand is >3.2 Å. However, in the Tyr bound structure, the hydroxyl group of the Tyr 
bound ligand is ~2.4 Å away from the side-chain hydroxyl of Ser213 (Table 3.2.3.1.1). At this 
close proximity, electrostatic and Van der Waals interactions become repulsive. This is 
consistent with a significant decrease in affinity of the binding site for Tyr and may explain the 
increase in distance from Phe211. Ser213 has been shown to play a crucial role in selectivity 
within the binding site of NmeDAH7PS and this is probably due to the unfavourable 
interaction with the hydroxyl functionality of Tyr.26 The location of residues, Phe211 and 
Ser213 on the β6a sheet at the tight-dimer interface and the interaction between this interface 
and the β2α2 loop means that interactions here may have implications for catalysis.  
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3.2.3.2 Phe, Trp and Tyr cause similar active site reorganisation 
 
The β2α2 loop contains the KPR(T/S) motif, which is important for catalysis and is intimately 
associated with residues of the adjacent monomer across the tight dimer interface.40,42,54,98 
The RMSD plots per residue (Figure 3.2.3.1) indicate that there is a new conformation 
adopted by the β2α2 loop in the presence of the allosteric ligands (Phe, Trp or Tyr) and that 
this new conformation is consistent for all structures containing an allosteric ligand (Figure 
3.2.3.2.1).  
 
Figure 3.2.3.2.1 Overlay of the Phe-, Trp-, Tyr-, Phe + PEP- and PEP-bound NmeDAH7PS structures indicating the 
new conformation of β2α2 loop and the loss of hydrogen bonds upon binding of allosteric effector. PEP-bound 
structure (green), Phe-bound structure (blue), Trp bound structure (red), Tyr bound structure (gold) and 
Phe+PEP-bound structure (grey). Hydrogen bonds broken upon ligand binding are indicated in black.  
 
At the variable concentrations at which these ligands were soaked into the enzyme, the 
structural effect on the β2α2 loop is analogous. This implies that binding affinity is the main 
contributor to the decreased inhibition observed for Tyr and Trp. The new conformation of 
the β2α2 loop is a result of three main structural changes. There is the loss of a hydrogen bond 
between Glu98 and residues, Asp148, Thr151 and Tyr155 of the β3α3 loop and α3 helix. Lys107 
loses hydrogen bonds across the tight dimer interface with His210ʹ and Glu176ʹ. Finally, the 
backbone carbonyl of the absolutely conserved Lys99 no longer forms a hydrogen bond with 
β2α2 loop 
Β6aʹ strand 
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the side-chain of Gln172 from the adjacent chain. These three changes, which are observed 
for all liganded structures contribute to the new conformation of β2α2 loop and may have 
significant implications for catalysis. 
 
3.2.3.3 Flipped binding mode of PEP caused by pre-organised active site 
Previous investigations into the Phe sensitive type Iα DAH7PS enzyme from E. coli indicated 
that PEP adopts a flipped binding mode at the active site in the presence of allosteric ligand 
(PDB code: 1KFL).22 What causes PEP to adopt this flipped binding mode and whether or not it 
adopts this binding mode in the regulated form of NmeDAH7PS remained unclear. A crystal 
structure was subsequently obtained via co-crystallisation of both PEP and Phe with 
NmeDAH7PS. Co-crystallisation of PEP with Tyr and Trp was not attempted due to time 
constraints and the very high concentrations required for ligand binding. The PEP+Phe-bound 
structure (PDB code: 5DCB) was refined to 2.05 Å and showed evidence for both ligands 
bound at full occupancy at their respective sites. Interestingly, like that of the EcoDAH7PS 
structure, PEP adopted a flipped orientation in the active site (Figure 3.2.3.3.1).  
 
Figure 3.2.3.3.1 A) Active site of the Phe+PEP-bound NmeDAH7PS (PDB code: 5DCB), indicating the presence of 
PEP at full occupancy. |Fo-Fc| map contoured at 3 σ. B) Allosteric site of the Phe+PEP-bound NmeDAH7PS (PDB 
code: 5DCB), indicating the presence of Phe at full occupancy. |Fo-Fc| map contoured at 3 σ. 
Comparison of the binding mode in the absence (PDB code: 4HSN) and presence (PDB code: 
5DCB) of Phe indicated some interesting differences. The dihedral angle between the 
carboxylate and the C2=C3 of PEP is significantly reduced in the presence of Phe from 44 ± 2° 
to 15 ± 1° (Figure 3.2.3.3.2). This is hypothesised from ab initio quantum chemistry 
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calculations to reduce the reactivity of the enol moiety of the substrate by reducing the 
charge build-up at C3 of PEP.
99 Interestingly the network of water molecules remains similar 
despite the new binding mode of PEP. However, the nucleophilic water (WAT1) identified 
from previous studies based on its proximity to C2 of PEP or inhibitor has moved.
100 The 
nearest water molecule to C2 of PEP (WAT1) is now located on the si face of PEP in the 
presence of Phe.  
 
Figure 3.2.3.3.2 A) All bonding interactions between PEP and active site from active enzyme (PDB code: 4HSN) 
and the dihedral angle between the carboxylate and the C=C of PEP B) All bonding interactions between PEP 
and active site from Phe-bound enzyme (PDB code: 5DCB) and the dihedral angle between the carboxylate and 
the C=C of PEP. Proposed nucleophilic water(WAT1) indicated by a double lined circle. 
 
The movement of Lys99 in the presence of Phe is conserved for all structures containing an 
allosteric ligand. This new position, adopted by Lys99 is correlated to the new conformation of 
the β2α2 loop and enables the formation of a salt bridge with the metal binding residue, 
Asp324. Another noticeable difference at the active site is the new conformation of Arg167 
from the α4 helix that can no longer form the salt bridge with the phosphate of PEP observed 
in the PEP-bound structure (PDB code: 4HSN) (Figure 3.2.3.3.2). The new conformation of 
these two residues makes the approach of PEP at the active site significantly different and 
may contribute to the new binding mode.  
 
44° 
15° 
A B 
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Comparison of the active site residues responsible for both PEP and E4P binding from the Phe-
bound (PDB code: 4UC5) and Phe+PEP-bound (PDB code: 5DCE) indicate no difference in their 
positioning (Figure 3.2.3.3.3). The similarity between the conformations and positioning of 
side-chains of the active site residues in these two structures regardless of the presence of 
PEP indicates that the active site is pre-organised for PEP binding in its flipped orientation in 
the presence of Phe. 
    
The new conformation of the active site residues also has implications for the other substrate 
E4P. During catalysis, the aldehyde of E4P requires activation as an electrophile for 
nucleophilic attack by the enol moiety of PEP.32,49,51,53,63 In the presence of allosteric ligand, 
the formation of the salt bridge between Lys99, part of the KPR(T/S) motif, and Asp324 
structurally hinders access of the aldehyde of E4P to the divalent metal ion. Furthermore, 
Arg101 from the conserved KPR(T/S) motif located on the β2α2 loop, responsible for binding 
the phosphate of E4P33,63 adopted a different conformation in all allosteric ligand bound 
NmeDAH7PS structures compared to Eco and SceDAH7PS (Figure 3.2.3.3.3). In the Phe-bound 
form of EcoDAH7PS, the equivalent Arg residue forms a salt bridge with Glu96. This has also 
been observed in two out of eight chains of the Tyr-regulated SceDAH7PS structure (PDB 
code: 1OF6). However, in NmeDAH7PS, Arg101 does not interact with Glu98, regardless of the 
presence or absence of PEP at the active site. Instead it adopts a similar conformation to what 
is observed in the PEP-bound structure (PDB code: 4HSN). The reorganisation of the β2α2 loop 
and surrounding residues in NmeDAH7PS may be responsible for this unique conformation of 
Arg101. In particular, the position of Lys107 and its interaction with Gln172 and Glu98 in the 
Phe-bound NmeDAH7PS structures may limit the ability of Arg101 to form a salt bridge with 
Glu98. The variability in conformation Arg from the KPR(T/S) motif may contribute to the 
increased sensitivity of EcoDAH7PS to concentrations of Phe reported previously.101 
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Figure 3.2.3.3.3 Active site of type Iα DAH7PS. PEP-bound NmeDAH7PS, PDB code: 4HSN (green), PEP and Phe-
bound EcoDAH7PS, PDB code: 1KFL (white), Phe-bound NmeDAH7PS, PDB code: 4UC5 (blue), PEP+Phe-bound 
NmeDAH7PS, PDB code: 5DCB (dark grey). A) Overlay of PEP binding site from EcoDAH7PS (PEP+Phe-bound), 
NmeDAH7PS (PEP-bound) and NmeDAH7PS (Phe-bound) illustrating the flipped binding mode of PEP, 
movement of catalytic Lys99 residue and overall structural conservation at the site. B) Overlay of EcoDAH7PS 
(PEP+Phe-bound), NmeDAH7PS (Phe-bound) and NmeDAH7PS (Phe+PEP-bound). Yellow arrow indicates 
channel for PEP binding as Lys99 partially gates the site. Green arrow indicates movement of Arg residue. 
A 
B 
β2α2 loop 
β2α2 loop 
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3.3 DISCUSSION 
An understanding of the molecular details that determine the selectivity of NmeDAH7PS to 
inhibition by the three aromatic amino acids was not well understood. It was found that the 
enzyme is most sensitive to Phe, which was in accordance with previous results, and indicates 
that the other aromatic amino acids have little effect on the enzyme at the likely cellular 
concentrations of these metabolites.97 The ITC experiments revealed a negative cooperative 
mechanism of binding Phe from the fit of a two-site sequential model to the binding isotherm. 
However, Trp and Tyr binding to the enzyme was not detectable by this experimental method, 
even though some inhibition of catalytic activity is observed at high concentrations.  
To aid in the elucidation of mechanism of allosteric inhibition, X-ray crystallographic data with 
these ligands bound at the allosteric site were sought. In these structures Tyr and Trp adopt a 
very similar binding mode to that observed for Phe at the allosteric site of NmeDAH7PS. The 
interactions of residues Asp8, Asp9, Gln153 and Ser182 in with the amino-carboxylate portion 
of the aromatic amino acid are nearly identical for all ligands. However, there are subtle 
differences in the interactions with residues, Phe211 and Ser213 deep within the pocket, 
which may explain the variation in sensitivity observed. The binding of Tyr in the site is 
unfavourable due to a repulsive interaction with the hydroxyl moiety of Ser213. This is 
obviously an important feature, as mutation of this residue to glycine has been shown to 
specifically change selectivity of this site to Tyr, therefore, it is not surprising that it is pivotal 
to ligand selectivity.26 Phe forms the strongest π-interaction with Phe211 at a distance of ~3.8 
Å and Trp forms the weakest interaction (~4.7 Å) and this may correlate to this increased 
affinity of the site for Phe. However, It is difficult to correlate differences in binding mode to 
binding affinity as Trp and Tyr binding cannot be observed by ITC. Therefore, it is uncertain 
whether these structural differences affect binding affinity or allosteric response, as inhibition 
at the same concentrations of aromatic amino acids varies considerably, but this cannot be 
correlated to the binding mode of the respective aromatic amino acid. 
All three aromatic amino acids have the same effect on the structural reorganisation of the 
PEP and E4P (β2α2 loop) binding site, which was shown to adopt the same conformation in the 
presence and absence of PEP. This similarity implies that the PEP binding site is pre-organised 
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for the binding of PEP in its flipped binding mode, regardless of what aromatic amino acid is 
bound at the allosteric site. The formation of a salt bridge between Lys99 and Asp324 may 
contribute to flipped binding mode of PEP.  
The new conformation of this site reduces the reactivity of both substrates. PEP reactivity is 
reduced through a reduction in the dihedral angle between carboxylate and enol 
functionality, thus reducing the accumulation of charge due to sp3 hybridisation at the C3 
position of PEP, ultimately decreasing its ability to act as a nucleophile during catalysis.99. 
Furthermore, the salt bridge blocks the access of E4P to the divalent metal ion, which is crucial 
for activation and catalysis. Remarkably, Arg101, which is responsible for binding the 
phosphate of E4P remains in the same conformation as is seen in the PEP-bound structure. 
This is contrary to what is observed for other type Iα DAH7PSs, where this residue forms a salt 
bridge with the equivalent residue to Glu98 in the presence of allosteric inhibitor. 
As sensitivity to regulation by Phe in NmeDAH7PS is reduced, compared to EcoDAH7PS (~30% 
at 100 µM Phe), perhaps it is not surprising that we see negative cooperativity in the binding 
isotherm of NmeDAH7PS from ITC. Whereby, occupation of one binding site decreases the 
binding affinity at the remaining binding site. Perhaps the increased sensitivity seen in 
EcoDAH7PS is a direct result of the ability to form this salt-bridge. The exact reasons for the 
formation of this salt bridge are difficult to ascertain, but imply that dynamics are very 
important for the conformations adopted by the β2α2 loop. 
The combination of regulatory features of NmeDAH7PS outlined above, make it unique, not 
only compared to other enzymes, but even to other characterised type Iα DAH7PS. This has 
interesting implications for the evolution of allostery in DAH7PS that are specific to the 
cellular environment and genome of the individual organism. 
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CHAPTER 4- IMPORTANCE OF INTERACTIONS AT THE 
TETRAMER INTERFACE OF NMEDAH7PS  
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C H A P T E R  4  P A R T  I - T h e  f u n c t i o n a l  u n i t  o f  
N m e D A H 7 P S  i s  d i m e r i c  
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4.1 INTRODUCTION 
Previous work in this area involved the mutation of a residue (E24Q) involved in a salt bridge 
interaction across the tetramer interface of EcoDAH7PS, yielding a dimeric form of the 
enzyme.31 Unfortunately, there were neither solution state nor functional studies reported for 
this variant from EcoDAH7PS. This residue and salt-bridge interaction is conserved at the 
tetramer interface of NmeDAH7PS and is formed by the interaction between Glu27 and 
Arg126.  
This study involved the construction of an Arg126Ser mutation at the tetramer interface to 
form a dimeric variant of NmeDAH7PS. This was done in order to identify the necessity for 
tetramerisation in NmeDAH7PS. The characterisation of this variant enzyme and comparison 
to NmeDAH7PSWT revealed remarkable similarities upon dimerisation.  
This drafted manuscript has been accepted for publication by PLoS ONE 
Heyes, L. C.*, Cross, P. J.*, Zhang, S.; Nazmi, A. R. & Parker, E. J. The functional unit of 
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synthase; E4P, erythrose 4-phosphate; PEP, phosphoenol pyruvate; Phe, phenylalanine; 
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ABSTRACT 
Neisseria meningitidis 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase 
(NmeDAH7PS) adopts a homotetrameric structure consisting of an extensive and a less 
extensive interface. Perturbation of the less extensive interface through a single mutation of 
a salt bridge (Arg126-Glu27) formed at the tetramer interface of all chains resulted in a 
dimeric DAH7PS in solution, as determined by small angle X-ray scattering, analytical 
ultracentrifugation and analytical size-exclusion chromatography. The dimeric 
NmeDAH7PSR126S variant was shown to be catalytically active in the aldol-like condensation 
reaction between D-erythrose 4-phosphate and phosphoenolpyruvate (PEP), and 
allosterically inhibited by L-phenylalanine (Phe) to the same extent as the wild-type enzyme. 
The dimeric NmeDAH7PSR126S variant exhibited a slight reduction in thermal stability by 
differential scanning calorimetry experiments and a slow loss of activity over time compared 
to the wild-type enzyme. Although NmeDAH7PSR126S crystallised as a tetramer, like the wild-
type enzyme, structural asymmetry at the less extensive interface was observed consistent 
with its destabilisation. The tetrameric association enabled by this Arg126-Glu27 salt-bridge 
appears to contribute solely to the stability of the protein, ultimately revealing that the 
functional unit of NmeDAH7PS is dimeric.     
 
Keywords:  
Allostery, Shikimate pathway, DAHPS, DAH7PS, Quaternary structure 
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INTRODUCTION 
The shikimate pathway is responsible for the biosynthesis of important aromatic 
compounds including the aromatic amino acids phenylalanine (Phe), tyrosine (Tyr) and 
tryptophan (Trp).18 The presence of this pathway in plants, microorganisms and 
apicomplexan parasites and its absence in mammals has drawn attention to the enzymes of 
this pathway as antimicrobial drug design targets 102.  3-Deoxy-D-arabino-heptulosonate 7-
phosphate synthase (DAH7PS) catalyses the first committed step of the shikimate pathway, 
which involves the aldol-like condensation of erythrose 4-phosphate (E4P) and 
phosphoenolpyruvate (PEP) to form 3-deoxy-D-arabino-heptulosonate 7-phosphate 
(DAH7P). Entry into the pathway is controlled by the allosteric regulation of DAH7PS by the 
pathway end products Phe, Tyr and Trp, or other intermediates of the pathway .20 
 
Despite significant sequence diversity, all known DAH7PS enzymes share a common (β/α)8-
barrel core and similar active site architectures formed by conserved residues that support a 
similar catalytic mechanism.35  On the basis of sequence and size, DAH7PS enzymes are 
classified into groups (type Iα, type Iβ and type II).  Each group features distinct structural 
elements appended to the core catalytic barrel that are associated with the allosteric 
inhibition of the enzymes and different quaternary structure associations.20,24,25,28,48,72,103 
The type I groups, type Iα and type Iβ, share approximately 30% identity, and although a 
common dimeric unit is shared between by enzymes of these groups, they form different 
homotetrameric structures.104  
 
The DAH7PS isolated from N. meningitidis (NmeDAH7PS), the causative agent of pyogenic 
meningitis and meningococcal septicaemia, belongs to the type Iα group. This protein 
adopts a homotetrameric assembly, and contains similar structural features to the other 
characterised type Iα DAH7PSs from Saccharomyces cerevisiae and Escherichia coli. S. 
cerevisiae and E. coli both express multiple isozymes of DAH7PS and the catalytic activity of 
each of these isozymes is sensitive to the presence of a different aromatic amino acid, 
however, the genome of N. meningitidis, encodes a single DAH7PS (NmeDAH7PS) which is 
most sensitive towards feedback inhibition by Phe.26 
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A comparison of the structure of the S. cerevisiae and E. coli enzymes with NmeDAH7PS 
reveals that although the single chain and dimeric units are superimposable, the two 
dimeric units that generate the homotetramer are oriented at different angles. The 
homotetrameric NmeDAH7PS comprises two interfaces, the more extensive (tight dimer) 
and the less extensive (tetramer interface) (Fig 1). The tight dimer interface involves 
interactions between 79 residues per chain and buries ~ 2800 Å2 or 18 % of the surface area 
between chains. The tetramer interface is far weaker and consists of 17 residues per chain 
and buries only ~510 Å2 or 3.8 % of the NmeDAH7PS chain. Both of these interfaces are 
comparable to the other structurally characterised type Iα DAH7PS enzymes.22,33 In the 
EcoDAH7PS structure (PDB code: 1QR7) the angle between tight dimers is ~22˚ less than 
that of NmeDAH7PS (PDB code: 4HSN). Conversely, the arrangement of tight dimers in 
SceDAH7PS (PDB code: 1OAB) is ~26˚ greater than that of NmeDAH7PS. This illustrates the 
variability at the tetramer interface between members of the same DAH7PS subfamily. 
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Fig 1. A). Quaternary structure of NmeDAH7PS (PDB code: 4HSN) indicating the tight dimer interface and 
tetramer interface. The core catalytic (β/α)8 barrel is coloured blue and the N-terminal and internal 
extensions are coloured red and yellow, respectively. Manganese metal ion (purple), ligand (PEP) and Glu27-
Arg126 salt bridge (green-sticks) A schematic of secondary structural features of monomeric NmeDAH7PS 
according to residue number, circles denote β-sheets and rectangles denote α-helices  B) Hydrogen bonding 
(red) and salt bridge (blue) interactions identified by analysis of each interface. Top. Tight-dimer. Bottom. 
Tetramer  C) Hydrophobic interactions (green) at each interface of NmeDAH7PS. Top. Tight-dimer. Bottom. 
Tetramer . Chain B, C and D are denoted `, `` and ``` respectively. 
 
 
Herein, we describe the disruption of the quaternary structure of NmeDAH7PS via 
mutagenesis of a single salt bridge at the tetramer interface, generating a dimeric species 
that we show to be the functional unit of NmeDAH7PS. 
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EXPERIMENTAL PROCEDURES 
Bacterial strains, plasmids, media and growth conditions 
 
Wild-type NmeDAH7PS 
Purification procedures and kinetic measurements were performed as previously 
described.26 
 
NmeDAH7PSR126S 
The variant R126S (NmeDAH7PSR126S) was constructed using a Quik Change Lightning 
Mutagenesis Kit using the pT7-7 wild-type plasmid as template. Primers used to introduce 
the mutation were FOR: 5’-CATCAATTTCCGTTTGAGCCAGGAGAGGCAGCCTG-3’ and REV: 5’- 
CAGGCTGCCTCTCCTGGCTCAAACGGAAATTGATG -3’.  The PCR product was transformed into 
Top10 cells.  Plasmids of the expected size, as determined by agarose gel, were DNA 
sequenced to identify those containing the successful mutation and transformed into BL21 
StarTM (DE3) cells.  Expression and purification were carried out as previously described for 
the wild-type enzyme.26 
 
Interface analysis 
Resmap105 and PISA106 were used to analyse and visualise the interfacing residues. Free energy 
calculations for the formation of interfaces were calculated from PISA. 
 
Differential Scanning Calorimetry 
DSC was performed on a NanoDSC (TA instruments). Protein solutions were dialysed in SEC 
buffer (10 mM BTP, pH 7.3, 100mM KCl and 200µM PEP) and the dialysis buffer was used as 
reference. A final protein concentration of 26 μM (1 mg/mL) was used for the DSC 
experiments, and prior to scanning, all solutions were degassed by stirring under vacuum. An 
excess pressure of 3 atm was applied to the cells during scanning. Buffer scans were run prior 
to protein scans. DSC scans were performed using a heating rate of 1 °C/min, and the data 
was analysed using the Nanoanalyze™ software supplied with the instrument. 
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Analytical Size Exclusion Chromatography  
To determine the molecular mass of NmeDAH7P synthase in solution, protein standards of 
known molecular mass were applied to a Superdex S200 column (GE Healthcare). β-Amylase 
(200 kDa), Alcohol dehydrogenase (150 kDa), ovalbumin (75 kDa), conalbumin (66 kDa) and 
carbonic anhydrase (29 kDa) were used as molecular weight standards. 
 
Analytical ultracentrifugation  
Sedimentation velocity experiments were performed in a Beckman Coulter XL-1 analytical 
ultracentrifuge equipped with UV/Vis scanning optics at 20 ⁰C. Reference buffer solution (10 
mM BTP, pH 7.3, 100 mM KCl, 200 µM PEP) and sample solutions were loaded into 12-mm 
double-sector cells with quartz windows, and mounted in an An-50 Ti 8-hole rotor. 
Protein samples at concentrations of 0.2, 0.4 and 1.2 mg/mL were centrifuged at 50,000 g and 
the absorbance data was collected at 277 nm or 276 nm for NmeDAH7PS and 
NmeDAH7PSR126S respectively. Radial scans collected between 5.8 cm and 7.2 cm with 0.003 
cm increments were then analysed with the continuous size distribution model using 
SEDFIT.107  The partial specific volume (v) of the protein samples (0.737734 mL/g), buffer 
density (1.005 g/mL) and buffer viscosity (0.01002 cp) were calculated using the program 
SEDNTERP.108 
 
Small angle X-ray scattering 
SAXS measurements – Measurements were performed at the Australian Synchrotron 
SAXS/WAXS beamline equipped with a Pilatus detector (1M, 170 mm x 170 mm, effective 
pixel size, 172 x 172 μm).  The wavelength of the x-rays was 1.0332 Å.  The sample–detector 
distance was 1600 mm, which provided an q range of 0.01–0.565 Å−1 [where q is the 
magnitude of the scattering vector, which is related to the scattering angle (2θ) and the 
wavelength (λ) as follows: q = (4π/λ) sinθ].   
Data were collected from a 2 mm glass capillary (Hampton Research) and the temperature 
was 25 °C.  Scattering data was collected from wild-type NmeDAH7PS and NmeDAH7PSR126S 
(initial concentration of 7 and 12 mg/mL, respectively, prior to SEC) in the buffer (10 mM BTP, 
pH 7.5, 100 mM KCl, 200 µM PEP).  Scattering from glucose isomerase at an initial 
concentration of 10 mg/ml was collected to calibrate the mass of scattering particles.  Data 
were collected in 2 second intervals.  2D intensity plots from the peak of the SEC run were 
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radially averaged, normalised to sample transmission and background subtracted.  
SAXS data analysis – Scattered intensity (I) was plotted versus q. Extrapolation of the DAH7PS 
I(q) profiles to zero angle [I(0)] and comparison with that of glucose isomerase standards 
indicated a molecular mass consistent with the NmeDAH7PS tetramer or dimer.  All samples 
were devoid of an increase in intensity at low q (increase is indicative of aggregation).  Radius 
of gyration (Rg) did not vary significantly over the concentrations measured, and all Guinier 
plots were linear for q·Rg < 1.3.  The data sets for structural analyses were recorded with 302 
data points over the range 0.0110 ≤ q ≤ 0.4 Å−1.  1D profiles were background subtracted and 
Guinier fits were made using PRIMUS.  Indirect Fourier transform was performed using 
GNOM109 to yield the function P(r), which gives both the relative probabilities of distances 
between scattering centers and the maximum dimension of the scattering particle Dmax. 
Theoretical scattering curves were generated from atomic coordinates and compared with 
experimental scattering curves using CRYSOL.110 
 
Kinetics 
The assay system for NmeDAH7PS was performed as previously described by monitoring the 
disappearance of PEP at 232 nm.26 Standard assay buffer was 50 mM BTP (pH 6.8) containing 
MnSO4 (100 µM) and variable concentrations of substrates PEP and E4P to a final volume of 1 
mL. Assays were carried out at 25 °C. 
 
NmeDAH7PSR126S - The reaction mixtures for the determination of the Km of E4P consisted of 
PEP (126 µM), MnSO4 (100 µM) and E4P (9–140 µM), in 50 mM BTP, pH 6.8 buffer. The 
reaction mixtures for the determination of the Km of PEP consisted of E4P (232 µM) and PEP 
(12–315 µM) in assay buffer. The reaction was initiated by the addition of NmeDAH7PSR126S (2 
µL, 1.3 mg/mL (final concentration-68 nM)).  
 
NmeDAH7PSWT - The reaction mixtures for the determination of the Km of E4P consisted of 
PEP (100 µM) and E4P (10-320 µM), in assay buffer. The reaction mixtures for the 
determination of the Km of PEP consisted of E4P (300 µM) and PEP (5-160 µM) in assay buffer. 
The reaction was initiated by the addition of NmeDAH7PSWT (2 µL, 0.6 mg/mL (final 
concentration-32 nM)).  Apparent Km and kcat values were determined by fitting the data to 
the Michaelis-Menten equation using Grafit (Erithicus). 
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Time dependent loss of activity 
Standard assays were performed which consisted of E4P (230 µM) and PEP (100 µM) in assay 
buffer to a final volume of 1 mL.  Assays were initiated by the addition of 2µl of ~1 mg/mL 
NmeDAH7PSWT or NmeDAH7PSR126S (final concentration-52 nM).  Assays were performed in 
triplicate and averaged at timepoints (0 hr, 2 hr, 4 hr, 6 hr, 18 hr and 24 hr). Both 
NmeDAH7PSWT and NmeDAH7PSR126S were diluted to 1 mg/mL at time 0 hr and kept at ~4 °C 
for the experiment duration. There was no loss of protein after 24 hr at 1 mg/mL calculated 
via absorbance at 280 nm using the calculated molar extinction coefficient of 31650 M-1 cm-1 
post experiment.111 
 
Inhibition 
Standard assays were performed which consisted of E4P (74 µM), PEP (162 µM) and the 
amino acid; Phe, Tyr or Trp (25 µM – 1 mM) in assay buffer.  Assays were were initiated by the 
addition of NmeDAH7PSR126S.  Assays were performed in triplicate. 
 
Isothermal titration calorimetry 
Binding of NmeDAH7PSWT and NmeDAH7PSR126S to Phe at pH 7 was measured by ITC using a 
VP- ITC unit operating at 298 K (Microcal, GE Health- care). Before use, the protein was buffer 
exchanged against binding buffer [0.5 mM MnSO4 in 50 mM BTP buffer (pH 7)] and all 
solutions were degassed in a vacuum. Protein concentration was measured by UV absorption 
immediately before titrations were started. The titrations were comprised of 28 injections, 
one 2 µL injection followed by 27 x 10 µL injections of Phe. The initial datum point was 
routinely deleted to allow for diffusion of ligand across the needle tip during the equilibration 
period. A heat of dilution experiment was measured independently and subtracted from the 
integrated data before curve fitting in Origin 7.0. For the binding of NmeDAH7PS to Phe, 15 
µM of NmeDAH7PSWT and NmeDAH7PSR126S were used and the syringe contained 1.2 mM 
Phe; and the data were fitted with the two-site sequential-binding model supplied by Micro-
Cal. 
 
Crystallisation of NmeDAH7PSR126S  
NmeDAH7PSR126S was expressed and purified as previously described for the wild-type 
enzyme.26 The resulting protein solution was concentrated to approximately 10 mg/ mL. 1 µL 
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of enzyme solution (9–11 mg/mL) was mixed with 1 µL of crystallisation buffer containing 0.1 
M Tris HCl (pH 7.3), 0.2 M trimethyl-amino-N-oxide (TMAO), 600 µM MnSO4 and 15–20 % 
(w/v) PEG 2000MME. Crystals were grown by hanging drop vapour diffusion over 500 µL of 
crystallisation buffer and the crystallisation trays were incubated at 20 ºC. Crystals began to 
form in 48 hours and were fully formed within seven days. Crystals were flash frozen using 
liquid nitrogen in a cryoprotectant solution containing reservoir solution and 20 % (v/v) 
PEG400. 
 
Crystallography and structure determination 
An X-ray diffraction dataset was collected at the Australian Synchrotron using the MX1 
beamline.112 The datasets were integrated and processed using XDS and Aimless.113,114 
Appropriate cut-off resolution was determined via CC1/2≥0.5 ensuring the data was complete 
in the highest resolution shell.115 Space group and unit cell parameters for NmeDAH7PSR126S 
were the same as those previously identified for the wild-type enzyme (PDB code 4HSN26) 
indicating that initial phases could be obtained via molecular replacement using the original 
structure as a search model in Phaser MR.116 All ligands and waters were removed from the 
search model (PDB code 4HSN) before molecular replacement was carried out. Refmac5 was 
used to generate the electron density map and this was manually analysed and refined in 
COOT (Table 1).117–119 The quality of the model was optimised by consecutive model building 
in COOT and refinement with Refmac5. Water molecules were added manually via 
interpretation of the │2Fo-Fc│map ensuring that they had the ability to hydrogen bond to at 
least one acceptor or donor. In all structures, no electron density for the 14 amino acids at the 
N-terminus of each NmeDAH7PSR126S chain could be found, which is attributed to these 
residues being part of a highly flexible allosteric region of the protein. Molprobity was used to 
assess structure quality during refinement cycles and before deposition.120 
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Table 1. Data collection and refinement statistics of NmeDAH7PS
R126S
 variant (PDB code: 4UCG)  
 NmeDAH7PS
R126S 
Data Collection  
Crystal system; space group Orthorhombic, P212121 
Unit cell parameters   
a, b, c (Å) 78.95, 132.7, 147.7 
α, β, γ (º) 90, 90, 90 
Resolution range (Å) 48.03-2.00 (2.03-2.00) 
Measurements 1558648 
Unique reflections 105375 
Redundancy 14.8 
Completeness (%) 100.0 (99.9) 
I/σ (I) 15.2 (1.5) 
Rmerge 0.152 
CC1/2 0.564 
Wilson B-value (Å)
2
 28.94 
Matthews coefficient 2.54 
Refinement  
Rfactor 0.1801 
Rfree 0.2200 
Chain length 351 
Observed number of residues 334 (Chain B & D), 335 (Chain C), 336 (Chain A) 
Water molecules 821 
Other (PEG’s, Mn, SO4
-
) 10 
Ligand 4 
Mean B (Å)
2
  
Protein 35.02 
Water 40.5 
Other 55.6 
Ligand (PEP) 29.63 at 0.75 occupancy 
r.m.s.d from target values  
Bond lengths (Å) 0.0100 
Bond angles  1.3466 
Dihedral angles 0.0749 
Ramachandran  
Preferred (%) 97.55 
Allowed (%) 1.84 
Outliers (%) 0.61 
PDB Entry 4UCG 
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RESULTS 
Interface analysis of interface and choice of mutation site 
The minor interface through which the tetramer is formed comprises primarily hydrophilic 
interactions, in contrast to the extensive hydrophobic interactions that contribute to the 
tight dimer interface (Fig 1).  Of note is the single salt bridge between Arg126 and Glu27 
from opposing tight dimers, which may play a role in determining the twist between tight 
dimers (Fig 1). E. coli DAH7PS shares a similar tetramer interface to that of NmeDAH7PS, and 
contains the same Glu-Arg salt-bridge. This salt bridge is not observed for S. cerevisiae 
DAH7PS, whose tetramer interface consists solely of hydrophobic interactions between four 
residues from each chain.  This salt bridge was disrupted by substitution of Arg126 to a 
serine residue and this change was chosen to maintain the hydrophilicity of the protein 
surface. 
 
The variant protein NmeDAH7PSR126S was created using site directed mutagenesis and 
purified following the protocol developed for the wild-type protein (NmeDAH7PSWT). 
NmeDAH7PSR126S had an expected mass of 77,300 Da, and showed similar thermal stability 
properties to the wild-type protein, with a melting temperature measured by differential 
scanning calorimetery of 47 ˚C (NmeDAH7PSWT displayed a melting temperature of 49˚C) (S1 
Fig). 
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NmeDAH7PSR126S is dimeric in solution 
Analysis of the quaternary structure assembly of the NmeDAH7PSWT and NmeDAH7PSR126S 
enzymes was carried out using both analytical size-exclusion chromatography (SEC) and 
analytical ultracentrifugation (AUC). SEC analysis revealed a clear difference in the solution 
behaviour of the two enzymes (Fig 2A).  The wild-type protein gave a clear symmetrical peak 
shape corresponding to a mass of 150 kDa.  Based on the theoretical molecular weight of a 
single wild type enzyme chain (38.7 kDa), this observation is consistent with a 
homotetrameric protein. Conversely, for NmeDAH7PSR126S variant no tetrameric species was 
observed.  An asymmetrical peak corresponding to a mass of ~66 kDa is consistent with the 
presence of a dimer under the conditions used for analysis. The same profile for each 
enzyme was observed when the samples were prepared for analysis and left at room 
temperature for 18 hours, indicating that the two enzymes observed form stable quaternary 
forms. 
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Fig 2. (A) Analytical SEC traces  of  NmeDAH7PS
WT
 and NmeDAH7PS
R126S 
at two different concentrations. 
NmeDAH7PS
WT
 1 mg/mL (red) and 0.2 mg/mL (orange). NmeDAH7PS
R126S
 1 mg/mL (blue) and 0.2 mg/mL 
(light blue). B. Calculated sedimentation coefficient c(s) distribution plot of wild-type NmeDAH7PS (top) and 
NmeDAH7PS
R126S
 (bottom). For both enzymes, the distribution of species for three different concentrations 
are shown: 0.2 mg/mL (red), 0.4 mg/mL (green) and 1.2 mg/mL (blue). The sedimentation velocity data, fit 
data and residuals from the fits are shown in the supplementary material (S2 Fig). 
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Sedimentation velocity experiments were carried out on NmeDAH7PSWT and 
NmeDAH7PSR126S enzymes. The absorbance versus radial position data for the 
NmeDAH7PSWT and NmeDAH7PSR126S variant are shown in Fig 2B. Fitting the data for 
NmeDAH7PSWT to a continuous size distribution model indicates the presence of a major 
species with a standardised sedimentation coefficient of 8.1 S (Fig 2B). The calculated mass 
of this species is 141 kDa, which is consistent with the expected mass of a homotetrameric 
species (theoretical mass of 154.6 kDa). For NmeDAH7PSR126S, the fit indicated the presence 
of a major species with a standardised sedimentation coefficient of 5.7 S (Fig 2B). This 
predominant species has a calculated mass of 69 kDa, consistent with the expected 
molecular weight of the homodimeric assembly (77.3 kDa). At all three concentrations 
measured (0.4, 0.8, 1.2 mg/mL), a minor species with a sedimentation coefficient of 3.7 S, 
corresponding to an expected molecular weight of 36 kDa was observed, which is consistent 
with the molecular weight of monomeric NmeDAH7PS (38.7 kDa).  
 
Small-angle X-ray scattering (SAXS) was employed to confirm the quaternary structure of 
NmeDAH7PS R126S in solution.  The scattering profile collected for the NmeDAH7PSR126S 
variant was compared to that collected for the wild-type enzyme (Fig 3, Table 2)).  The 
difference between the scattering intensities at low angles is indicative of a change in 
molecular weight and suggests these two enzymes adopt distinct oligomeric assemblies.  
The radius of gyration (Rg) calculated from the scattering pattern of NmeDAH7PS
R126S variant 
using the indirect Fourier transform function, (P(r)), was ~ 26 Å and the maximum diameter 
of the scattering particle, Dmax, was calculated as ~ 95 Å using GNOM.
109  These values are in 
close agreement with the tight-dimer generated from the NmeDAH7PSR126S crystal structure 
(Rg of ~ 25 Å and Dmax of ~ 86 Å).  Similarly, CRYSOL
110 was used to directly compare the 
collected data to the hypothetical scattering from the NmeDAH7PSR126S tetramer and dimer 
generated from the crystal structure.  These data clearly show the NmeDAH7PSR126S variant 
adopts a dimeric structure in solution comparable to that of the NmeDAH7PSR126S tight-
dimer (Fig 3B).  
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Table 2: SAXS parameters for NmeDAH7PS
WT
 and NmeDAH7PS
R126S
 variant. 
Structural parameters NmeDAH7PSWT NmeDAH7PSR126S 
Rg (Å)[from P(r)] 38 ± 1 27 ± 1 
Rg (Å)[Guinier] 37 ± 1 27 ± 1 
Dmax (Å)[from P(r)] 110 ± 5 95 ± 5 
I(0) (cm
-1
)[from Guinier] 0.113 ± 0.01 0.090 ± 0.01 
Hydrated volume (Da
3
) [from P(r)] 224,000 ± 230 110,900 ± 110 
Theoretical volume (Da
3
)[from CRYSOL] 222,900 101,300  
 
 
Fig 3. SAXS scattering profiles collected for NmeDAH7PS
WT
 and NmeDAH7PS
R126S
.  (A) Overlay of the 
scattering data of NmeDAH7PS
WT
 (closed circles) and NmeDAH7PS
R126S
 variant (open circles) and (B) CRYSOL 
fits of the NmeDAH7PS
R126S
 variant data to the theoretical scattering data generated from the R126S 
tetramer (dotted line) and tight-dimer (dashed line).  The discrepancies of the fit of the theoretical scattering 
of tetrameric and dimeric forms to the experimentally determined data (χ) were calculated as 22.80 and 0.67 
respectively.  
 
NmeDAH7PSR126S is active 
NmeDAH7PSR126S was observed to be catalytically active with parameters that are 
comparable with those of the wild-type enzyme (Table 3). The apparent Km
PEP
 of 
NmeDAH7PSR126S is 25 µM, which is similar to that observed for the wild-type enzyme (15 
µM). The NmeDAH7PSR126S displays a lower Km
E4P (13.4 µM) than the wild-type enzyme (37 
µM). However, there is a noticeable decrease in specific activity for the dimeric variant. This 
implies that tetramerisation may have some influence on catalysis by NmeDAH7PS. 
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Table 3. Kinetic parameters of NmeDAH7PS WT and NmeDAH7PS
R126S 
.  
Organism Km(PEP) (µM) Km(E4P) (µM) kcat (s
-1) kcat/Km(PEP) kcat/Km(E4P) 
NmeDAH7PSWT 15 ± 1 37 ± 2 27.1 ± 0.1 1.8 0.7 
NmeDAH7PSR126S 25 ± 1 13.4 ± 0.3 12.6 ± 0.1 0.5 0.9 
Apparent Km values were determined at high concentrations of the second substrate. 
 
NmeDAH7PSR126S shows time-dependent loss of activity 
Comparison of stability of NmeDAH7PSWT and the NmeDAH7PSR126S was carried out by 
measuring the activity of the enzymes over a 24 hour period.  NmeDAH7PSWT lost ~10% 
catalytic activity, whereas the dimeric variant was far less stable and was observed to retain 
less than 60% of its activity after 24 hours (Fig 4).   
 
Fig 4. Catalytic activity of NmeDAH7PS
R126S
 (blue) NmeDAH7PS
WT
 (red) over 24 hour time period relative to 
maximum activity observed for each enzyme at the beginning of the experiment.  
 
NmeDAH7PSR126S binds and is inhibited by Phe 
As for the wild-type enzyme, NmeDAH7PSR126S is inhibited to the largest extent by Phe and to 
a lesser extent by Tyr and Trp (Fig 5A). Isothermal titration calorimetry experiments were 
employed to illustrate that the affinity of the dimeric enzyme for Phe, was not altered upon 
mutation (Fig 5B). For NmeDAH7PSR126S cooperativity was observed in the binding isotherm. 
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The data were fitted to a two-site sequential model giving KD values for NmeDAH7PS
R216S of 
1.2 ± 0.7 µM for the first binding event and 33 ± 3 µM for the second binding event. This 
indicates similar Phe binding characteristics to those observed for NmeDAH7PSWT 26. 
 
 
 
Fig 5. A. Effect of the aromatic amino acids, Phe (black), Tyr (red) and Trp (blue) on the catalytic activity of  
NmeDAH7PS
R126S
 (open circles) in comparison to data previously reported for the wild-type enzyme (closed 
circles).
26
 B. Isothermal titration calorimetry binding isotherm for NmeDAH7PS
R126S
 fit to a two-site 
sequential binding model. 
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NmeDAH7PSR126S crystallises as a tetramer 
The crystal structure of the NmeDAH7PSR126S variant was determined by X-ray diffraction. This 
structure was refined to a resolution of 2.0 Å and crystallised in an orthorhombic space group 
(P212121). Data collection and refinement statistics are shown in table 1. This space group is 
different to NmeDAH7PSWT (PDB code 4HSN), which crystallised in the monoclinic (P1211) 
space group.26  
 
The asymmetric unit for NmeDAH7PSR126S structure (PDB code: 4UCG) contains four chains 
interacting to provide a homotetramer, resembling the arrangement of wild-type 
NmeDAH7PS. Like the wild-type enzyme, the NmeDAH7PSR126S tetramer has two distinct 
interfaces between the chains.  The tight dimer interface remains extensive, burying 14% of 
the surface area of the monomeric unit, but is smaller than NmeDAH7PSWT (18%). The 
tetramer interface, on which the R126S substitution is located, is far smaller, burying 3.8% of 
the surface of the monomeric unit in NmeDAH7PSWT and this is reduced to 3.4% for the 
NmeDAH7PSR126S.  Superposition of the NmeDAH7PSR126S homotetramer on the 
NmeDAH7PSWT protein yields an RMSD of 0.61 Å (1328 Cα atoms), whereas superposition of 
NmeDAH7PSR126S dimeric units on those of the wild-type protein gives RMSD values between 
0.18-0.25 Å.  These values are consistent with the small decrease in rotation of ~2˚of the 
dimeric units with respect to each other at the tetramer interface, and this change may also 
account for the difference in space group between the NmeDAH7PSR126S and NmeDAH7PSWT 
structures. 
 
According to PISA server calculations106, the NmeDAH7PSR126S crystal structure displays a 
theoretical solvation free energy gain (ΔG) for the formation of the tight dimer interface of -
16.1 and -16.5 kcal/mol, correlating to the chain A-chain B and chain B-chain D interfaces 
respectively106. This value is less that what is observed for the NmeDAH7PSWT enzyme, where 
the ΔG values are -20.1 kcal/mol and -18.1 kcal/mol. The lower values are indicative of a 
weakening of the tight dimer interface in NmeDAH7PSR126S.  
 
The ΔG for formation of the tetramer interface in NmeDAH7PSR126S are -6.5 and -9.1 kcal/mol 
for the chain A-chain C and chain B-chain D interfaces respectively (interface interactions are 
shown in S3 Fig, supplementary material). Comparison of this with the ΔG for formation of the 
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tetramer interface in NmeDAH7PSWT of -6.9 and -7.0 kcal.mol, provides interesting insight into 
the structural asymmetry at the tetramer interface in NmeDAH7PSR126S. The structural 
asymmetry observed in the crystal structure of NmeDAH7PSR126S may contribute to the in-
solution dimerisation of this variant. This directly implicates the Arg126-Glu27 salt bridge in 
the formation of a symmetrical tetramer interface in NmeDAH7PSWT. Comparison of the 
surrounding residues in the crystal structure of NmeDAH7PSR126S with that of NmeDAH7PSWT 
illustrates this structural asymmetry. Tyr26, adjacent to Glu27, adopts a new, or alternate 
conformation in three of the four chains and in this new conformation, it forms a hydrogen 
bond with the backbone amine of Glu17. This position was previously occupied by a water 
molecule in the NmeDAH7PSWT structure (Fig 6). Furthermore, His219, located at the centre of 
the tetramer, adopts several alternative conformations in the NmeDAH7PSR126S structure as a 
result of this asymmetry.   
 
 
Fig 6. Tetramer interface of NmeDAH7PS
WT 
(green) (PDB code:4HSN) and NmeDAH7PS
R126S
 (cyan) indicating the 
variable positioning of Tyr26 in place of the conserved water molecule from the NmeDAH7PS
WT
. The loss of salt 
bridge between Glu27 and Arg126 for the NmeDAH7PS
R126S
 variant is also illustrated. 
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DISCUSSION 
A key feature of proteins is their tendency to form multimeric structures, usually homomers 
with even numbers of subunits all derived from the same gene, generating symmetry related 
interfaces, resulting in a functional biological assembly.75 The DAH7PS family of proteins 
adopts a variety of homotetrameric forms, and like many other homotetramers, these 
tetramers are dihedral in nature and comprise dimers of dimers.  Whereas the type Iα 
proteins share a common dimer subunit with the type Iβ group, they have a unique, small 
tetramer interface.  
  
A single residue exchange in the small tetramer interface resulted in a solution- state dimer.  
The presence of this dimer and the absence of tetramer were confirmed by three 
independent solution-state techniques.  The SAXS measurements also confirm that, as 
expected, the dimeric form adopts the assembly of the dimeric assembly of the parent 
protein. In contrast to these-solution state measurements, the protein crystallises as a 
tetramer.  Some minor disruption and asymmetry has been introduced by the substitution 
indicating that this interface may be less stable.  It should be noted that the dimeric form was 
observed by SAXS measurements even at relatively high concentrations, suggesting the crystal 
packing and crystallisation conditions favour the tetrameric form.  Similar observations have 
been made with other related systems.  The equivalent salt bridge of the E. coli Phe sensitive 
enzyme was disrupted by the mutation of Glu24 to Gln.  This also resulted in a tetrameric 
crystalline form, however the enzyme was reported to be dimeric in solution, although no 
functional studies of this protein were provided.31 Likewise, the tetrameric type Iβ enzyme 
from Pyrococcus furiosus has also been disrupted by mutation to form a mixture of dimeric 
and tetrameric forms in solution.104  In this case the protein also crystallised as the tetramer. 
The dimeric NmeDAH7PS retained its catalytic and allosteric properties.  Catalysis was 
observed and both Phe binding and response was measured, revealing that the primary 
functional unit can be considered to be dimeric.  The tetrameric form appears to provide 
advantage by a boost in catalytic rate and increased protein stability; the NmeDAH7PSR126S 
enzyme lost significantly more catalytic activity over a long period than the wild-type 
tetrameric protein, and this instability may contribute to the reduction in kcat. Once again 
parallels can be drawn here from the studies with the P. furiosus DAH7PS.  The thermal 
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stability of this protein, derived from a hyperthermophilic source, was significantly reduced by 
disruption of the tetramer .104 
 
These studies may help shed light on the common evolution and evolutionary divergence of 
the DAH7PS proteins into the different classes. There is some evidence that dihedral 
homotetramers become established through the interaction of symmetrical dimers for which 
the largest interface is included. It has been shown that the symmetrical nature of the 
tetramer interface in NmeDAH7PS may be a contributing factor to tetramerisation. It is 
becoming increasingly clear is that both type Iα and type Iβ DAH7PS proteins are functional 
through a similar dimeric structure.  Type Iα proteins differ in the extent of this interface, as 
the allosteric machinery including an N-terminal extension and a β-hairpin contributes to the 
interactions that form the extensive dimer interface and provide the binding site for Phe.  
Furthermore, it is notable that the binding of Phe to both the tetrameric and dimeric forms of 
NmeDAH7PS is inhibitory and follows a two-site sequential model suggesting that both the 
allosteric and catalytic function can be provided by the dimeric unit. 
 
This investigation clearly illustrates the importance of a single salt-bridge at tetramer interface 
of NmeDAH7PS and has implications for the evolution of quaternary structure in this family of 
enzymes. 
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C H A P T E R  4  P A R T  I I - T h e  r o l e  o f  t h e  c e n t r a l  
h i s t i d i n e s  
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4.2 INTRODUCTION 
Of the twenty natural amino acids, histidine (His) is the most versatile. It can form π-π 
stacking, cation-π and hydrogen-π interactions with His as well as other aromatic amino acids. 
Furthermore, it also plays a major role in the coordination of metal ions. In proteins, the pKa of 
His has a very broad range, meaning that it can play the role of both donor and acceptor.121 
 
The Arg126-Glu27 salt bridge across the Chain A-C and Chain B-D interface has been shown to 
be critical to the solution state tetrameric structure of NmeDAH7PS. However, there is one 
interaction across the diagonal interface of the NmeDAH7PS (Figure 4.2.1). The area of 
contact between chains A and D (B and C) is limited to ~30 Å2 (~0.2% of solvent-accessible 
area of the single chain). This consists of a π-stacking interaction at a distance of ~3.6 Å 
between the imidazole rings of His219, located on the loop connecting the β6a and β6b strands 
of the β-hairpin insertion. The four His219 residues at the intersections of the two-fold axis 
are intriguing and contribute to the interaction between the two tight dimers. They may also 
have an important role in the twist of the tight dimers relative to one another at the tetramer 
interface. In addition, there is also a shared proton forming a hydrogen bond between the Nε 
atoms of the His219 residues of chains A and C (B and D). The four histidines that make up this 
interaction in NmeDAH7PS are conserved for the Phe sensitive isozyme of EcoDAH7PS and 
show very similar characteristics.50 The location of these histidines has recently been 
hypothesised as a possible novel allosteric site for EcoDAH7PS.122 
 
However, in the presence of allosteric or active site inhibitor, one or both of these π-stacking 
interactions are lost. In the crystal structures containing the inhibited form of DAH7PS (PDB 
code: 4UC5, 4UMA, 4UMB, 4UMC) the central histidine residues (Figure 4.2.1) adopt several 
conformations implying an increase in the flexibility of these residues and a change in the 
association between the tight dimers at the tetramer interface.100  
 
  - 88 - 
 
 
Figure 4.2.1 NmeDAH7PS
WT
 tetramer indicating the superposition of the E-vinyl phosphonate bound (PDB code: 
4UMA) (magenta), Phe-bound (PDB code: 4UC5) and PEP-bound (PDB code: 4HSN) (green) illustrating the 
multiple rotamer positions that His219 adopts when an inhibitor is bound at either site. The two-fold axes 
interaction is depicted with double headed arrows. 
 
There is unexplained electron density in the |Fo-Fc| maps for the region including these 
residues when the enzyme is in its inhibited state (PDB code: 4UC5 and 4UMA). This is in 
accordance with the ability of a molecule, ligand or metal ion to bind here. In the Phe-bound 
crystal structure a single sulphate molecule has been modelled into the |Fo-Fc| maps, 
however, when the enzyme has an active-site inhibitor bound such as the E-vinyl 
phosphonate, the residues either coordinate a molecule, metal ion, ligand or adopt several 
conformations (Figure 4.2.2).  
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It has been shown that upon disruption of the tetramer, NmeDAH7PS does not experience 
any major functional changes. However, the calculated theoretical solvation free energy gain 
for the formation of the tight dimer interface was reduced in the dimeric variant. Mutation of 
the only interaction across the diagonal interface of the tetramer may illustrate the 
importance of tetramer formation in NmeDAH7PS and the importance of the dihedral angle 
between tight dimers. This alteration may have an effect on the ability of the allosteric binding 
loop to close as there is a hydrogen bond formed between Glu17, the backbone carbonyl of 
Leu18 and the sidechain N of His219 in the Phe-bound structure (PDB code: 4UC5). It may also 
have a direct effect on the interactions at the interface as the allosteric modifications of 
NmeDAH7PS (N-terminal extension-Glu17, Leu18 and the β-hairpin insertion-His219) are 
crucial for the formation of both the tight dimer and tetramer interfaces. The interaction of 
the β-hairpin insertion with the catalytic β2α2 loop observed in the PEP-bound NmeDAH7PS 
structure (PDB code: 4HSN) may implicate this residue (also present in the Phe sensitive 
isozyme from EcoDAH7PS) in catalysis as well as the conferral of regulation in NmeDAH7PS. 
 
 
Figure 4.2.2 |Fo-Fc| maps of the four His219 residues. A) Phe-bound crystal structure (PDB code: 4UC5) 
indicating the modelling of a sulphate molecule into the position between the flexible residues. B) E-vinyl 
phosphonate crystal structure (PDB code: 4UMA) indicating the unmodelled |Fo-Fc| electron density at the 
centre of the histidine residues and the coordinating geometry undertaken by each His219 
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4.3 RESULTS 
4.3.1 Kinetics and inhibition of NmeDAH7PSHis219Ala variant 
 
The kinetic parameters of the NmeDAH7PSHis219Ala variant enzymes were determined under 
the conditions stated for NmeDAH7PSWT (section 7.1.27). 
 
  PEP K
M 
(µM) E4P KM (µM) kcat (s
-1
) kcat/KM (PEP) kcat/KM (E4P) 
NmeDAH7PSHis219Ala
 
17 ± 1 24 ± 2 8.9 ± 0.1 0.5 0.4 
NmeDAH7PSWT 15 ± 1 37 ± 2 27.1 ± 0.2 1.8 0.7 
Table 4.3.1.1 Kinetic parameters of NmeDAH7PS
His219Ala
 variant enzyme  
 
The kinetic characterisation of NmeDAH7PSHis219Ala indicates that the mutation does not have a 
large effect on the kinetic parameters for this enzyme. The KM for PEP remains constant and 
the KM for E4P is slightly less than that of the NmeDAH7PS
WT. However, the kcat is reduced 
compared to NmeDAH7PSWT (Table 4.3.1.1). 
 
The inhibitory effect of Phe on the NmeDAH7PSHis219Ala variant is very similar to that observed 
for the NmeDAH7PSWT enzyme at all concentrations of Phe tested (Figure 4.3.1.1). This result 
implies that the communication of allosteric signal to the active site is not mediated in any 
way by this residue.  
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Figure 4.3.1.1 Inhibition studies of NmeDAH7PS
His219Ala
 in the presence of varying concentrations of allosteric 
effector, Phe. NmeDAH7PS
His219Ala
 (blue) and NmeDAH7PS
WT 
(green)  
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4.3.2 Isothermal titration Calorimetry 
 
Isothermal titration calorimetry (ITC) experiments were employed to assess if substitution of 
His219 has an effect on the binding of the allosteric inhibitor, Phe. It is evident that the 
binding isotherm can be fit to a two-site sequential binding model, which is the same as 
NmeDAH7PSWT. However, the affinity of Phe for both sites has decreased. The KD for binding 
at the first site of this variant enzyme is 4 ± 1 µM which indicates similar affinity to the 
NmeDAH7PSWT. The second binding event is weaker than the first; following the same trend 
as NmeDAH7PSWT, with a KD of 32 ± 2 µM (Figure 4.3.2.1C).  
Figure 4.3.2.1 A) Raw data from ITC experiment involving the titration of 1.2 mM Phe into 20µM 
NmeDAH7PS
His219Ala
 variant, illustrating fit to the two-site sequential binding model. B) Comparison of the 
thermodynamic parameters for binding at both sites NmeDAH7PS
WT
 (blue) and NmeDAH7PS
His219Ala
 (dark 
green). C) Comparison of dissociation constant (KD) at both sites of the sequential binding model, 
NmeDAH7PS
WT
 (blue) and NmeDAH7PS
His219Ala
 (dark green). 
This binding isotherm is similar to the NmeDAH7PSWT in that the binding at the first site 
decreases the affinity at the second site, which is in agreement with the negative 
cooperativity identified previously for this NmeDAH7PSWT. However, inspection of the 
thermodynamic parameters indicates that binding of Phe at the second site is entropically 
A 
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unfavourable in the NmeDAH7PSHis219Ala variant and this may contribute to the greater KD for 
Phe binding at the second site compared to NmeDAH7PS (Figure 4.3.2.1B).  
 
4.3.3 Analytical size exclusion chromatography 
 
Analysis of the quaternary structural assembly of the enzyme NmeDAH7PSHis219Ala and 
NmeDAH7PSWT was carried out by analytical size exclusion chromatography (SEC). The 
NmeDAH7PSHis219Ala variant eluted at a similar volume to NmeDAH7PSWT, indicating, that it 
adopts the same tetrameric structure in solution (Figure 4.3.3.1). 
 
Figure 4.3.3.1 Analytical size exclusion chromatography, indicating the similarity on quaternary structure 
between NmeDAH7PS
His219Ala
 (dark green) and NmeDAH7PS
WT
 (blue) at 0.7 mg/mL. 
 
 
4.3.4 Crystallography 
 
Two crystal structures of the NmeDAH7PSHis219Ala variant were determined by X-ray diffraction. 
The apo structure was refined to a resolution of 2.21 Å and crystallised in the same space 
group as NmeDAH7PSWT (P1211) (PDB code: 4HSN). The Phe-bound structure crystallised in 
the same monoclinic space group and was refined to a resolution of 2.00 Å. The asymmetric 
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unit for both NmeDAH7PSHis219Ala structures contains a homotetramer made up of two tight 
dimers. Data collection and refinement statistics are shown in Table 4.3.4.1. 
 
Crystal structures of the NmeDAH7PSHis219Ala variant in the presence and absence of Phe 
indicate that the enzymes structure is very similar to the NmeDAH7PSWT. RMSD plots per 
residue indicate that the tight dimer remains largely unaffected by the His to Ala substitution 
and does not show any regions of significant variation (Figure 4.3.4.1).  
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Figure 4.3.4.1 A) RMSD plot per residue between the PEP-bound NmeDAH7PS
WT
 structure (PDB code: 4HSN) 
and the apo NmeDAH7PS
His219Ala
. B) RMSD plot per residue between the Phe-bound NmeDAH7PS
WT
 structure 
(PDB code: 4UC5) and the Phe-bound NmeDAH7PS
His219Ala 
 
Alignment of the whole structures indicates that comparison of the tetrameric unit of the apo 
form of NmeDAH7PSHis219Ala to the PEP-bound NmeDAH7PSWT (PDB code: 4HSN) yielded an 
RMSD for the alignment of 1252 Cα atoms of 0.349 Å. Comparison of the Phe-bound 
NmeDAH7PSHis219Ala to the Phe-bound NmeDAH7PSWT (PDB code: 4UC5) yielded an RMSD for 
the alignment of 1368 Cα atoms of 0.260 Å. Inspection of the |Fo-Fc| map for the Phe ligand as 
well as the temperature factors indicate that Phe is present in the allosteric site at full 
occupancy.  This indicates that the substitution of these central histidines has minimal effect 
on the structure of NmeDAH7PS and its allosteric binding site (Figure 4.3.4.2). There is no 
variation in the dihedral angle between tight dimers in the NmeDAH7PSHis219Ala variant 
compared to the NmeDAH7PSWT, indicating that the interface interactions are conserved in 
this variant. However, the similarity observed for this structure may arise from the network of 
water molecules located at the tetramer interface in both variant structures in the absence of 
these residues (Figure 4.3.4.2). 
 
A B 
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Figure 4.3.4.2 Occupation of the central region of the tetramer by a network of water molecules upon removal 
of Hi219 side-chain. A) |2Fo-Fc| map contoured at 1 σ comparing the PEP-bound NmeDAH7PS
His219Ala 
variant to 
the PEP-bound NmeDAH7PS
WT 
structure (PDB code: 4HSN) B) |2Fo-Fc| map contoured at 1 σ comparing the Phe-
bound NmeDAH7PS
His219Ala 
variant to the Phe-bound NmeDAH7PS
WT 
structure (PDB code: 4UC5). C) Network of 
water molecules interacting with residues Glu17 and Leu18 of the N-terminal binding loop in the Phe-bound 
NmeDAH7PS
His219Ala 
structure. D) |Fo-Fc| map contoured at 3 σ indicating presence of Phe at the allosteric site at 
full occupancy. 
 
Superimposition of the tetramer for NmeDAH7PSHis219Ala and NmeDAH7PSWT for both the Phe-
bound and PEP-bound structures, indicates that the mutation does not have much of an effect 
on the substituted residue. The position of Cα residue 219 remains in the same position. This 
implies that interactions at the tetramer interface are not dependent on this residue in the 
crystalline form. This could however be due to the replacement of His219 by a network of 
water molecules upon mutation to alanine that do not exist in either PEP- or Phe-bound 
NmeDAH7PSWT structures. In the presence of Phe, when His219 adopts its secondary 
conformation, it forms a hydrogen bond with Glu17 and the backbone carbonyl of Leu18. The 
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water molecules present instead of His219 in the Phe-bound NmeDAH7PSHis219Ala variant 
crystal structure may contribute to the closure of the allosteric binding loop when Phe binds 
at the allosteric site. This may be due to the ability of these water molecules to mimic certain 
characteristics of the His219 residue by forming hydrogen bonds with Glu17 and Leu18 of the 
N-terminal extension. 
 
NmeDAH7PS
His219Ala
   
 L-Phenylalanine PEP 
Data Collection   
Crystal system; space group Monoclinic, P1211 Monoclinic, P1211 
Unit cell parameters    
a, b, c (Å) 73.45, 142.12, 74.92 73.72, 134.10, 76.13 
α, β, γ (º) 90, 96.58, 90 90, 96.88, 90 
Resolution range (Å) 74.43-2.00 (2.03-2.00) 75.58-2.21 (2.26-2.21) 
Measurements 755228 579636 
Unique reflections 101790 75734 
Redundancy 7.4 (6.6) 7.7 (7.6) 
Completeness (%) 99.1 (95.9) 100.0 (100) 
I/σ (I) 15.2 (2.2) 19.1 (3.0) 
Rmerge 0.091 (0.813) 0.088 (0.700) 
CC1/2 0.710 0.779 
Wilson B value (Å)2 22.19 32.16 
Matthews coefficient 2.55 (51.77) 2.54 (51.65) 
 
Refinement 
  
Rwork 0.2041 0.1910 
Rfree 0.2543 0.2437 
Chain length 351 351 
Observed number of residues 345 (Chain A, B & C) 347 (Chain A) 334 (Chain A), 332 (Chains B & 
D), 330 (Chain C) 
Water molecules 730 384 
Other 8 (Mn2+, SO4
2-, Cl-) 8 (Mn2+, SO4
2-, EDO, PEG, Cl-) 
Ligand 4 (Phe), 1 (PEP) 2 (PEP) 
Mean B (Å)2   
Protein 32.26 46.68 
Water 35.37 41.47 
Other 38.03 59.88 
Ligand 24.98, 36.69 42.24 
R.m.s.d from target values   
Bond lengths (Å) 0.0123 0.0113 
Bond angles  1.5065 1.4226 
Dihedral angles 0.0852 0.0763 
Ramachandran   
Preferred (%) 96.59 96.30 
Allowed (%) 3.05 3.40 
Outliers (%)  0.36 0.30 
PDB Entry - - 
Table 4.3.4.1 Data collection and refinement statistics of NmeDAH7PS
His219Ala
 variant in the presence and 
absence of Phe  
4.4 DISCUSSION 
 
The NmeDAH7PSHis219Ala variant shows no sign of significant variation from the NmeDAH7PSWT 
enzyme in any of the experimental methods used for characterisation. It remains tetrameric in 
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solution, indicating that this single mutation is not sufficient to disrupt the quaternary 
structure. However, the specific activity of this variant has reduced significantly upon 
mutation. This is consistent with what was observed for the NmeDAH7PSArg126Ser variant (Part 
I) and implies that interactions at the tetramer interface affect catalytic turnover.  
The inhibition of NmeDAH7PSHis219Ala by Phe is the same as NmeDAH7PSWT, and the negative 
cooperativity observed between binding sites is consistent with the NmeDAH7PSWT. The 
reduced affinity of the second allosteric site of the two-site sequential model obtained from 
the ITC binding isotherm for Phe, may be due to the inability to form hydrogen bonds 
between the sidechain of Glu17 and the backbone carbonyl of Leu18 of the N-terminal 
extension with residue 219 in the absence of the His219 sidechain. This interaction is 
observed in the Phe-bound NmeDAH7PSWT structure (PDB code: 4UC5). These hydrogen 
bonds may aid in the closure of the N-terminal extension over the bound ligand. However, this 
feature does not have an effect on the inhibition caused by Phe at any concentration obtained 
from kinetic inhibition assays. 
The crystal structures of the Phe-bound and apo forms of NmeDAH7PSHis219Ala indicate that 
there is a significant increase in the number of water molecules at the interface, which may 
replace the His side-chains in the NmeDAH7PSHis219Ala variant. The similarity between crystal 
structures of the NmeDAH7PSHis219Ala variants and NmeDAH7PSWT is unsurprising as crystal 
packing effects govern the interactions seen at these notoriously weak interfaces, like that 
seen in the dimeric NmeDAH7PSArg126Ser variant (PDB code: 4UCG), which crystallised as a 
tetramer. 
Overall, this residue is not observed to be crucial for the functionality of NmeDAH7PS. This 
provides further evidence for the lack of importance of the interactions at the interface for 
enzyme function. Taken together with what was observed for the NmeDAH7PSArg126Ser variant, 
the necessity to form this interface in NmeDAH7PS is negligible. This may have direct 
implications for the evolution of a tetrameric interface in other type Iα enzymes. 
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CHAPTER 5- EXPOSING THE COMMUNICATION OF ALLOSTERIC 
SIGNAL IN NMEDAH7PS VIA THE CHARACTERISATION OF 
SEVERAL VARIANT ENZYMES  
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5.1 INTRODUCTION 
 
Having collected a crystal structure of the Phe-bound form of NmeDAH7PS, described in 
chapter 3, attempts were made to identify structural changes upon Phe binding, with a view 
to attempt to elucidate a communication pathway between allosteric and active sites. While 
there is no observable major conformational change in NmeDAH7PS upon Phe binding in the 
crystalline form, it is evident that there is a subtle reorganisation of the hydrogen bonding 
network that connects allosteric and active sites in this enzyme. This reorganisation is believed 
to be involved in the reduction of catalytic efficiency and the affinity of the active site for both 
substrates.26,123 Removal of the redundancy of the hydrogen bonds present in the PEP-bound 
structure (PDB code: 4HSN) and comparison with those from the Phe-bound structure (PDB 
code: 4UC5) reveals the hydrogen bonds that are broken and formed upon Phe binding to 
NmeDAH7PS in the crystalline form. Focusing only on the functional tight dimer of 
NmeDAH7PS, it is evident that the reorganisation is centred around the β2α2 loop and its 
interaction with surrounding residues at the tight dimer interface, as well as the N-terminal 
allosteric binding loop as it becomes ordered upon Phe binding (Figure 5.1.1 A and B). 
Chapter three described how the binding of Phe at the allosteric site caused a change in the 
conformation of the β2α2 loop. This may be related to the reorganisation of the electrostatic 
network of residues on and surrounding the loop. The reorganisation of this network is 
intimately associated with the binding of Phe at both sites of the NmeDAH7PS tight dimer. 
Careful inspection of this reorganisation upon Phe binding, highlighted several ionisable 
residues that may be involved in the communication of allosteric signal, both within the same 
chain as well as with the adjacent chain across the tight dimer interface (Figure 5.1.1 C). In the 
PEP-bound crystal structure (PDB code: 4HSN), Glu98 is connected to the allosteric site of the 
same chain via hydrogen bonds with Tyr155, Thr151 and the backbone peptide amino group 
of Asp148, located on the β3α3 loop and α3  helix respectively. Lys107 forms interactions 
across dimer interface with the backbone carbonyl of His210ʹ and the side-chain of His209ʹ 
and Glu176ʹ. However, in the Phe-bound structure (PDB code: 4UC5), the local environment 
of these residues as well as others on the β2α2 loop changes dramatically. It is likely that this 
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reorganisation is due to the allosteric signal transmitted from the allosteric site upon Phe 
binding.  
  
 
Figure 5.1.1 A) PEP-bound NmeDAH7PS (PDB code:4HSN) indicating hydrogen bonds broken upon Phe binding; 
Chain A (cyan), Chain B (green).B) Phe-bound NmeDAH7PS indicating hydrogen bonds formed upon Phe 
binding; Chain A (magenta), Chain B (Orange). Cα depicted as spheres, Chain A (red), Chain B (magenta). 
Mn
2+
shown as black sphere. PEP and Phe shown as yellow dots. All hydrogen bonds are depicted as black 
dashed lines Hydrogen bonds obtained from PEP- and Phe-bound NmeDAH7PS structures (PDB code: 4HSN and 
4UC5) using HBOND.
124
 C) Schematic of hydrogen bond reorganisation upon Phe binding localised to the β2α2 
loop (coloured according to A and B).  
Unfortunately, this analysis is not enough to confidently deduce a hydrogen bonding network 
linking remote sites. This is because we cannot discount the crystal packing effects, which may 
limit the conformations explored during the reorganisation of this network in the crystalline 
form, or the acquirement of an energy minimum by the protein that does not properly reflect 
what may occur in solution. This gave rise to a more in depth investigation into the 
transmission of this allosteric signal, with a view to properly define the role of each ionisable 
A B 
C 
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residue in the transfer of this allosteric signal, through monitoring the pKa variations over the 
course of a molecular dynamics (MD) simulation.  
This work has been submitted for publication and is located in Appendix A6  
This manuscript has been submitted to: Journal of the American Chemical Society 
Heyes, L. C.*, Lang, E. J. M.*, Jameson. G. B. & Parker, E. J. pKa variations expose allosteric 
communication pathways. JACS XX, XXX-XXX (XXXX). 
 
(*) denotes co-first author 
 
Prof G. B. Jameson provided useful insight into the manuscript. E. J. M. Lang performed the 
molecular dynamics simulations and pKa analysis and contributed to the writing of the 
manuscript. Prof E.J. Parker designed experiments and contributed to the writing of the 
manuscript. The author of this thesis contributed to the writing of the manuscript and 
carried out the pH-dependent kinetic inhibition experiments, crystallography, crystal 
structure analysis and the pH dependent isothermal titration calorimetry experiments.  
 
Allostery is the process by which enzyme activity is regulated by cellular metabolites has 
received considerable attention in this thesis. When allostery takes place without major 
conformational change, the mechanisms involved are often difficult to delineate. These long 
range interactions between remote sites of a protein involving minimal conformational 
change have been theorised to be mediated by changes in the frequencies and amplitudes of 
atomic motions (dynamics).81 The allosteric mechanism of NmeDAH7PS involves changes in 
dynamics, making the mechanisms difficult to resolve. Previous studies involving the 
combination of biophysical methods, such as NMR, ITC, MD and single molecule FRET have 
been successful in assessing the role of structure and dynamics in allosteric cooperativity in a 
number of different systems.88,125–130 
 
It has been hypothesised that interaction networks that are formed or broken contribute 
significantly to allosteric communication in proteins.131 The subtle reorganisation of residues 
within these contact networks have both an enthalpic and entropic contribution.132 The 
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sensitivity of these networks to a single amino-acid substitution has highlighted the 
importance of interactions between individual residues of these networks.133 The work 
described in Appendix A6 details a novel approach to understanding these long range 
connections involving structural, MD and experimental studies. It involved monitoring the 
long range coulombic interactions, hydrogen bonding interactions and desolvation effects, 
which contribute to changes in pKa value of ionisable residues in the protein (calculated using 
PROPKA).134 A significant variation in calculated pKa value implies a substantial change in the 
local electrostatic environment of a residue, associated with a reorganisation of the hydrogen 
bonding network within the protein, which can occur upon binding of an allosteric effector.135  
 
The activity of NmeDAH7PS is allosterically controlled through subtle changes in dynamics and 
does not undergo a large conformational change, making the mechanism of signal 
transduction intriguing. The β2α2 loop, located within mutual proximity of both active and 
allosteric sites of each tight dimer, has been shown to be one of the most flexible regions of 
the protein during MD simulations for both the Phe-bound and Phe-free state, but was found 
to be more flexible in the Phe-bound state. The loop is intrinsically associated with residues of 
the β6a and β6b sheets, which make up a large portion of the predominantly hydrophobic 
allosteric site at tight-dimer interface. ITC experiments have shown that binding of Phe to the 
allosteric site of NmeDAH7PS has a large entropic character that may contribute to the 
negative cooperativity between the allosteric sites of the enzyme.  
 
Deep within the allosteric site, hydrophobic side-chains are abundant and have been shown to 
play a crucial role in recognition and selectivity of the allosteric aromatic ligand (Chapter 3). 
Interactions between the allosteric site hydrophobic residues and the allosteric ligand alter 
the interactions between the β-hairpin insertion and the β2α2 loop across the tight dimer 
interface. 
 
Several residues identified from structural and MD simulations have been proposed to play a 
role in communication of the allosteric signal between the active and allosteric site, all of 
which are intrinsically associated with the dynamics of the β2α2 loop. Some of these 
interactions occur within the same chain, while others occur between chains, across the tight 
dimer interface. There are several residues that in the presence of Phe have been predicted 
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from the MD simulations to adopt a significantly altered pKa value, in the presence or absence 
of an allosteric ligand. These residues are postulated to make up a hydrogen bonding network 
in the active enzyme and undergo significant reorganisation in the presence of Phe. This 
hydrogen bonding network is reorganised so as to reduce the rate of catalysis, and the 
apparent KM’s for both substrates.
26,123 Such a highly specific mechanism may have 
implications for the flux and control of the entire shikimate biosynthetic pathway in N. 
meningitidis and enable us to shed light on the allosteric mechanisms used in other organisms 
and enzymes from other biosynthetic pathways in nature.20 
 
5.1.1 Hydrophobically driven binding event sets allostery in motion 
 
The allosteric binding site of NmeDAH7PS largely consists of hydrophobic residues, which are 
involved in the recognition and binding of aromatic amino acids, in particular, Phe. The 
residues that make up this hydrophobic pocket are located at the interface of the two chains 
of the tight dimer. Phe211, Val214 and Val223 are from the β hairpin insertion, Leu177 and 
Leu181, located on the α4 helix and α4β5 loop and Ile12 and Val15 located on the N-terminal 
extension of the adjacent chain. Some of these residues have already been implicated in the 
allostery of the Phe sensitive isozyme from E. coli.101 It has been shown that in the absence of 
the first 15 residues that make up the allosteric binding loop, allostery was abolished.101  Phe 
209 (211 in NmeDAH7PS), Val 221 (223 in NmeDAH7PS), Leu175 (177 in NmeDAH7PS) and 
Leu179 (181 in NmeDAH7PS) were also shown to be very important for allostery in 
EcoDAH7PS;101  however, the reason for the loss of activity was not identified. Unfortunately, 
these experiments were largely inconclusive as there was no biophysical characterisation 
reported, nor any structural information to explain the loss of allostery seen in EcoDAH7PS.  
 
Upon binding of Phe at the allosteric site, the N-terminal extension closes over the bound 
ligand and forms several hydrogen bonds via Asp8, Asp9, Gln153 and the backbone nitrogen 
of Ser182. Stabilisation of this closed conformation occurs when hydrogen bonds are formed 
between Asp8 of the allosteric binding loop, Gln153 on the α3 helix and Lys216, which forms 
part of the β6aβ6b loop. 
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This study involves the generation of two point mutants (NmeDAH7PSPhe211Ala and 
NmeDAH7PSVal223Ala) and describes the structural, biophysical and functional characterisation 
of the influence of these residues in the allosteric mechanism of NmeDAH7PS. 
 
5.1.2 Hydrogen bonding network reorganisation mediates allosteric signal transduction 
 
The active site of NmeDAH7PS is predominantly made up of positively charged residues, 
which are involved in binding the negatively charged substrates. PEP binds deep within the 
active site, forming interactions with residues: Lys188, Arg236, Arg94 and Lys99. E4P is 
predicted to bind to the KPR(T/S) motif, part of the highly flexible β2α2 loop, which has a role 
in mediating substrate binding and catalysis. The positioning of this loop is controlled by a 
network of residues, which have been shown to adopt different bonding partners in the 
presence and absence of Phe. 
The residues identified as having potential roles in this network predicted from the structural 
and pKa analysis described in chapter 5 are: Glu98, Lys99, Lys107, Asn111, Asp148, Thr151, 
Tyr155, Gln172ʹ and Glu176ʹ, as well as a crystallographically conserved water molecule. The 
Cα of Glu98, located towards the N-terminal end of the β2α2 loop moves ~2.5 Å upon binding 
of Phe. In the PEP-bound structure (PDB code: 4HSN), Glu98 forms hydrogen bonds with the 
backbone nitrogen of Asp148 and the side-chain hydroxyl groups of Thr151 and Tyr155, from 
the β3α3 loop and α3 helix. This loop contains Gln153, which is responsible for binding the 
amine moiety of Phe (Figure 5.1.2.1). In the Phe-bound NmeDAH7PSWT structure (PDB code: 
4UC5), Glu98 forms new hydrogen bonds with Gln172ʹ and Asn111, which was involved in a 
hydrogen bond with the backbone carbonyl of His210ʹ from the β6a sheet in the PEP-bound 
enzyme (Figure 5.1.2.1). Glu98 also comes into proximity to form a salt-bridge with Lys107 
and interacts with Glu176ʹ via a shared water molecule. This water molecule is not however 
conserved for the duration of MD simulations of the Phe-bound state of NmeDAH7PSWT. 
When this reorganisation occurs upon Phe binding, it is not surprising that the positioning of 
the adjacent residue Lys99 is also affected. As this residue is part of the absolutely conserved 
KPR(T/S) motif, and has involvement in proton transfer during catalysis, its new conformation 
may contribute to the flipped binding mode of PEP, where the divalent active site metal ion is 
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no longer in close proximity to the carboxylate of PEP, nor accessible for coordination by the 
aldehyde of E4P.22,28 The residue Lys107 is located towards the C-terminal end of the β2α2 
loop and in the PEP-bound NmeDAH7PSWT structure. This residue forms a salt bridge across 
the tight dimer interface with Glu176ʹ and hydrogen bonds with His 209ʹ and the backbone 
carbonyl of His210ʹ. In the presence of Phe, these interactions are lost, in part due to the 
movement of the β2α2 loop and β6a sheet, which contains Phe211ʹ, believed to contribute to 
allosteric ligand recognition. In the presence of Phe, Lys107 forms a new hydrogen bond with 
Gln172ʹ and has been shown from MD simulations to interact with Glu98 directly, even if this 
interaction is > 3.4 Å in the crystal (Figure 5.1.2.1).  
The aforementioned ionisable and polar residues are hypothesised to have a critical role in 
both catalysis and regulation. Systematic mutation of each residue presumably involved in this 
reorganisation upon binding of the allosteric effector molecule was completed in order to 
determine their involvement in the network. In doing so, improving our understanding of how 
the allosteric signal is propagated from the allosteric site in NmeDAH7PS, resulting in a 
functional response at the active site. 
All variant enzymes were designed to remove the side-chain functionality of respective 
residues in order to determine their involvement in the mediation of allosteric signal. The 
mutated residues include: Glu98, Lys107, Gln172 and Glu176. Conversely, a variant was made 
based on the pKa predictions, where Glu176ʹ was calculated to undergo a significant change in 
pKa in the presence of Phe. In light of this observation, a variant was generated to enable the 
formation of hydrogen bonds within the hydrogen bonding network, but with the inability to 
undergo a change in pKa. Generation of the NmeDAH7PS
Glu176Gln variant appropriately satisfied 
these criteria, as it was considered that this change may have a unique effect on the 
communication of allosteric signal. 
The kinetic, thermodynamic and structural characterisation of these variant enzymes may 
help to elucidate the mechanism employed by NmeDAH7PS to achieve allostery and provide a 
general understanding of allostery in other type Iα DAH7PS from different organisms. These 
studies reveal how NmeDAH7PS is regulated without significant conformational change, 
extensive accessory domains, or protein complex formation, as is seen in various type Iβ and 
type II DAH7PS enzymes.20  
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Figure 5.1.2.1. Hydrogen bonding network, in the presence of PEP (green) and in the presence of Phe (blue), 
obtained from structural alignment of the tight dimers of NmeDAH7PS (PDB codes: 4HSN and 4UC5). Hydrogen 
bonds indicated in green and blue respectively. The conserved water molecule from Phe-bound structure is 
shown as a red sphere. 
 
 
 
  
β2α2 loop 
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5.2 RESULTS FROM ALLOSTERIC BINDING SITE VARIANTS 
5.2.1. Kinetic characterisation of allosteric binding site variants 
 
The kinetic parameters of the allosteric binding site NmeDAH7PS variant enzymes were 
determined under the conditions used for NmeDAH7PSWT (section 7.1.27). The kinetic 
parameters obtained for these allosteric site variant enzymes are shown in Table 5.2.1.1. The 
NmeDAH7PSPhe211Ala variant has a KM for PEP of 6 ± 1 µM, which is lower than that of 
NmeDAH7PSWT, indicating higher affinity of the active site for this variant for PEP. It also 
exhibits a ~2-fold increase in the KM for E4P of 71 ± 6 µM. The kcat for this variant was also 
reduced to ~60% of that observed for NmeDAH7PSWT. The NmeDAH7PSVal223Ala variant has 
similar kinetic properties to the NmeDAH7PSWT, with a KM for the substrates E4P and PEP of 36 
± 4 µM and 16 ± 2 µM respectively. The kcat for this variant is also very similar to the 
NmeDAH7PSWT with a value of 32 ± 0.2 s-1. 
 
 PEP K
M 
(µM) E4P K
M
 (µM) k
cat
 (s
-1
) kcat /KM (PEP) kcat /KM (E4P) 
NmeDAH7PSPhe211Ala 6 ± 1 71 ± 6 15 ± 0.2 2.5 0.2 
NmeDAH7PSVal223Ala 16 ± 2 36 ± 4 32 ± 0.2 2.0 0.9 
NmeDAH7PSWT 15 ± 1 37 ± 2 27.1 ± 0.1 1.8 0.7 
Table 5.2.1.1 Kinetic parameters of NmeDAH7PS
Phe211Ala 
and NmeDAH7PS
Val223Ala
 variants. Equivalent 
parameters for NmeDAH7PS
WT
 are given as a comparison. All kinetic assays were carried out at high 
concentrations of other substrate. 
 
5.2.2. Allosteric binding site variants are less sensitive to Phe 
 
Inhibition kinetics were carried out using standard assay procedures (section 7.1.27) in the 
presence of varying concentrations of Phe (50–1000 µM). Sensitivity to Phe was severely 
reduced for both allosteric site variant enzymes. NmeDAH7PSPhe211Ala was found to be 
insensitive to inhibition by Phe at all concentrations tested. NmeDAH7PSVal223Ala was inhibited 
by Phe, but the level of inhibition was decreased severely compared to NmeDAH7PSWT, where 
62% residual activity was maintained at 1 mM Phe, compared to the 12% retained for 
NmeDAH7PSWT (Figure 5.2.2.1).  
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Figure 5.2.2.1 Inhibition of NmeDAH7PS
Phe211Ala
 variant (khaki) and NmeDAH7PS
Val223Ala
 variant (purple) 
compared to the NmeDAH7PS
WT 
enzyme (blue) at varying concentrations of phenylalanine (0-1000 µM). 
Saturating substrate concentrations were used for all experiments.  
 
Standard ITC protocols were employed to elucidate the mechanism of decreased sensitivity to 
Phe observed for these variant enzymes (section 7.1.29). The insensitivity of 
NmeDAH7PSPhe211Ala variant to high concentrations of Phe can be identified from the isotherm, 
where the protein did not undergo any heat change upon injection of Phe into the cell. 
Therefore, NmeDAH7PSPhe211Ala no longer possesses the ability to bind Phe, implicating Phe211 
directly in the binding of Phe at the allosteric site. The binding isotherm for the titration of Phe 
into NmeDAH7PSVal223Ala is indicative of a very low affinity for Phe. The extremely high molar 
ratio obtained from this experiment renders the fit and calculated KD meaningless. The shape 
of the curve may explain the reduction in inhibition seen for this variant enzyme compared to 
NmeDAH7PSWT, which is a likely result of weaker binding at the allosteric site (Figure 5.2.2.2). 
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Figure 5.2.2.2 Raw data of the ITC experiments for the binding of Phe to NmeDAH7PS
Phe211Ala
and  
NmeDAH7PS
Val223Ala
 Using the VP-ITC Microcal™ Left. NmeDAH7PS
Phe211Ala
(1.2mM Phe and 16µM enzyme) 
Right. NmeDAH7PS
Val223Ala 
(20mM Phe and 20µM enzyme). 
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5.2.3. Allosteric binding site variants adopt tetrameric quaternary structure in solution 
 
Analytical size-exclusion chromatography (SEC) was employed to identify whether the 
quaternary structure of these variant enzymes was altered upon introduction of respective 
mutations. The main peak for NmeDAH7PSPhe211Ala and NmeDAH7PSVal223Ala eluted from the 
column after the same volume of isocratic flow as NmeDAH7PSWT. This indicates that they 
adopt the same tetrameric solution-state quaternary structure (Figure 5.2.3.1).  
 
Figure 5.2.3.1 Analytical size exclusion chromatography traces of NmeDAH7PS
WT
 (blue), NmeDAH7PS
Phe211Ala
 
variant (khaki), NmeDAH7PS
Val223Ala 
variant (purple). Concentrations used for the experiment varied from 0.6-
0.7 mg/mL. 
 
5.2.4. Crystallography of allosteric binding site variants 
 
In order to identify structural differences of these two allosteric binding site variant enzymes 
that may contribute to their lessened affinity for Phe, crystal structures of both 
NmeDAH7PSPhe211Ala and NmeDAH7PSVal223Ala were obtained by X-ray diffraction methods. 
Crystals of these variant proteins were grown using procedures described in section 7.1.30 
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and 7.1.31. The soaking of Phe into these structures was achieved using procedures described 
in 7.1.32. Data collection and refinement statistic are shown in table 5.2.4.1. 
NmeDAH7PS  Val223Ala Val223Ala Phe211Ala 
 L-Phenylalanine PEP - 
Data Collection    
Crystal system; space group Orthorhombic, P212121 Monoclinic, P1211 Orthorhombic, P212121 
Unit cell parameters     
a, b, c (Å) 73.62, 75.43, 143.94 73.26, 135.62, 75.99 78.68, 135.73, 149.36 
α, β, γ (º) 90, 90, 90 90, 96.27, 90 90, 90, 90 
Resolution range (Å) 75.43-1.70 (1.74-1.70) 75.53-1.84 (1.88-1.84) 100.45-2.35 (2.41-2.35) 
Measurements 645375 480663 964977 
Unique reflections 88844 126857 67384 
Redundancy 7.3 (7.3) 3.8 (3.8) 14.3 (14.8) 
Completeness (%) 100.0 (100.0) 99.6 (99.3) 100.0 (100) 
I/σ (I) 14.5 (2.27) 13.4 (1.66) 19.4 (2.51) 
Rmerge 0.095 (0.769) 0.054 (0.942) 0.104 (0.986) 
CC1/2 0.763 0.531 0.909 
Wilson B value (Å)2 16.10 25.26 42.10 
Matthews coefficient 2.63 (53.25) 2.47 (50.2) 2.63 (53.24) 
 
Refinement 
   
Rwork 0.1516 0.1623 0.2097 
Rfree 0.1782 0.1970 0.2589 
Chain length 351 351 351 
Observed number of 
residues 
345 (Chain A & B) 332 (Chain A, B, C & D) 333 (Chain A+B), 332 (Chain 
C), 328 (Chain D) 
Water molecules 613 733 333 
Other 18 (Mn2+, Cl-, EDO, PEG) 12 (Mn2+, SO4
2-, Cl-, EDO, PEG) 9 (PEG, EDO, Mn2+) 
Ligand 2 (Phe) 4 (PEP) 1 (PEP) 
Mean B (Å)2    
Protein 17.66 32.80 44.76 
Water 26.82 36.18 42.15 
Other 47.78 59.43 65.14 
Ligand 14.51 30.83 63.06 
R.m.s.d from target values    
Bond lengths (Å) 0.0121 0.0130 0.0116 
Bond angles  1.4671 1.5248 1.4850 
Dihedral angles 0.0888 0.0912 0.0814 
Ramachandran    
Preferred (%) 97.11 97.66 96.38 
Allowed (%) 2.65 2.19 3.39 
Outliers (%)  0.14 0.15 0.23 
PDB Entry 5D04 5D03 5D09 
Table 5.2.4.1 Data collection and refinement statistics of NmeDAH7PS
Val223Ala
 variant in the presence and 
absence of Phe and the NmeDAH7PS
Phe211Ala
 variant (PDB code: 5D03, 5D04 & 5D09)  
 
Unfortunately, a Phe-bound structure of the NmeDAH7PSPhe211Ala variant enzyme could not be 
obtained, which correlates to the lack of evidence for Phe binding or inhibition from ITC and 
kinetic experiments. However, at the high concentrations (>5 mM) used for soaking Phe into 
crystals of NmeDAH7PSVal223Ala variant, a structure was obtained with Phe-bound at the 
allosteric site at full occupancy. 
  - 111 - 
Crystal structure of apo NmeDAH7PSPhe211Ala 
A single crystal structure of the apo NmeDAH7PSPhe211Ala variant was determined by X-ray 
diffraction. The structure was refined to a resolution of 2.35 Å and crystallised in an 
orthorhombic space group, (P212121). Inspection of the structure highlights some differences 
to the NmeDAH7PSWT structure. Alignment of the tight dimers of the NmeDAH7PSPhe211Ala 
variant to the PEP-bound NmeDAH7PSWT (PDB code: 4HSN) yielded an RMSD of 0.387-0.494 Å. 
The regions of most significant variation were localised to the highly flexible β2α2 loop, which 
adopts a different conformation to what was observed for the PEP-bound NmeDAH7PSWT 
(Figure 5.2.4.1A). The reason for the absence of PEP from this structure remains unclear, but 
may be an artefact of the crystallisation procedure. It is important to bear this in mind when 
considering the structural changes associated with this mutation. 
 
 
 
 
Figure 5.2.4.1 Root mean squared deviation of the tight dimer averaged for both chains. A) Comparison 
between PEP-bound NmeDAH7PS
Phe211Ala
 (khaki) and PEP-bound NmeDAH7PS
WT 
(PDB code: 4HSN). B) 
Comparison between PEP-bound NmeDAH7PS
Val223Ala
 (purple) and PEP-bound NmeDAH7PS
WT 
(PDB code: 4HSN). 
C) Comparison between Phe-bound NmeDAH7PS
Val223Ala
 (purple) and Phe-bound NmeDAH7PS
WT 
(PDB code: 
4UC5).  
A 
B C 
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The β2α2 loop (res. 95-120) responsible for binding E4P illustrates an interesting difference 
between the apo-NmeDAH7PSPhe211Ala and PEP-bound NmeDAH7PSWT. Asn111 in the PEP-
bound NmeDAH7PSWT structure forms a hydrogen bond with the backbone carbonyl of 
His210ʹ from the adjacent chain of the tight dimer. However, upon mutation of Phe211 to 
alanine, the distance between Asn111 and His210ʹ is too large for the formation of a hydrogen 
bond. The loss of this structural stabilisation may contribute to the RMSD between the β2α2 
loops of these structures. The variation in conformation of this loop, may also clarify the 
decreased binding affinity for E4P obtained from kinetic studies. 
 
Figure 5.2.4.2. A) Structural alignment of NmeDAH7PS
Phe211Ala
 variant and PEP-bound NmeDAH7PS
WT
 (PDB 
code: 4HSN) illustrating the loss of hydrogen bond at the tight dimer interface. |2Fo-Fc| map coloured in blue 
and contoured at 1.0 σ to illustrate mutation. B) Structural alignment of the PEP-bound NmeDAH7PS
Val223Ala 
variant and PEP-bound NmeDAH7PS
WT
 (PDB code: 4HSN) illustrating the conservation of residue positions at 
the active site. PEP |Fo-Fc| omit map coloured in green and contoured at 3.0 σ. 
 
Crystal structures of Phe- and PEP-bound NmeDAH7PSVal223Ala 
Two crystal structures of the NmeDAH7PSVal223Ala variant were determined by X-ray diffraction 
methods, one PEP-bound and the other Phe-bound. The PEP-bound structure was refined to a 
resolution of 1.84 Å and crystallised in the same space group as the PEP-bound NmeDAH7PSWT 
(PDB code: 4HSN) (P1211). The RMSD for the alignment of the tight dimers of the PEP-bound 
NmeDAH7PSVal223Ala variant to the PEP-bound NmeDAH7PSWT structure was 0.119-0.237 Å. 
These structures are remarkably similar (Figure 5.2.4.1B) with no observed regions of 
structural variation. This is reiterated for the PEP binding site and β2α2 loop, which remain in 
  - 113 - 
the same conformation when comparing the two enzymes (Figure 5.2.4.3B). It is perhaps not 
surprising that the kinetic parameters obtained for the NmeDAH7PSVal223Ala variant are similar 
to the NmeDAH7PSWT. 
 
The Phe-bound structure crystallised in an orthorhombic space group (P21221) and was 
refined to a resolution of 1.70 Å. The asymmetric unit for the Phe-bound NmeDAH7PSVal223Ala 
structure (PDB code: 5D04) only contained the tight dimer as opposed to the tetramer, seen 
in all other structures, which may be due to the extensive twist of the tight dimers relative to 
each other for this variant compared to the Phe-bound NmeDAH7PSWT (with an inter-dimer 
angle increase of ~10°). The RMSD for the alignment of the tight dimers of the Phe-bound 
NmeDAH7PSVal223Ala variant to the Phe-bound NmeDAH7PSWT structure (PDB code: 4UC5) was 
0.308-0.339 Å, indicative of minimal variation between the tight dimers in these structures.  
 
 
Figure 5.2.4.3. A) Structural alignment of the Phe-bound NmeDAH7PS
Val223Ala 
variant and Phe-bound 
NmeDAH7PS
WT
 (PDB code: 4UC5) illustrating the conservation of residue positions at the allosteric site. Phe |Fo-
Fc| omit map coloured in green and contoured at 3.0 σ and |2Fo-Fc| map coloured in blue and contoured at 1.0 
σ to illustrate mutation. B) Structural alignment of the Phe-bound NmeDAH7PS
Val223Ala 
variant and Phe-bound 
NmeDAH7PS
WT
 (PDB code: 4HSN) active site. 
 
 
Interestingly, the central histidines (His219) (described in chapter 4) in the Phe-bound 
NmeDAH7PSVal223Ala structure engage in the same π-stacking interaction across the diagonal 
interface, and the Arg126-Glu27 salt bridge remains present in this structure. This indicates 
that the important interface contacts remain, even when the tight dimers are rotated by ~10°.  
ʹ 
ʹ 
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Inspection of the mutation site indicates no change in the position of the β6b sheet on which 
this mutation is located and more specifically, there is no change in the position of Cα for 
Ala223 (Figure 5.2.4.3A). This implies that other residues within the site can facilitate Phe 
binding in the same way as is seen in NmeDAH7PSWT (PDB code: 4UC5) at high concentrations 
used for Phe soaking. 
5.3 RESULTS FROM HYDROGEN BONDING NETWORK VARIANTS 
 
5.3.1 Kinetics and inhibition of hydrogen bonding network variants 
 
Kinetic assays were carried out according to procedures described in (section 7.1.27). 
Characterisation of these hydrogen bonding network variant enzymes indicated some 
interesting differences in kinetic parameters when compared to NmeDAH7PSWT. All kinetic 
constants are shown in table 5.3.1.1.  
 PEP K
M 
(µM) E4P K
M
 (µM) k
cat
 (s
-1
) kcat /KM (PEP) kcat /KM (E4P) 
NmeDAH7PSGlu98Ala 2 ± 0.2 29 ± 2 12 ± 0.2 6.0 0.4 
NmeDAH7PSLys107Ala - - - - - 
NmeDAH7PSGln172Ala 30 ± 4 97 ± 8 47.5 ± 2.1 1.6 0.5 
NmeDAH7PSGlu176Ala 17 ± 2 45 ± 3 15.3 ± 0.6 0.9 0.3 
NmeDAH7PSGlu176Gln 15 ± 1 79 ± 8 23.5 ± 0.8 1.6 0.3 
NmeDAH7PSWT 15 ± 1 37 ± 2 27.1 ± 0.2 1.8 0.7 
Table 5.3.1.1 Kinetic parameters of NmeDAH7PS
Glu98Ala
, NmeDAH7PS
Lys107Ala
, NmeDAH7PS
Gln172Ala
, 
NmeDAH7PS
Glu176Ala
 and NmeDAH7PS
Glu176Gln
. All kinetic assays were carried out at high concentrations of other 
substrate (PEP-100 µM and E4P 250–500 µM). 
 
Kinetic parameters for the NmeDAH7PSLys107Ala variant enzyme could not be determined as this 
enzyme was found to be completely inactive during testing. The KM for substrates, E4P and 
PEP in the NmeDAH7PSGlu98Ala variant are 29 ± 2 µM and 2 ± 0.2 µM respectively, which 
indicate an increase in affinity for PEP compared to NmeDAH7PSWT. However, the kcat of this 
variant is also less than half of the NmeDAH7PSWT.  
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Interestingly, the NmeDAH7PSGln172Ala variant enzyme exhibits increased kinetic parameters 
for both substrates, with KM values of 97 ± 8 µM and 30 ± 4 µM for E4P and PEP respectively. 
The kcat for this variant enzyme however has increased to 47.5 ± 2.1 s
-1. The intimate 
association between this residue and residues, Lys99 and Arg101 of the conserved KPR(T/S) 
motif on the β2α2 loop observed in the PEP-bound NmeDAH7PS
WT structure, may have 
interesting implications for catalysis in this variant. 
The KM of substrates, E4P and PEP for the NmeDAH7PS
Glu176Ala variant are 45 ± 3 µM and 17 ± 
2 µM respectively, which are similar to that of NmeDAH7PSWT, however, the kcat of 15.3 ± 0.6 
s-1 is less than that of the NmeDAH7PSWT. The NmeDAH7PSGlu176Gln variant has a KM for PEP of 
15 ± 2 µM, which is similar to the NmeDAH7PSWT. The KM for E4P was 79 ± 9 µM and it 
remains unclear as to why the affinity for E4P is decreased. The kcat for NmeDAH7PS
Glu176Gln of 
23.5 ± 0.8 s-1 is also similar to that of the NmeDAH7PSWT. 
 
Inhibition kinetic assays were carried out on all variant enzymes in the presence of 50–1000 
µM Phe as previously described (section 7.1.27) and the results are displayed in figure 5.3.1.1.  
 
Figure 5.3.1.1. Inhibition plot for all variant enzymes at varying phenylalanine concentrations (50-1000 µM). 
NmeDAH7PS
Glu98Ala
 variant (brown), NmeDAH7PS
Gln172Ala 
variant (orange), NmeDAH7PS
Glu176Ala
 variant (teal), 
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NmeDAH7PS
Glu176Gln 
variant (pink) and NmeDAH7PS
WT 
(blue). Saturating substrate concentrations were used for 
all measurements.  
The allosteric regulation of NmeDAH7PSGlu98Ala was severely attenuated at all concentrations 
of Phe tested, indicating that this residue is somehow involved in the communication of 
allosteric signal. Conversely, NmeDAH7PSGln172Ala showed increased sensitivity to Phe. 
Interestingly, the inhibitory response of NmeDAH7PSGlu176Ala at low concentrations of Phe is 
increased, but at high concentrations (> 200 µM), the effect plateaus, implying that there is a 
limit to the regulatory effect of Phe in the NmeDAH7PSGlu176Ala variant. This residue may 
contribute to the formation of the Phe-bound state of the enzyme. A similar mutation 
involving the same residue in NmeDAH7PSGlu176Gln showed a similar trend in sensitivity to Phe 
as NmeDAH7PSWT at all concentrations tested. The response however, was somewhat 
attenuated.  
5.3.2 Hydrogen bonding network variants adopt tetrameric solution state quaternary 
structure 
 
Analytical SEC was employed to determine the solution-state quaternary structure of the 
aforementioned variant enzymes. All variant enzymes were shown to elute after the same 
volume of isocratic flow as NmeDAH7PSWT, demonstrating retention of the native tetrameric 
assembly in solution (Figure 5.3.2.1).  
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Figure 5.3.2.1 Overlaid Analytical size exclusion chromatography traces of NmeDAH7PS
WT
 (blue), 
NmeDAH7PS
Glu98Ala
 (brown), NmeDAH7PS
Lys107Ala 
(yellow), NmeDAH7PS
Gln172Ala 
(orange), NmeDAH7PS
Glu176Ala 
(light blue), NmeDAH7PS
Glu176Gln 
(pink). Concentrations used for the experiment varied from 0.6–0.7 mg/mL. 
5.3.3 Phe binding characteristics of hydrogen bonding network variants 
 
The total free energy (ΔG) of binding, which can be determined experimentally using ITC, is 
multifactorial and represents the contribution from a number of molecular interactions 
including: van der Waals interactions, hydrogen bonding, hydration, conformational entropy, 
electrostatic and ionisation effects, contributions due to conformational transitions and the 
loss of translational and rotational freedom.136 The enthalpic and entropic contributions to ΔG 
can be obtained from these isotherms via the Gibbs free energy equation (ΔG = ΔH - TΔS). This 
provides interesting insight into the intrinsic properties of Phe binding when compared across 
a range of variant enzymes. 
 
The dissociation constants and thermodynamics of Phe binding to the aforementioned variant 
enzymes were determined by ITC. Phe was titrated into the calorimeter cell containing 
NmeDAH7PS variants and binding isotherms obtained. The binding isotherm of Phe to 
NmeDAH7PSGlu98Ala, NmeDAH7PSGln172Ala and NmeDAH7PSGlu176Gln were fit to a two-site 
sequential binding model, like that of the NmeDAH7PSWT. However, the binding isotherm of 
NmeDAH7PSGlu176Ala and NmeDAH7PSLys107Ala could only be fit to a one-site model, indicating a 
significant change in the characteristics of Phe binding, especially with respect to the 
cooperativity between allosteric sites of the enzyme. 
 
The KD for Phe binding to each site of NmeDAH7PS
Glu98Ala was 5 ± 1 µM and 29 ± 5 µM 
respectively, illustrating the reduction in affinity for both sites compared to NmeDAH7PSWT 
(Figure 5.3.3.1A). From the thermodynamic parameters of NmeDAH7PSGlu98Ala it can be 
inferred that binding at the first site is entropically driven, as is the case for NmeDAH7PSWT. 
The contribution to the free energy of binding at the second site however consists more 
equally of entropic and enthalpic components compared to NmeDAH7PSWT. The variation in 
binding characteristics for the second site, may explain the reduction in binding affinity 
observed. Overall the binding is slightly more entropically favourable than NmeDAH7PSWT in 
the NmeDAH7PSGlu98Ala variant. 
 
A 
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The KD values for the binding of Phe at both sites of NmeDAH7PS
Gln172Ala were 14 ± 4 µM and 
17 ± 3 µM respectively (Figure 5.3.3.1B). This indicates weaker binding at the first site than 
NmeDAH7PSWT, whereas binding at the second site remains similar to NmeDAH7PSWT. This 
may suggest a small disruption in the cooperativity between allosteric sites. The 
thermodynamic parameters obtained from the NmeDAH7PSGlu172Ala binding isotherm indicate 
that binding at both sites remains similar to NmeDAH7PSWT. However, binding at the second 
site is slightly more entropically unfavourable and this may contribute to the similarity in the 
binding affinity of Phe at both sites.  
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Figure 5.3.3.1 A). ITC data for the titration of 1.2 mM Phe into 18 µM NmeDAH7PS
Glu98Ala
 variant (brown) B) ITC 
data for the titration of 1.2 mM Phe into 16 µM NmeDAH7PS
Gln172Ala
 variant (orange) Top: Raw data from ITC 
experiment fit to the two-site sequential binding model Middle. Comparison of the thermodynamic parameters 
for binding at both sites with NmeDAH7PS
WT
 (blue) Bottom. Comparison of dissociation constant (KD) at both 
sites of the sequential binding model with NmeDAH7PS
WT
 (blue). All ITC isotherms were fit and their 
corresponding heat of dilutions subtracted using OriginLab® version 7.0. 
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The KD of Phe binding to the inactive NmeDAH7PS
Lys107Ala variant, obtained from a one site 
binding model is 1.0 ± 0.1 µM, indicative of tighter binding than the NmeDAH7PSWT (Figure 
5.3.3.2A). The molar ratio for Phe binding to this variant was only 0.47 after 48 hours of 
dialysis. Crystallographic studies have shown that Phe was present in the crystal structure at 
~0.6-0.7 occupancy when it was excluded from the crystallisation condition (section 7.6.5). 
This is consistent with the molar ratio of ligand to enzyme observed by ITC before dialysis over 
48 hours, giving a small increase in molar ratio for the titration (Figure A.5.4). This may explain 
why only a single site binding model could be fit to the data. Unfortunately attempts to 
dialyse Phe totally out of the enzyme before titration were unsuccessful.  
 
The low KD for this variant, when Phe was occupying ~half of all binding sites is intriguing. The 
binding isotherm indicates a very large enthalpic contribution to binding at the allosteric site 
as well as a highly unfavourable entropic contribution. The presence of Phe in this variant 
implies that comparisons should only be made with the second binding event of 
NmeDAH7PSWT. Interestingly, the entropic component to binding in of Phe to 
NmeDAH7PSLys107Ala implies that binding is now driven primarily by electrostatic interactions 
(ΔH contributions) and that the entropic penalty incurred upon Phe binding has already been 
paid. Unfortunately, the thermodynamic parameters obtained from this binding isotherm may 
be influenced by the reduction in binding sites accessible to Phe and therefore deductions 
based on these characteristics remain tentative. 
 
The KD of Phe binding to the NmeDAH7PS
Glu176Ala variant, obtained from a one site binding 
model was 1.5 ± 0.1 µM (Figure 5.3.3.2B) with a molar ratio of 0.9. Inspection of the 
thermodynamic parameters of this binding interaction shows that there is a large enthalpic 
contribution to binding of Phe at this site, with no entropic contribution. The fit of this binding 
isotherm to a one site binding model implies that the un-cooperative allostery between the 
Phe binding sites exhibited by NmeDAH7PSWT is lost in this variant.  
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Figure 5.3.3.2 A). ITC data for the titration of 0.11 mM Phe into 21µM NmeDAH7PS
Lys107Ala
 variant (yellow) B) ITC 
data for the titration of 0.2 mM Phe into 22 µM NmeDAH7PS
Glu176Ala
 variant (light blue) Top. Raw data from ITC 
experiment fit to a one-site binding model.  Middle. Comparison of the thermodynamic parameters for binding 
at both sites with NmeDAH7PS
WT
 (blue). Bottom. Comparison of dissociation constant (KD) at both sites of the 
sequential binding model with NmeDAH7PS
WT
 (blue). All ITC isotherms and graphs were fit and their 
corresponding heat of dilutions subtracted using OriginLab® version 7.0. 
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Phe binding is tighter in these two variant enzymes (NmeDAH7PSLys107Ala and 
NmeDAH7PSGlu176Ala) than NmeDAH7PSWT. The thermodynamic characteristics are also similar, 
and thus implicate that the salt-bridge formed between these two residues in the PEP-bound 
NmeDAH7PSWT structure is important for the cooperativity between binding sites during Phe 
binding. The vastly different thermodynamic character for Phe binding to these variants 
indicates that in the absence of this salt bridge, the entropic cost for Phe binding may already 
be satisfied before titration of Phe into the calorimeter.  
The KD values for Phe binding at both sites of NmeDAH7PS
Glu176Gln were 2 ± 1 µM and 9 ± 1 µM 
respectively, and are similar to that of NmeDAH7PSWT (Figure 5.3.3.3). This is perhaps not 
surprising, as the interactions that Gln176 makes with surrounding residues are likely to be 
similar to those made by Glu176 in NmeDAH7PSWT. Inspection of the thermodynamic 
parameters illustrate that binding of Phe to this variant has a greater enthalpic contribution to 
binding at both sites than NmeDAH7PSWT. 
 
Figure 5.3.3.3 ITC data for the titration of 1.2 mM Phe into 16 µM NmeDAH7PS
Glu176Gln
 variant (pink) A) Raw 
data from ITC experiment fit to two-site sequential binding model B) Comparison of the thermodynamic 
parameters for binding at both sites with NmeDAH7PS
WT
 (blue) C) Comparison of dissociation constant (KD) at 
both sites of the two-site sequential binding model with NmeDAH7PS
WT
 (blue). All ITC isotherms and graphs 
were fit and their corresponding heat of dilutions subtracted using OriginLab® version 7.0. 
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5.3.4 Crystallographic characterisation of hydrogen bonding network variants  
 
Crystal structures of these variant enzymes in the presence and absence of Phe were obtained 
using X-ray diffraction methods, in order to structurally rationalise the characteristics of Phe 
binding and the kinetic properties observed for these variant enzymes. Crystals of the 
NmeDAH7PS variants were grown using procedures describe in sections 7.1.30 and 7.1.31. The 
soaking of Phe into these structures was achieved using the procedures described in section 
7.1.33.  
The structural differences in these variants, not only compared to the NmeDAH7PSWT, but to 
other variant structures in the presence and absence of Phe, may illuminate the importance of 
interactions between the mutated residues in the network. The structural variation upon 
removal of the ionisable side-chains of residues involved in the network may better our 
understanding of how allostery is communicated between distant sites of NmeDAH7PS and 
help illustrate the role of each residue in the transfer of this allosteric signal. All ligands were 
present at full occupancy unless otherwise stated.  
 
Comparison of the RMSD per residue for the tight dimer of all Phe-absent variant enzymes to 
the PEP-bound NmeDAH7PSWT structure (PDB code: 4HSN), indicate that the region with the 
most significant structural variation is the β2α2 loop (res. 95-120). Comparisons of the RMSD 
per residue for the tight dimer of the Phe-bound variant structures with the Phe-bound 
NmeDAH7PSWT (PDB code: 4UC5) indicate that the regions of most significant variation is also 
localised to the β2α2 loop (res 95-120) as well as the β8α8 loop and α8 helix (res. 305-349). 
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Figure 5.3.4.1 Comparison of the root mean squared deviation of all Phe-absent variant enzymes against the 
PEP-bound NmeDAH7PS
WT
 structure (PDB code: 4HSN) NmeDAH7PS
Glu98Ala
 (brown), NmeDAH7PS
Gln172Ala
 
(orange), NmeDAH7PS
Lys107Ala
 (yellow), NmeDAH7PS
Glu176Ala
 (light blue), NmeDAH7PS
Glu176Gln
 (pink).  
 
Figure 5.3.4.2 Root mean squared deviation of all Phe-bound variant enzymes against Phe-bound 
NmeDAH7PS
WT
 structure PDB code: 4UC5. NmeDAH7PS
Glu98Ala
 (brown), NmeDAH7PS
Lys107Ala
 (yellow), 
NmeDAH7PS
Gln172Ala
 (orange), NmeDAH7PS
Glu176Ala
 (light blue) and NmeDAH7PS
Glu176Gln
 (pink).  
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Crystal structures of Phe- and PEP-bound NmeDAH7PSGlu98Ala 
Two crystal structures of the NmeDAH7PSGlu98Ala variant were determined by X-ray diffraction. 
The PEP-bound structure was refined to a resolution of 2.50 Å and crystallised in the same 
space group as the PEP-bound NmeDAH7PSWT structure (P1211) (PDB code: 4HSN). Data 
collection and refinement statistics are shown in Table 5.3.4.1. The RMSD for the alignment of 
the tight dimers of the PEP-bound NmeDAH7PSGlu98Ala variant to the PEP-bound NmeDAH7PSWT 
structure was 0.235-0.358 Å. This indicates a very similar overall structure for this variant 
enzyme. These structures are remarkably similar (Figure 5.3.4.1), however the most drastic 
difference between the two structures is localised to the β2α2 loop on which this mutation sits.  
 
Figure 5.3.4.3 A) |Fo-Fc| map coloured in green and contoured at 3.0 σ to illustrate the presence of PEP at full 
occupancy in the active site. B) Structural alignment of PEP-bound NmeDAH7PS
Glu98Ala
 (brown) (PDB code: 5CZ0) 
with PEP-bound NmeDAH7PS
WT 
(green) (PDB code: 4HSN) indicating the variability within the same structure 
upon this mutation and the loss of connection to residues of the β3α3 loop. |2Fo-Fc| map coloured in blue and 
contoured at 1.0 σ to illustrate mutation. Chain A, indicating new position of the β2α2 loop C) Chain B, indicating 
the preservation of the position of the  β2α2 loop. 
 
In NmeDAH7PSGlu98Ala the hydrogen bonds that link the β2α2 loop with residues of the β3α3 loop 
and the α3 helix are lost. This indicates the removal of a crucial link between the allosteric and 
active site within the same chain, which may contribute to the higher affinity of this variant for 
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PEP, as PEP binding is no longer mediated by the interaction between the β2α2 loop  and 
residues, Asp148, Thr151, and Tyr155. The variability in conformation of the N-terminal end of 
the β2α2 loop between chains of the aligned dimer indicates greater flexibility in this region for 
NmeDAH7PSGlu98Ala (Figure 5.3.4.1 B & C). Interestingly, the active site ligand PEP adopts the 
same conformation to that observed in the PEP-bound NmeDAH7PSWT even though the 
residues around it in at least one of the chains have moved considerably (Figure 5.3.4.3). There 
is a small repositioning of residue, Glu145 (also located on the β3α3 loop), which is involved in 
the binding and positioning of the nucleophilic water molecule, responsible for the attack of 
the oxocarbenium ion reaction intermediate.100 This residue has moved closer to the C2 
position of PEP, probably due to the loss of interaction between Glu98 and the β3α3 loop and 
α3 helix. The restriction on the position of Glu145 incurred by these hydrogen bonds is lost in 
this mutation and thus, may explain the decreased KM observed in kinetic assays for PEP in 
NmeDAH7PSGlu98Ala. 
 
The Phe-bound structure of NmeDAH7PSGlu98Ala was refined to a resolution of 2.42 Å and 
crystallised in the same space group as the Phe-bound NmeDAH7PSWT structure (P1211) (PDB 
code: 4UC5). Data collection and refinement statistics are shown in table 5.3.4.1. The RMSD 
for the alignment of the tight dimers of the Phe-bound NmeDAH7PSGlu98Ala variant to the Phe-
bound NmeDAH7PSWT structure was 0.192-0.381 Å, indicative of a high similarity between 
these structures (Figure 5.3.4.2). Comparison of these structures indicates that the only region 
of the protein that adopts a different conformation in the presence of Phe is the β2α2 loop.   
 
The binding of Phe in the allosteric site of the NmeDAH7PSGlu98Ala variant enzyme is very similar 
to the Phe-bound NmeDAH7PSWT. This is perhaps not surprising as the distance between Cα of 
the mutated residue and Cα of allosteric Phe is ~22 Å from the allosteric site of the adjacent 
chain across the tight dimer interface and ~19 Å from the allosteric site within the same chain. 
The reorganisation of the network observed in the Phe-bound NmeDAH7PSWT cannot occur in 
NmeDAH7PSGlu98Ala variant upon removal of the Glu side-chain. As a result, both Gln172ʹ and 
Asn111, which were involved in hydrogen bonds with Glu98 in the Phe-bound NmeDAH7PSWT 
structure adopt different rotamers. The amide functionality of Asn111 is no longer able to 
form a hydrogen bond with any other residue and Gln172ʹ does not form hydrogen bonds with 
residues of the β2α2 loop, but instead forms a hydrogen bond with the sidechain of Glu176ʹ 
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located on the same helix. The side-chain of Lys107 could not be resolved due to partial 
disorder as it too is intimately associated with the aforementioned residues in the Phe-bound 
NmeDAH7PSWT structure. This may be an artefact of the resolution that this structure was 
determined at, as the side-chains of several residues of the β2α2 loop were also unresolved. 
The crucial link between the active and allosteric site of the same chain and its influence on 
communication with the β2α2 loop across the tight dimer interface that this residue affords in 
NmeDAH7PSWT may explain the reduced sensitivity to Phe observed in kinetic studies for this 
variant. 
 
 
Figure 5.3.4.4 A) Structural alignment of Phe-bound NmeDAH7PS
Glu98Ala
 (brown) (PDB code: 5CZS) with Phe-
bound NmeDAH7PS
WT
 (blue) (PDB code: 4UC5) indicating the inability of res. 98 to form the hydrogen bonds 
that it does in the NmeDAH7PS
WT
. |2Fo-Fc| map coloured in blue and contoured at 1.0 σ to illustrate mutation, 
the similar positioning of this loop and the presence of PEP (0.75 occ.) in its upright conformation at the active 
site of NmeDAH7PS
Glu98Ala
 B) Allosteric binding site indicating the conservation of structural characteristics in 
NmeDAH7PS
Glu98Ala
. |Fo-Fc| map coloured in green and contoured at 3.0 σ to illustrate presence of Phe at full 
occupancy. 
 
Interestingly, the presence of PEP is evident at the active site of the Phe-bound 
NmeDAH7PSGlu98Ala variant enzyme and has been modelled in at 0.75 occupancy. Chapter 4 
showed that in the presence of Phe, PEP adopted a flipped binding mode. However, in the 
NmeDAH7PSGlu98Ala variant enzyme, PEP binds in its normal reactive position (albeit at 0.75 
occupancy) in a conformation that resembles that observed in the active enzyme. The 
interactions that this residue makes with other residues of the β2α2 loop, as well as Gln172ʹ 
and Glu176ʹ in the Phe+PEP-bound NmeDAH7PSWT structure (PDB code: 5DCB) are therefore 
likely to be important to the flipped binding mode of PEP. In the absence of the Glu side-chain, 
the active site is not sufficiently reorganised to bind PEP in its flipped binding mode. This may 
be a significant contributor to the reduction in allosteric response observed from kinetic 
studies in NmeDAH7PSGlu98Ala (Figure 5.3.1.2). 
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Crystal structures of Phe- and PEP-bound NmeDAH7PSGln172Ala 
Two crystal structures of the NmeDAH7PSGln172Ala variant were determined by X-ray diffraction. 
The PEP-bound structure was refined to a resolution of 2.68 Å and crystallised in the same 
space group as NmeDAH7PSWT (P1211) (PDB code: 4HSN). Data collection and refinement 
statistics are shown in table 5.3.4.1. The RMSD for the alignment of the tight dimers of the 
PEP-bound NmeDAH7PSGln172Ala variant to the NmeDAH7PSWT structure (PDB code: 4HSN) was 
0.270-0.449 Å. These structures are similar, but again show greater variation, localised to the 
β2α2 loop (Figure 5.3.4.1).  
 
Gln172ʹ in the PEP-bound NmeDAH7PSWT structure forms an important hydrogen bond with 
the backbone carbonyl and peptide amino group of Lys99 and Arg101 respectively. The 
importance of Lys99 to catalysis100 and its positioning at the N-terminal end of the β2α2 loop 
highlight the possible influence of Gln172ʹ on catalysis. In the NmeDAH7PSGln172Ala variant 
enzyme, the β2α2 loop from the only chain that could be resolved was shifted with an average 
RMSD from the alignment of the tight-dimer of 1.42 Å. The partial disorder of the β2α2 loop in 
three of the four chains of the tetramer is indicative of increased flexibility in this region and 
may be a result of the loss of the aforementioned interactions with the β2α2 loop. In the chain 
where the β2α2 loop could be resolved, interactions between residue 172ʹ and the backbone 
carbonyl of Lys99, as well as the backbone peptide amino group of Arg101 were lost. The salt 
bridge between the side-chains of Lys107 and Glu176ʹ has also been compromised in this 
variant (Figure 5.3.4.5B). Interestingly, the result of the loss of these interactions are visible in 
the crystal structure, where Lys107 and Lys99 adopt different positions and conformations in 
the PEP-bound NmeDAH7PSGln172Ala variant compared to PEP-bound NmeDAH7PSWT (Figure 
5.3.4.5B).  
 
The partial disorder for residues of the β2α2 loop resulted in the inability to resolve the side-
chain of Lys107 in all four chains. While this is probably a result of the failure to form a salt 
bridge with Glu176ʹ, it may be due to the low resolution that this dataset was collected at. The 
new position of this loop in the presence of PEP may have direct implications for the binding of 
substrates. Lys99 adopts a significantly different position and is no longer in a conformation 
able to form a hydrogen bond with the carboxylate of PEP. The new conformation of residues 
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(97-101) at the N-terminal end of this loop may also contribute the increased KM for 
substrates, PEP and E4P. The hydrogen bonds between Glu98 and residues Asp148, Thr151 
and Tyr155 of the β3α3 loop and α3 helix are no longer present in the NmeDAH7PS
Gln172Ala 
variant structure. The previously outlined residues involved in the formation of Phe-bound 
network; Glu98, Lys99 and Lys107 all adopt different conformations in this variant in the 
presence of PEP compared to the PEP-bound NmeDAH7PSWT structure. Therefore, 
NmeDAH7PSGln172Ala may be primed for inhibition by Phe due to the lack of stabilising effect 
provided by Ala172ʹ on the β2α2 loop. This may contribute to the hyper-sensitivity of this 
variant to concentrations of Phe.  
 
Figure 5.3.4.5 A) Binding mode of PEP in the active site of NmeDAH7PS
Gln172Ala
. |Fo-Fc| map coloured in green 
and contoured at 3.0 σ to illustrate presence of PEP in the site at full occupancy. B) Comparison of the 
positioning of the β2α2 loop in NmeDAH7PS
Gln172Ala
 (orange) with that of the NmeDAH7PS
WT
 (green) (PDB code: 
4HSN) illustrating the loss of hydrogen bonds between residues of the β2α2 loop and Ala172 in the 
NmeDAH7PS
Gln172Ala
 variant. |2Fo-Fc| map coloured in blue and contoured at 1.0 σ to illustrate the mutation.   
 
The Phe-bound structure was refined to a resolution of 2.30 Å and crystallised in the same 
space group as the PEP-bound NmeDAH7PSWT (P1211). Data collection and refinement 
statistics are shown in table 5.3.4.1. The RMSD for the alignment of the tight dimers of the 
Phe-bound NmeDAH7PSGln172Ala variant to the Phe NmeDAH7PSWT structure (PDB code: 4UC5) 
was 0.140-0.252 Å. This is indicative of a very similar overall structure for this variant enzyme 
and there are no regions of obvious variation (Figure 5.3.4.2). 
 
The Phe binding site for the NmeDAH7PSGln172Ala remained unaffected by the mutation and the 
residues that make up the site were in the same position as was observed in the Phe-bound 
Β2α2 loop 
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NmeDAH7PSWT structure (Figure 5.3.4.6A). The β2α2 loop also adopts the same conformation 
as that of the Phe-bound NmeDAH7PSWT structure (Figure 5.3.4.6B). This implies that the 
allosteric effect of Phe binding on this loop and the surrounding residues remains largely 
unaffected by this mutation and indicates that it may not influence the formation of the Phe-
bound network described previously. It must be noted that the conformations explored by the 
protein in the crystalline form are limited and may not totally reflect what may occur in 
solution, therefore, the similarity between conformations of the β2α2 loop may be an artefact 
of crystal packing effects during the soaking experiment. However, the similarity between the 
Phe-bound NmeDAH7PSGln172Ala structure and the Phe-bound NmeDAH7PSWT structure is in 
accordance with the MD work done in chapter 5, where this residue was not highlighted as 
being crucial to the formation of the Phe-bound “regulated” network. 
 
Taken together with what was observed in the PEP-bound NmeDAH7PSGln172Ala variant, it 
seems that the enzyme may be primed for inhibition by Phe, but can still undergo the 
reorganisation in the presence of Phe to form the Phe-bound network of interactions. This 
may explain the hypersensitivity of this variant enzyme to Phe even when Phe binding is 
slightly weaker than the wild-type enzyme, shown by ITC. 
  
Figure 5.3.4.6 A) Binding mode of Phe in the allosteric site of NmeDAH7PS
Gln172Ala
. |Fo-Fc| map coloured in green 
and contoured at 3.0 σ to illustrate presence of Phe in the site at full occupancy. B) Comparison of the 
positioning of the β2α2 loop in Phe-bound NmeDAH7PS
Gln172Ala
 (orange) with that of the Phe-bound 
NmeDAH7PS
WT
 (blue) (PDB code: 4UC5), illustrating the loss of hydrogen bonds between residues of the β2α2 
loop and Ala172 in the NmeDAH7PS
Gln172Ala
 variant. |2Fo-Fc| map coloured in blue and contoured at 1.0 σ to 
illustrate the mutation.   
 
Β2α2 loop 
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Crystal structure of Phe+ PEP-bound NmeDAH7PSLys107Ala 
A single crystal structure of the NmeDAH7PSLys107Ala variant was determined by X-ray 
diffraction methods. The PEP+Phe double liganded structure was refined to a resolution of 
1.75 Å and crystallised in the same space group as the PEP-bound NmeDAH7PSWT (P1211) (PDB 
code: 4HSN). Data collection and refinement statistics are shown in table 5.3.4.2. The RMSD 
for the alignment of the tight dimers of this variant to the Phe-bound NmeDAH7PSWT structure 
(PDB code: 4UC5) was 0.216-0.323 Å and the RMSD for the alignment of the tight dimers of 
this variant to the Phe+PEP NmeDAH7PSWT structure (PDB code: 5DCB) was 0.206-0.249 Å. This 
indicates that this enzyme is again similar to both Phe-bound structures of NmeDAH7PSWT but 
does show subtle differences in the structure of the β2α2 loop. Unfortunately, a crystal 
structure without the allosteric ligand Phe was unable to be obtained, as even when Phe was 
not soaked into the crystal, the ligand was present at the allosteric site at ~0.6-0.7 occupancy. 
This may be due to the high affinity that this enzyme displayed for Phe from the ITC 
experiments, and indicates that Phe may have remained bound to this variant throughout the 
purification. 
 
The Phe binding site remained largely intact in the NmeDAH7PSLys107Ala variant enzyme. A 
structural alignment of the Phe binding site indicates large conservation of the structural 
features that make up the site (Figure 5.3.4.7A). PEP was bound in this structure in a flipped 
orientation, very similar to that seen for Phe+PEP-bound NmeDAH7PSWT (PDB code: 5DCB) 
(Figure 5.3.4.7.B). Perhaps what is most interesting, is the conformation adopted by the β2α2 
loop in the presence of allosteric ligand. In the NmeDAH7PSLys107Ala variant, Arg101, part of the 
conserved KPR(T/S) motif (believed to be responsible for binding the phosphate of E4P) adopts 
a new conformation, where it forms a salt bridge with Glu98 like that observed in the Phe-
bound EcoDAH7PS and Tyr bound SceDAH7PS structures (PDB codes: 1KFL and 1OF6). Arg101 
also forms hydrogen bonds with the backbone carbonyl of Lys99 and the side-chain oxygen of 
Gln172ʹ (Figure 5.3.4.8A). This new conformation adopted by Arg101 upon mutation of Lys107, 
causes a small reorganisation of the hydrogen bonding network of the β2α2 loop.  
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Figure 5.3.4.7 Double liganded NmeDAH7PS
Lys107Ala
 variant A) Allosteric binding site indicating the conservation 
of structural characteristics in NmeDAH7PS
Lys107Ala
 variant compared to NmeDAH7PS
WT
 (PDB code: 4UC5). |Fo-
Fc| map coloured in green and contoured at 3.0 σ to illustrate presence of Phe at full occupancy. B) Active site 
indicating the similarity of the side-chain conformations that make up the site for NmeDAH7PS
Lys107Ala
 (yellow) 
compared to NmeDAH7PS
WT
 (blue) (PDB code: 4UC5). |Fo-Fc| map coloured in green and contoured at 3.0 σ to 
illustrate presence of PEP in the site, in a flipped binding mode at full occupancy. 
 
Comparison of the new conformation of Arg101 to that observed in the Phe-bound, or 
Phe+PEP-bound structures of NmeDAH7PSWT (PDB codes: 4UC5 and 5DCB) indicates that the 
ability of this residue to appropriately bind the phosphate functionality of E4P during catalysis 
may be severely reduced. Interestingly, the conformation of this Arg residue in the double 
liganded structure from EcoDAH7PS (PDB code: 1KFL) is the same as is observed for the 
NmeDAH7PSLys107Ala variant (Figure 5.3.4.8B). The removal of the Lys107 side-chain may reduce 
the steric hindrance encountered by Arg101, enabling the formation of a salt bridge with 
Glu98.  
 
The salt bridge formed between Lys107 and Glu176ʹ across the tight dimer interface in the 
PEP-bound NmeDAH7PSWT structure may have two roles. Firstly, it may be involved in the 
stabilisation the β2α2 loop during catalysis, ensuring that the KPRT motif is in a conformation 
appropriate for the binding and catalysis of substrates. Secondly, limiting the ability to form a 
salt bridge between Arg101 and Glu98, which may result in the tighter, more enthalpically 
driven binding of Phe, where communication between both Phe binding sites is lost. 
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Figure 5.3.4.8 A) NmeDAH7PS
Lys107Ala
 variant active site, illustrating the salt-bridge and hydrogen bonds formed 
between Arg101 and Glu98, Asn111 and Gln172. |2Fo-Fc| map coloured in blue and contoured at 1.0 σ to 
illustrate the new conformation of Arg101 and the mutation of Lys107. B) Active site alignment of double 
liganded NmeDAH7PS
Lys107Ala
 (yellow) (PDB code: 5D05), Phe-bound NmeDAH7PS
WT 
(blue)
 
(PDB code: 4UC5), 
Double liganded NmeDAH7PS
WT 
(PDB code: 5DCB) and the double liganded EcoDAH7PS (wihte) (PDB code: 
1KFL) indicating the similarity between EcoDAH7PS and the NmeDAH7PS
Lys107Ala
 variant in the conformation 
adopted by the β2α2 loop.  
 
Crystal structures of Phe-bound and apo NmeDAH7PSGlu176Ala 
Two crystal structures of the NmeDAH7PSGlu176Ala variant were determined by X-ray diffraction 
methods. Unfortunately, attempts to obtain a PEP-bound structure of this variant were not 
successful. However, the apo structure was refined to a resolution of 2.40 Å and crystallised in 
an orthorhombic space group (P212121). Data collection and refinement statistics are shown in 
table 5.3.4.2. The RMSD for the alignment of the tight dimers of the apo NmeDAH7PSGlu176Ala 
variant to the PEP-bound NmeDAH7PSWT structure (PDB code: 4HSN) was 0.537-0.710 Å. The 
RMSD for the alignment of the tight dimers of the apo NmeDAH7PSGlu176Ala variant to the Phe-
bound NmeDAH7PSWT structure (PDB code: 4UC5) was 0.862-1.017 Å. This indicates that there 
are differences between the apo NmeDAH7PSGlu176Ala enzyme and both the Phe- and PEP-
bound NmeDAH7PSWT structures. Analysis of this RMSD per residue indicates again that the 
region with the most significant variation is the β2α2 loop (Figure 5.3.4.1).  
 
Glu176ʹ is intrinsically involved in the stabilisation of this loop in the PEP-bound NmeDAH7PSWT 
structure, via a salt bridge across the tight dimer interface with Lys107. Inspection of the 
variation seen for the β2α2 loop indicates that in the apo NmeDAH7PS
Glu176Ala structure it 
Β2α2 loop 
Β2α2 loop 
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adopts a conformation that is different to both the Phe-bound and PEP-bound NmeDAH7PSWT 
(Figure 5.3.4.9). 
 
Although Lys107 adopts a new position in the apo NmeDAH7PSGlu176Ala structure, and the 
partial disorder of its side-chain as well as other residues on the loop is indicative of greater 
flexibility, a hydrogen bond between Glu98 and Gln172ʹ is evident, like that seen in the Phe-
bound NmeDAH7PSWT structure. This is interesting, as it seems that in the NmeDAH7PSGlu176Ala 
variant, the absence of the Lys107-Glu176ʹ salt bridge may prime the β2α2 loop for entry into 
its Phe-bound conformation.  
 
As the loss of interaction between Glu98 and residues of the β3α3 loop and α3 helix was also 
observed for the PEP-bound NmeDAH7PSGln172Ala, it may explain the hyper-sensitivity to Phe at 
low concentrations for both of these variants during kinetic studies as one of the important 
interactions for the PEP-bound state of NmeDAH7PSWT is no longer present. However, this 
conclusion is speculative and cannot be validated as this structure was obtained in the absence 
of PEP. 
 
Figure 5.3.4.9 Comparison of the positioning of the β2α2 loop in the apo NmeDAH7PS
Glu176Ala
 (cyan) with 
NmeDAH7PS
WT
, illustrating the change in interactions between residues of the β2α2 loop and Gln172 in the 
NmeDAH7PS
Glu176Ala
 variant. |2Fo-Fc| map coloured in blue and contoured at 1.0 σ to illustrate the mutation. A) 
Comparison between the apo NmeDAH7PS
Glu176Ala 
(cyan) and the PEP-bound NmeDAH7PS
WT
 (green) (PDB code: 
4HSN). B) Comparison between the apo NmeDAH7PS
Glu176Ala 
(cyan) and the Phe-bound NmeDAH7PS
WT
 (blue) 
(PDB code: 4UC5). 
 
Β2α2 loop 
Β2α2 loop 
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The Phe-bound structure was refined to a resolution of 2.04 Å and crystallised in a monoclinic 
space group (P1211). Data collection and refinement statistics are shown in table 5.3.4.2. The 
RMSD for the alignment of the tight dimers of the Phe-bound NmeDAH7PSGlu176Ala variant to 
the Phe-bound NmeDAH7PSWT structure (PDB code: 4UC5) was 0.347-0.669 Å. This indicates 
that there is some variation between these two structures, which is localised to the β2α2 loop.  
 
The Phe binding site shows a high degree of structural conservation in the NmeDAH7PSGlu176Ala 
variant (Figure 5.3.4.10A). The β2α2 loop adopts a different conformation to that seen in the 
Phe-bound NmeDAH7PSWT structure in all four chains of the NmeDAH7PSGlu176Ala enzyme. In 
the Phe-bound NmeDAH7PSWT structure Gln172ʹ forms a hydrogen bond with both Lys107 and 
Glu176ʹ indicating that Glu176ʹ may be important for the formation of the Phe-bound 
hydrogen bonding network, as a hydrogen bond between Lys107 and Gln172ʹ is not formed in 
the NmeDAH7PSGlu176Ala variant enzyme (Figure 5.3.4.10B).  The loss of this structural stability, 
may explain the partial disorder observed for residues of the β2α2 loop in the presence of Phe 
in NmeDAH7PSGlu176Ala.  
 
 
Figure 5.3.4.10 A) Binding mode of Phe in the allosteric site of NmeDAH7PS
Glu176Ala
. |Fo-Fc| map coloured in 
green and contoured at 3.0 σ to illustrate presence of Phe in the site at full occupancy. B) Comparison of the 
positioning of the β2α2 loop in Phe-bound NmeDAH7PS
Glu176Ala
 (cyan) with that of the Phe-bound NmeDAH7PS
WT
 
(blue) (PDB code: 4UC5), |2Fo-Fc| map coloured in blue and contoured at 1.0 σ to illustrate the mutation.   
 
Β2α2 loop 
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The alignment of all four chains of the tetramer illustrates the significant variability in the 
position of the β2α2 loop. This is indicated in Figure 5.3.4.11, where the residues that make up 
the β2α2 loop adopt different positions in all four chains and in chain B, four residues of this 
loop could not be resolved. Considering the resolution (2.04 Å) of this structure and the high 
degree of disorder in this loop resulting in the limited backbone and side-chain resolvability, 
there is a high degree of flexibility in this region. The increased flexibility of the β2α2 loop may 
be correlated to the loss of a hydrogen bond between Lys107 and Gln172ʹ in the presence of 
Phe. Noticeably in chain B, for which several residues are not resolved, Arg101 forms a salt 
bridge with Glu98, like that seen in the NmeDAH7PSLys107Ala variant. This is intriguing, and could 
possibly aid in the correlation between ITC results between NmeDAH7PSLys107Ala and 
NmeDAH7PSGlu176Ala. The findings for NmeDAH7PSGlu176Ala also reiterates what was found for 
the NmeDAH7PSLys107Ala variant, where the removal of the Lys107-Glu176ʹ salt bridge across 
the tight dimer interface by their respective mutations has interesting implications for the 
conformation adopted by the β2α2 loop, that may be correlated to the ability to form the salt 
bridge between Arg101 and Glu98. The similarities observed between NmeDAH7PSLys107Ala and 
NmeDAH7PSGlu176Ala variants, further implicates the Lys107-Glu176ʹ salt bridge and the 
formation of the Arg101-Glu98 salt bridge in the one-site, largely enthalpically driven binding 
isotherm obtained for these two variants. 
 
Figure 5.3.4.11 Alignment of all four monomers of the NmeDAH7PS
Glu176Ala
 variant enzyme coloured by chain. 
Chain A (cyan), Chain B (dark blue), Chain C (sky blue) and Chain D (grey).  
Β2α2 loop 
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Crystal structures of Phe- and PEP-bound NmeDAH7PSGlu176Gln 
Two crystal structures of the NmeDAH7PSGlu176Gln variant were determined by X-ray diffraction 
methods. The PEP-bound structure was refined to a resolution of 1.87 Å and crystallised in the 
same space group as the PEP-bound NmeDAH7PSWT (P1211) (PDB code: 4HSN). Data collection 
and refinement statistics are shown in table 5.3.4.1. The RMSD for the alignment of the tight 
dimers of the PEP-bound NmeDAH7PSGlu176Gln variant to the PEP-bound NmeDAH7PSWT 
structure (PDB code: 4HSN) was 0.151-0.258 Å. This indicates the high degree of similarity 
between structures. The formation of hydrogen bonds between Gln176ʹ and Lys107, the kind 
seen in the PEP-bound NmeDAH7PSWT are also evident in this crystal structure. This indicates 
that the same hydrogen bonds can be formed in the PEP-bound structure of this variant upon 
the change from Glu to Gln (Figure 5.3.4.12). Furthermore, the positioning and conformation 
of the β2α2 loop remains unchanged in NmeDAH7PS
Glu176Gln. Ultimately, this indicates that 
there are no observable structural differences between the PEP-bound NmeDAH7PSGlu176Gln 
and the PEP-bound NmeDAH7PSWT, which is in accordance with what was hypothesised for 
this variant. This observation may also explain the retention of the sequential two-site binding 
model by ITC.   
 
Figure 5.3.4.12 A) Binding mode of PEP in the active site of NmeDAH7PS
Glu176Gln
. |Fo-Fc| map coloured in green 
and contoured at 3.0 σ to illustrate presence of PEP in the site at full occupancy. B) Similarity in conformation of 
the β2α2 loop in NmeDAH7PS
Glu176Gln
 (pink) with that of the NmeDAH7PS
WT
 (green) (PDB code: 4HSN) illustrating 
the retention of hydrogen bonds between residues of the β2α2 loop and residues: Gln172 and Gln176 in the 
NmeDAH7PS
Glu176Gln 
variant. |2Fo-Fc| map coloured in blue and contoured at 1.0 σ to illustrate the hydrogen 
bond between Lys107 and Gln176.   
Β2α2 loop 
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The Phe-bound crystal structure of the NmeDAH7PSGlu176Gln was refined to a resolution of 2.70 
Å and crystallised in the same space group as the PEP-bound NmeDAH7PSWT structure (PDB 
code: 4HSN) (P1211). Data collection and refinement statistics are shown in table 5.3.4.2. The 
RMSD for the alignment of the tight dimers of the Phe-bound NmeDAH7PSGlu176Gln variant to 
the Phe-bound NmeDAH7PSWT structure (PDB code: 4UC5) was 0.218-0.287 Å. This indicates 
large structural similarity between these structures. However, the poor resolution of this 
structure limits the confidence in identification of structural variation in this variant. 
Figure 5.3.4.13 A) Binding mode of Phe in the allosteric site of NmeDAH7PS
Glu176Gln
. |Fo-Fc| map coloured in 
green and contoured at 3.0 σ to illustrate presence of Phe in the site at full occupancy. B) Comparison of the 
positioning of the β2α2 loop in Phe-bound NmeDAH7PS
Glu176Ala
 (pink) with that of the Phe-bound NmeDAH7PS
WT
 
(blue) (PDB code: 4UC5) illustrating the new conformation of Asn111 and its loss of hydrogen bond with Glu98. 
The conserved water that links residues 98, 111 and 176 in the NmeDAH7PS
WT 
structure is shown as a small red 
sphere.  
Inspection of the Phe binding site of the NmeDAH7PSGlu176Gln variant indicates the structural 
similarity to the allosteric site of the Phe-bound NmeDAH7PSWT structure. The residues 
surrounding the β2α2 loop illustrate the lack of structural change in the NmeDAH7PS
Glu176Gln 
variant. Interestingly, Asn111 in this structure does form a hydrogen bond with Glu98 in this 
variant enzyme (Figure 5.3.4.13). The conserved water molecule that links Glu98, Asn111 and 
Glu176 in two chains of the Phe-bound and in all four chains of the double liganded 
NmeDAH7PSWT structures (PDB codes: 4UC5 & 5DCB), could not be resolved in the 
NmeDAH7PSGlu176Gln structure and may again be a result of the low resolution of this structure. 
Furthermore, inferences based on subtle variations in the positions of side-chains are also 
A B 
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dubious at this resolution. Overall, this variant enzyme shows little difference to 
NmeDAH7PSWT, which is perhaps not surprising due to the subtle change in the side-chain of 
Glu176ʹ. 
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 NmeDAH7PS Glu98Ala NmeDAH7PS Glu98Ala NmeDAH7PS Lys107Ala NmeDAH7PS Gln172Ala NmeDAH7PS Gln172Ala 
 L-Phenylalanine PEP L-Phenylalanine and PEP L-Phenylalanine PEP 
Data Collection      
Crystal system; space 
group 
Monoclinic, P1211 Monoclinic, P1211 Monoclinic, P1211 Monoclinic, P1211 Monoclinic, P1211 
Unit cell parameters       
a, b, c (Å) 73.32, 142.33, 74.59 73.85, 135.25, 76.04 75.33, 141.03, 76.03 73.17, 141.85, 74.76 73.07, 138.02, 76.27 
α, β, γ (º) 90, 96.84, 90 90, 95.95, 90 90, 97.02, 90 90, 96.40, 90 90, 96.03, 90 
Resolution range (Å) 74.06-2.42 (2.47-2.42) 75.63-2.50 (2.56-2.50) 74.46-1.75 (1.78-1.75) 47.28-2.30 (2.35-2.30) 75.85-2.68 (2.78-2.68) 
Measurements 440483 335301 1195557 505973 158867 
Unique reflections 57783 50068 158105 67189 42187 
Redundancy 7.6 (7.1) 6.7 (6.8) 7.6 (7.4) 7.5 (7.6) 3.8 (3.8) 
Completeness (%) 99.8 (97.1) 97.7 (97.6) 100.0 (99.7) 100.0 (100.0) 99.8 (100) 
I/σ (I) 11.0 (1.76) 9.0 (2.27) 16.9 (2.14) 14.6 (2.3) 12.8 (1.7) 
Rmerge 0.156 (0.906) 0.122(0.753) 0.079 (0.869) 0.094 (0.870) 0.069 (0.619) 
CC1/2 0.702 0.784 0.68 0.716 0.707 
Wilson B value (Å)2 31.4 40.77 20.70 36.65 53.96 
Matthews coefficient 2.54 (51.65) 2.48 (50.53) 2.64 (53.38) 2.54 (51.54) 2.52 (51.15) 
 
Refinement 
     
Rwork 0.1910 0.2003 0.1495 0.1859 0.1956 
Rfree 0.2457 0.2639 0.1756 0.2319 0.2586 
Chain length 351 351 351 351 351 
Observed number of 
residues 
345 (Chain A, B & C) 346 (Chain 
D) 
333 (chain A) 332 (Chain B, C 
&D) 
345 (Chain A, B & C) 346 (Chain 
D) 
345 (Chain A, C &D) 343 (Chain 
B) 
332 (Chain A, B & C) 333 (Chain 
D) 
Water molecules 331 112 1132 232 14 
Other 8 (Mn2+, EDO, PEG) 8 (Mn2+, SO4
2-, EDO) 15 (Cl-, SO4
2-, PEG, Mn2+) 10 (EDO, PEG, SO4
2-, Mn2+) 4 (Mn2+, EDO) 
Ligand 8 (PEP(0.75 occ.), Phe) 4 (PEP) 8 (PEP, Phe) 4 (Phe) 4 (PEP) 
Mean B (Å)2      
Protein 35.55 47.79 23.59 47.91 63.65 
Water 30.13 37.02 29.96 42.47 42.10 
Other 43.87 74.15 57.68 71.73 66.03 
Ligand 46.66, 26.38 64.35 21.65, 17.71 (PEP, Phe) 39.17 87.17 
R.m.s.d from target 
values 
     
Bond lengths (Å) 0.0101 0.0111 0.0103 0.0097 0.0088 
Bond angles  1.3819 1.4309 1.3868 1.3300 1.2587 
Dihedral angles 0.0721 0.0743 0.0826 0.0738 0.0679 
Ramachandran      
Preferred (%) 96.48 95.54 97.62 96.87 95.73 
Allowed (%) 3.37 4.16 2.16 2.98 4.04 
Outliers (%)  0.15 0.30 0.22 0.15 0.23 
PDB Entry 5CZS 5CZ0 5D05 XXXX XXXX 
Table 5.3.4.1 Data collection and refinement statistics for NmeDAH7PS
Glu98Ala
 and NmeDAH7PS
Gln172Ala
 in the presence and absence of Phe as well as NmeDAh7PS
Lys107Ala
 in the 
presence of both PEP and Phe. (PDB codes: 5CZS, 5CZ0, 5D05, XXXX and XXXX) (XXXX-un-deposited structure) .
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 NmeDAH7PS Glu176Ala NmeDAH7PS Glu176Ala NmeDAH7PS Glu176Gln NmeDAH7PS Glu176Gln 
 L-Phenylalanine Apo L-Phenylalanine PEP 
Data Collection     
Crystal system; space 
group 
Monoclinic, P1211 Orthorhombic, P212121 Monoclinic, P1211 Monoclinic, P1211 
Unit cell parameters      
a, b, c (Å) 75.65, 140.83, 77.27 78.38, 135.37, 74.68 73.43, 139.70, 75.12 73.54, 135.55, 76.01 
α, β, γ (º) 90, 98.56, 90 90, 90, 90 90, 95.83, 90 90, 96.27, 90 
Resolution range (Å) 76.41-2.04 (2.08-2.04) 100.47-2.40 (2.46-2.40) 46.89-2.70 (2.81-2.70) 75.55-1.87 (1.90-1.87) 
Measurements 772315 922106 312591 455196 
Unique reflections 101442 62994 41374 121730 
Redundancy 7.6 (7.2) 14.6 (14.0) 7.6 (7.7) 3.7 (3.8) 
Completeness (%) 99.9 (98.7) 100.0 (99.9) 99.9 (99.9) 99.9 (100.0) 
I/σ (I) 18.6 (2.6) 19.5 (2.3) 17.4 (2.2) 11.7 (1.77) 
Rmerge 0.079 (0.696) 0.122 (1.21) 0.074 (1.014) 0.054 (0.890) 
CC1/2 0.808 0.772 0.851 0.600 
Wilson B value (Å)2 28.40 41.08 64.12 31.20 
Matthews coefficient 2.68 (54.09) 2.62 (53.01) 2.52 (51.25) 2.48 (50.38) 
 
Refinement 
    
Rwork 0.1706 0.2006 0.2182 0.1761 
Rfree 0.2057 0.2557 0.26835 0.2207 
Chain length 351 351 351 351 
Observed number of 
residues 
345 (All four chains) 332 (Chains A, C &D), 333 
(Chain B) 
343 (Chains A, B & C), 344 
(Chain D) 
333 (Chain A, C &D) 334 (Chain 
B) 
Water molecules 745 230 17 640 
Other 7 ( Cl-, Mn2+) 8 (EDO, Mn2+, SO4
-) 7 (EDO, Mn2+, Cl-) 11 (Mn2+, EDO, SO4
2-) 
Ligand 4 (Phe) - 4 (Phe) 4 (PEP) 
Mean B (Å)2     
Protein 31.58 42.13 85.44 38.53 
Water 34.50 34.95 81.91 40.80 
Other 37.79 55.65 84.77 57.57 
Ligand 22.77 N/A 68.93 38.47 
R.m.s.d from target 
values 
    
Bond lengths (Å) 0.0107 0.0118 0.0095 0.0114 
Bond angles  1.3910 1.4816 1.2953 1.4502 
Dihedral angles 0.0803 0.0799 0.0668 0.0863 
Ramachandran     
Preferred (%) 97.06 96.68 96.71 97.15 
Allowed (%) 2.35 3.02 3.00 2.63 
Outliers (%)  0.59 0.30 0.29 0.22 
PDB Entry 5CZT XXXX XXXX 5D02 
Table 5.3.4.2 Data collection and refinement statistics for NmeDAH7PS
Glu176Ala
 and NmeDAH7PS
Glu176Gln
 in the presence and absence of Phe. (PDB codes:5CZT, XXXX, XXXX and 
5D02) (XXXX-un-deposited structure).
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5.4 DISCUSSION 
Several variants of NmeDAH7PS were generated to better our understanding of how 
NmeDAH7PS communicates allostery between its active and allosteric sites. Two mutants 
were designed to elucidate the importance of hydrophobic interactions within the allosteric 
site. A further five variant enzymes were designed to understand the importance of hydrogen 
bonding network reorganisation in the transfer of allosteric information.  
 
Hydrophobic binding pocket has important role in Phe binding  
 
The structural and functional characterisation of the two allosteric site variant enzymes has 
reiterated the importance of hydrophobic interactions in the allosteric binding pocket for 
ligand recognition and binding. The findings illustrate the importance of the β-hairpin insertion 
for allostery, on which both Phe211 and Val223 are located. Both of these residues were 
shown by kinetics to be crucial to the sensitivity of NmeDAH7PS to Phe and this reduction or 
loss of sensitivity to Phe appears to be due primarily to a reduction or loss of binding affinity 
for Phe.  
 
Contrary to previous studies, this investigation illustrated the importance of Phe211 for the 
binding of Phe. It has been shown that the edge to face π-stacking interaction provided by 
Phe211, or the structural organisation of the allosteric site provided by the aromatic ring of 
Phe211 prior to Phe binding are crucial to Phe binding in NmeDAH7PS.  
 
Crucial connection to allosteric site within same chain is important for regulation 
 
The active site of NmeDAH7PS is connected to the allosteric site within the same chain, via 
Glu98 located at the N-terminal end of the β2α2 loop. Glu98 interacts with residues: Asp148, 
Thr151 and Tyr155 from the β3α3 loop and α3 helix. Gln153, also located on β3α3 loop has a role 
in binding the amine moiety of Phe. Mutation of Glu98 resulted in a decreased KM for the 
substrate PEP and implies that the interaction, which connects allosteric and active sites within 
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the same chain may compromise the apparent affinity of NmeDAH7PSWT for its natural 
substrate. In the NmeDAH7PSGlu98Ala variant, PEP was bound in its reactive conformation in the 
presence of Phe, unlike that observed for NmeDAH7PSWT. This suggests that Glu98 may be 
involved in the inversion of the binding mode of PEP, and is an important contributor to the 
allosteric mechanism of NmeDAH7PSWT. This finding is probably due to the loss of the ability 
for this residue to take part in the postulated hydrogen bonding network via interactions with 
Lys107, Asn111 and Gln172ʹ. The involvement of this residue in the allosteric mechanism of 
NmeDAH7PS is proven by the significant decrease in sensitivity to Phe at all concentrations 
tested for this variant.  
 
Interactions across the tight dimer interface are crucial for the allosteric mechanism o 
NmeDAH7PS 
 
There is a notable interaction across the tight dimer interface in the PEP-bound enzyme 
consisting of a salt bridge between Lys107 of the β2α2 loop and Glu176ʹ of the α4 helix. Both of 
these residues were mutated in this study, with interesting results. Unfortunately, the 
NmeDAH7PSLys107Ala variant was catalytically inactive, due to the retention of Phe, revealed by 
ITC and crystallographic studies. The binding isotherm was however fit to a one-site binding 
model, a feature that was also evident for NmeDAH7PSGlu176Ala. The thermodynamic 
parameters indicated a very large enthalpic and minimal entropic contribution to binding in 
both of these variants.  
 
Taken together, the binding isotherms for these two variants suggest that the Lys107-Glu176ʹ 
salt bridge is a contributor to the entropic penalty paid upon Phe binding to NmeDAH7PSWT. 
Therefore in the absence of the Lys107-Glu176ʹ salt bridge, in these variants, the entropic 
penalty has already been paid, thus reducing the entropic contribution to the binding 
isotherm.  Crystal structures of these variants highlighted an important feature that may result 
from the loss of the Lys107-Glu176ʹ salt bridge. In the presence of Phe, a salt bridge between 
Arg101 and Glu98 was evident in all four chains of NmeDAH7PSLys107Ala and in one chain of 
NmeDAH7PSGlu176Ala. This new interaction, within the β2α2 loop may contribute to the enthalpic 
character of the binding isotherm in these variants. 
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The high degree of disorder in the β2α2 loop when Phe is present at full occupancy in 
NmeDAH7PSGlu176Ala may correlate to the limited inhibition achieved by Phe at concentrations 
> 200 µM. The hyper-sensitivity to Phe at low concentrations, observed for the 
NmeDAH7PSGlu176Ala variant suggests that the loss of stabilising interactions between Glu176ʹ 
and the β2α2 loop in the absence of Phe may prime the variant for inhibition by Phe.  
 
The correlation between these two variants experimentally illustrates the importance of the 
Lys107-Glu176ʹ salt bridge in propagation and mediation of the allosteric signal, as well as the 
formation of the active and Phe-bound interaction networks around the β2α2 loop in 
NmeDAH7PS.  
 
It was postulated that Gln172ʹ, located on the same α4 helix as Glu176ʹ, would have a crucial 
involvement in the allosteric mechanism of NmeDAH7PSWT. Gln172ʹ forms interactions with 
Lys99 and Arg101 of the conserved KPR(T/S) motif in the PEP-bound NmeDAH7PSWT structure 
and both Glu98 and Lys107 of the β2α2 loop in the Phe-bound NmeDAH7PS
WT structure. 
However, the role of Gln172ʹ in the reorganisation of the β2α2 loop in the presence of Phe was 
not found to be the case and is in agreement with MD simulations, which do not highlight it as 
an important residue in the formation of the Phe-bound network. The lack of involvement of 
Gln172ʹ during regulation by Phe was exposed by the Phe-bound crystal structure of the 
NmeDAH7PSGln172Ala variant, where the β2α2 loop adopted the same conformation as that 
observed in the Phe-bound NmeDAH7PSWT structure. Its involvement with the β2α2 loop during 
catalysis however, was found to be far more revealing. The catalytic rate and KM for both 
substrates increased in the NmeDAH7PSGln172Ala variant. The PEP bound crystal structure of this 
variant indicated that partial disorder for the β2α2 loop was evident three of four chains. This 
observation suggests that Gln172ʹ may have a key role in determining the conformations 
available to the β2α2 loop.  
 
The hyper-sensitivity to low concentrations of Phe, observed for both the NmeDAH7PSGln172Ala 
and NmeDAH7PSGlu176Ala may be a result of the loss of interaction with the β2α2 loop observed 
in their respective Phe-less crystal structures. The loss of these interactions with the β2α2 loop 
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in the absence of Phe suggests that these variants may be primed for inhibition by Phe. The 
differences in catalytic rate observed for these variants implies that this feature unlikely to be 
a direct result of absolute activity.  
 
Conclusion  
  
The complicated network of interactions between residues of the β2α2 loop across the tight 
dimer interface with the β-hairpin insertion and α4 helix and within the same chain with 
residues of the β3α3 loop and α3 helix have been identified in this study. The experimental 
results have a high level of redundancy due to the complexity of these interaction networks. 
However, the extensive description of the structural and functional relationships between the 
variants involved in this study has illustrated the importance of these residues to the 
propagation and conferral of allosteric signal. It has been shown that careful control of the 
dynamics of the β2α2 loop by residues on or surrounding it are crucial to both catalysis and 
regulation in NmeDAH7PS. 
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CHAPTER 6- SUMMARY AND FINAL REMARKS 
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This thesis describes a detailed investigation of the structure and function of NmeDAH7PS. This 
has involved a detailed study of the active site of NmeDAH7PS as a as a potential target for the 
development of novel antibiotics against bacterial meningitis. Investigations into the 
quaternary structure of NmeDAH7PS have also identified the importance of the tetrameric 
assembly of this enzyme for catalysis and allostery. Perhaps most importantly, this thesis 
explains in detail the subtleties of the allosteric mechanism adopted by this enzyme in the 
absence of large conformational change. This study has revealed that allostery is mediated by 
the interactions between the β2α2 loop and surrounding ionisable residues of the tight dimer. 
This chapter entails a summary of the key findings from the previous chapters and identifies 
the avenues for future work on this enzyme. It also illustrates the applicability of this work to 
other systems in nature. 
6.1 Stereochemistry of inhibitor enables accommodation of nucleophilic water, which is 
crucial for potency 
The structural and functional analysis of three highly ligand-efficient PEP-mimicking inhibitors 
of NmeDAH7PS has revealed the important characteristics required for potency. These 
characteristics have been shown to be in accordance with the stereochemistry of the catalytic 
mechanism and are centred on the nucleophilic attack of water at C2 of the oxocarbenium ion 
during catalysis. The conformation of the facial selectivity of the nucleophilic attack has been 
identified by the correlation between inhibitor potency and the favourable hydrogen bonding 
geometry and optimal van der Waals interactions with an active site water molecule in close 
proximity to C2 of all inhibitor and substrate bound structures (PDB codes: 4HSN, 4UMA, 
4UMB and 4UMC).26 However, the active site of NmeDAH7PS has been shown to most 
effectively accommodate a planar mimic or intermediate (E-vinyl phosphonate), implying that 
the planar oxocarbenium ion is an important high energy intermediate in catalysis.68–70 Based 
on transition state theory, an enzyme will bind most strongly to the transition state, therefore 
an enzyme that is able to mimic characteristics of this state will have the greatest potency.69 
Accommodation of this active site water molecule by this inhibitor and a stronger coulombic 
interaction with Lys99 are believed to be the main contributors to the inhibitor potency. 
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This is likely to provide a platform for future work in this area, which would involve the 
extension of this highly atom-efficient inhibitor137 into a seven carbon oxocarbenium 
intermediate mimic containing this planar phosphonate functionality at C2 and a rotatable 
isosteric phosphonate or phosphate functionality for occupation of the E4P binding site, 
similar to the bisphosphate inhibitors.54,138 This work will also involve the addition of backbone 
hydroxyl moieties in order to obtain more contacts within the site as they have been shown to 
be important for the affinity of E4P within the active site of EcoDAH7PS.49,53 This synthetic 
scheme would involve a carbohydrate scaffold of correct stereochemistry as the starting point 
(Figure 6.1.1).  
 
Figure 6.1.1 Extension and functionalisation of the highly atom efficient E-vinyl phosphonate inhibitor, 
oxocarbenium ion intermediate mimic 
 
Furthermore, given this structural understanding of the PEP binding site and the inhibitory 
potency dictated by interactions at this site, it is possible to computationally screen the site 
with a library of small ligands in order to identify new optimal contacts within the NmeDAH7PS 
active site. The extensive work previously done in the area of fragment-based-ligand-discovery 
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(FBLD) involving library screening, compound selection  and experimental testing, including: 
STD-NMR, Water LOGSY, DSF, ITC and crystallography will provide great resources in these 
attempts.139–147 The extensive knowledge of the NmeDAH7PS active site as well as the stability 
and proven crystallisation conditions would bode well in the deduction of structure-activity 
relationships (SAR). The culmination of this approach with that of the reaction intermediate 
based drug discovery previously mentioned may lead to the design and synthesis of an 
inhibitor that appropriately accommodates a large percentage of the chemical space present 
within the site.  
6.2 The allosteric site of NmeDAH7PS is selective for aromatic amino acids, in particular, Phe    
The aromatic amino acid, Phe was found to be the most potent feedback inhibitor of 
NmeDAH7PS and this potency was highly correlated to binding affinity. The important 
interactions distinguishing binding affinity between these aromatic amino acids are localised 
to the β6a strand. The steric hindrance generated by the hydroxyl of Ser213, was found to act 
as a selectivity filter in this enzyme, negating the binding of Tyr, which is in agreement with 
previous work.26 The recruitment of Phe211 and its π-stacking interaction with the aromatic 
ring of the amino acid were identified as important contributors to the binding affinity of the 
aromatic amino acid.  
Nonetheless, it is apparent that this site is extremely selective for the binding of these 
aromatic amino acids, in that, the movement of the β-hairpin insertion is linked to the 
hydrophobicity of the aromatic ligand. Furthermore, the N-terminal “allosteric binding loop” is 
highly selective for the amino carboxylate functionality, forming several electrosatic 
interactions. The allosteric site exhibits a high selectivity for these aromatic amino acids and 
lack of promiscuity between them. Therefore, attempts to target this site with effective 
alternative inhibitors would prove difficult.   
While Neisseria meningitidis expresses a single DAH7PS, other organisms express multiple 
paralogues that are each sensitive to feedback inhibition by a single aromatic amino acid. E. 
coli and S. cerevisiae both exhibit this characteristic; however, S. cerevisiae lacks the Trp 
sensitive paralogue. Interestingly, the Trp sensitive DAH7PS from E. coli has not had any 
structural or functional investigation. Given the understanding of the selectivity between Phe 
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and Tyr in these organisms, the characteristics that make up a Trp selective site are not well 
understood. A full investigation into the Trp sensitive paralog from EcoDAH7PS could give 
valuable insight into the sensitivity of NmeDAH7PS to high concentrations of Trp. 
6.3 Hydrophobic interactions are important for allostery in NmeDAH7PS 
Two variant NmeDAH7PS enzymes were made to better understand the ligand recognition of 
the largely hydrophobic allosteric site. Both of these point mutations (NmeDAH7PSPhe211Ala and 
NmeDAH7PSVal223Ala) are located on the β-hairpin insertion and were shown to be important 
for ligand binding. Phe211 was shown to be crucial for Phe to bind at any concentration, 
whereas substitution of Val223 exhibited reduced affinity for Phe.  
This work has focused on residues important for ligand recognition; however, future work 
should aim to identify the contribution of hydrophobic interactions to the communication of 
allosteric information in NmeDAH7PS. The work in this thesis on the transduction of an 
allosteric signal has focused entirely on ionisable and hydrogen bonding residues, but, the 
contribution of these hydrophobic residues to the transferal of allosteric signal should not be 
discounted. There are several hydrophobic residues that may be important for the conferral of 
regulation in NmeDAH7PS including but not limited to: Phe119 on the β2α2 loop, Phe144 on 
the β3α3 loop, Tyr155 on the α3 helix and Leu177 and Leu181 on the α4 helix. Successive 
mutations of these residues and their characterisation may illustrate their role in the allosteric 
response of NmeDAH7PS.   
 
6.4 Allosteric inhibitor binding pre-organises active site to bind PEP in a flipped (un-reactive) 
orientation. 
Crystallographic studies have shown that in the presence of allosteric effector, the active site 
of NmeDAH7PS undergoes a structural reorganisation. Such reorganisation, which occurs at 
high enough concentrations for all ligands (Phe, Trp and Tyr) is associated with a change in the 
binding mode of PEP, resulting in a “flipped” and unreactive binding orientation. This active 
site reorganisation is the same in the presence and absence of PEP and suggests that the site is 
pre-organised for binding PEP in this inverted orientation.  
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The reorganisation of the site also has implications for the other substrate E4P, where the new 
conformation adopted by residue Lys99, resulted in the formation of a salt-bridge with the 
metal coordinating residue, Asp324. This interaction may hinder the coordination of the 
aldehyde functionality of E4P to the divalent metal ion. Further investigations into the 
importance of this interaction would involve targeting the residues that may contribute to this 
flipped orientation in the enzymes regulated state. It has already been shown for the 
NmeDAH7PSGlu98Ala variant, that PEP adopted a normal (active) binding mode in the presence 
of Phe. Therefore, it can be inferred that the residues of the β2α2 loop and their interactions 
with surrounding residues are important for the new “flipped” binding mode of PEP.  
ITC experiments, involving the binding of the substrate PEP in the presence and absence of 
Phe may give a thermodynamic understanding of substrate binding to NmeDAH7PS in its 
inhibited state. There is likely to be changes in the binding isotherm, which may give insight 
into the mechanism of PEP binding in the presence of Phe.  
6.5 Treatment of the dimer as the functional unit of NmeDAH7PS 
The presence of a tetrameric interface in NmeDAH7PS was found to be unnecessary for 
catalytic function and regulation. The removal of a salt bridge (Arg126-Glu27) at the tetramer 
interface resulted in a dimeric NmeDAH7PS that had similar kinetic and Phe binding 
characteristics to the wild-type enzyme. Furthermore, removal of the only interaction (His219-
His219) at the Chain A-D and B-C interface also resulted in an enzyme with similar 
characteristics to the wild-type enzyme. The similarity between these two variant enzymes 
and the NmeDAH7PSWT enabled treatment of NmeDAH7PS as a functional dimer for the 
experiments described in chapter 5.  
An interesting finding from these investigations was the potential role of Glu17 in the closure 
of the N-terminal tail over the bound ligand. Glu17, located slightly towards the N-terminus 
from Glu27 (part of the salt bridge) and forms a hydrogen bond with His219 located on the 
β6aβ6b loop in the presence of Phe. The interaction of Glu17 with His219, implicates it in the 
closure of the allosteric binding loop and the communication between chains of the tight 
dimer. Characterisation of this variant may provide further insight into importance of the 
interactions between chains of tight dimer for the regulation of NmeDAH7PS  
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6.6 Entropically driven method of allostery employed by NmeDAH7PS  
The isotherm for binding of Phe to NmeDAH7PS is indicative of an entropically driven allosteric 
ligand binding event. The increased flexibility of NmeDAH7PS in the presence of Phe has also 
been observed in the MD simulations, where an increase in the amplitude and a decrease in 
frequency of atomic motions was evident for large regions of the enzyme (β2α2 loop, β3α3 loop, 
α3 helix and β-hairpin insertion) as well as the loss of correlated motions between residues in 
the Phe-bound state.  This increase in flexibility is evident despite the ordered nature of the 
allosteric binding loop upon Phe binding. The correlation between these two methods has 
interesting implications for the method of allostery in NmeDAH7PS. 
 
Further work in this area would involve trying to understand the flexibility incurred on 
NmeDAH7PS upon Phe binding using NMR relaxation experiments, however, even the dimeric 
variant remains very large for such a technique at this point. This technique may provide 
insight into the conformational entropy changes in this enzyme upon Phe binding and may 
reveal the local contributions to the changes in heat capacity.148 Another method that could be 
used to better understand this hypothesis would be to use ITC methods at a variety of 
temperatures to obtain the heat capacity (ΔCp) changes in NmeDAH7PS during Phe 
binding.149,150 A combination of these methods, with the aid of the MD and crystallographic 
studies would provide valuable insight to the entropically driven allostery adopted by 
NmeDAH7PS. 
 
6.7 Ionisable side-chains mediate the allosteric signal in NmeDAH7PS 
A method of understanding the mechanism of allostery adopted by NmeDAH7PS has involved 
the structural (X-ray crystallography), computational (MD) and pH dependence studies. These 
studies have illustrated the importance of ionisable residues in the catalysis and regulation of 
NmeDAH7PS. Initial structural studies described the reorganisation of electrostatic and 
hydrogen bonding partners in the presence of allosteric ligand. This hypothesis was 
investigated by MD studies, which also highlighted other residues with potential roles in the 
formation of the network that were unobservable from the structural analysis. This is due to 
the fact that MD illustrates protein dynamics, rather than the static picture that is delivered by 
the crystal structure. 
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The involvement of these residues in the allosteric network was identified via monitoring the 
pKa fluctuations of ionisable residues in the protein, thus giving an understanding of the 
changes in the local environment of residues upon Phe binding. The allosteric effect of Phe 
was shown to be dependent on the pH at which the kinetic measurements were carried out. 
This observation implies that limitation of the pKa changes of the highlighted residues required 
for communication of allosteric information in NmeDAH7PS can be achieved changing the pH. 
This finding showed that networks, involving ionisable residues are involved in transmission of 
the allosteric signal to the active site.  
This methodology, while focusing on a small selection of residues, gives insight into the 
dynamics of NmeDAH7PS during allostery. However, the methods described are not in solution 
(crystal packing effects) and/or are purely computational (possibly biased by the crystal 
structure conformation), therefore it would be beneficial to get an understanding of the 
dynamics of NmeDAH7PS experimentally. The use of hydrogen/deuterium exchange mass 
spectrometry experiments may be revealing for this investigation. This techniqe may give an 
experimentally validated understanding of the interactions between residues in solution and 
shed light on the dynamics of these interactions predicted by MD.151  
6.8 Regulatory effects of Phe binding occur both within the same chain and across the tight 
dimer interface 
These investigations have highlighted several residues that are important for the transmission 
of allosteric signal. The transmission of this signal has been shown to propagate via two 
general pathways (Figure 7.8). The first, within the same chain, consists of interactions 
between Glu98 of the β2α2 loop and Asp148, Thr151 and Tyr155 of the β3α3 loop and α3 helix 
respectively. The importance of this set of connections has been illustrated in the 
NmeDAH7PSGlu98Ala variant, where the allosteric response to Phe binding was severely 
attenuated.  
The second pathway is far more complex and extends across the tight dimer interface. It 
involves interaction of Lys107 of the β2α2 loop with Gln172ʹ and Glu176ʹ, of the α4 helix. Lys 
107 also interacts with residues of the β6a strand (His209ʹ and the peptide amino group of 
His210ʹ, adjacent to Phe211ʹ). The removal of the side-chains of some of these residues had a 
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variety of effects on the catalysis and regulation of NmeDAH7PS. The high redundancy 
encountered when making single point variant enzymes makes delineation of the exact 
network challenging. However, it has been shown that the Lys107-Glu176ʹ salt bridge is crucial 
for modulating the binding affinity of Phe as well as the cooperativity observed in the binding 
isotherm between allosteric sites of the tight dimer. Crystallographic studies have implicated 
the formation of a salt bridge between Arg101 and Glu98 in this high affinity for Phe. This 
feature is observed in the Phe-bound crystal structure of the Phe-sensitive paralogue from E. 
coli.101 
Figure 7.8.1 The communication of allostery both within the same chain and the adjacent chain via the tight 
dimer interface. Red arrows indicate communication of allostery. Yellow arrows indicate ligand binding. 
Allosteric Phe shown as magenta star and the active site ligand is shown as a green rectangle. 
It has also been shown that the absence of the Gln172 side-chain reduces the affinity of the 
enzyme for its substrates, but increases the rates of catalysis. This residue potentially has a 
role in the stabilisation of the β2α2 loop during catalysis and in its absence, the loss of 
interactions between Gln172ʹ and the backbone carbonyl of Lys99 and the peptide amino 
group of Arg101, may prime NmeDAH7PS for entry into its regulated state. This may explain 
the hypersensitivity of this variant to concentrations of Phe. This feature is also observed to 
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some degree in the NmeDAH7PSGlu176Ala variant, which also displayed increased sensitivity to 
Phe at low concentrations. 
Instead of breaking these connections and revealing the functional effects, which has been 
described in detail here, further work should aim to strengthen the identified interactions 
connecting allosteric and active sites. This would involve, changing hydrogen bonding residues 
into salt-bridge forming residues and may result in enzymes with the ability to bind Phe, but 
the inability to undergo the appropriate allosteric mechanisms. This may assist in the 
deconvolution of the intra and inter chain contributions to allosteric regulation by Phe. 
It may also be useful to test the aforementioned variant enzymes across a wide range of pH 
values, in order to marry their allosteric sensitivity at varying pH to their proposed pKa change 
observed from the pKa calculations. Identification of the effects of Phe at a variety of 
concentrations on apparent Km values for these variants may also give interesting insight into 
their contribution to the allosteric signal and may enable better understanding of the kinetics 
and binding isotherms of these variants. This would provide in the methodologies used to 
determine the communication pathway(s) in NmeDAH7PS.  
6.9 Conclusion 
The complicated interplay of residues in NmeDAH7PS required for catalysis and regulation are 
very challenging to deconvolute. The subtle mechanisms adopted by the enzyme to achieve 
the requirements of the cell revolve around a single catalytic loop. While identification of the 
importance of this loop is relatively trivial, a true understanding of its dynamic motion is 
difficult to ascertain. The next step in the NmeDAH7PS chapter will be to employ dynamic 
techniques to better understand the interplay between residues of this loop and surrounding 
residues, substrates and synthetic inhibitors. While it is very selective and system specific, the 
methodologies employed to understand this enzyme extend far beyond this and can be 
applied to any protein that is up- or down-regulated by its local environment.  
It is truly fascinating that nature has evolved such a simple, yet intricate mechanism to achieve 
and regulate the flux of the shikimate pathway in NmeDAH7PS based on the cellular demand 
for metabolites. 
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CHAPTER 7- GENERAL EXPERIMENTAL DETAILS 
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7.1.1 Reaction conditions and work-up 
All reactions were carried out in flame dried glassware under an inert atmosphere of nitrogen 
gas and stirred with magnetic stirrers unless otherwise stated. Removal of solvents in vacuo 
was carried out using a rotary evaporator under reduced pressure with the water bath not 
exceeding 40 °C unless otherwise stated. Solid products were dried using an oil pump vacuum. 
Reactions at -78 °C were cooled using a bath of solid carbon dioxide/acetone. 
7.1.2 Solvents and reagents 
Reagents were obtained from commercial suppliers and used without further purification. 
Before use, solvents were dried by passage through alumina columns in a solvent purification 
system custom built by the Chemistry Department workshop. 
DOWEX® 50WX8-100 was used in a packed column (~1x10cm). Before use ~100 mL of 4M 
aqueous hydrochloric acid was passed through the column and then the column was brought 
to neutral pH with continuous washing with water. Thorough regeneration involved washing 
with hydrochloric acid as stated above, followed by 50-100 mL 1M aqueous sodium hydroxide 
solution. The sodium hydroxide solution was washed off the column with multiple column 
volumes of water until the eluate was near neutral pH. This was followed by another acid wash 
before use. 
7.1.3 Chromatography  
Merck Kieselgel 60F254 pre-coated aluminium-backed plates were used for thin layer 
chromatography. Visualisation of spots was achieved using a UV lamp (254 nm), and by 
staining with basic potassium permanganate solution or phosphomolybdic acid (PMA), 
followed by gentle heating with a hot air gun. Flash chromatography was carried out using 
Silica 60 230-400 mesh and analytical grade solvents. 
7.1.4 NMR spectroscopy 
NMR spectroscopy was carried out on an Agilent 400NMR and Varian VNMR 500 
spectrometers. 1H-NMR spectra were calibrated to the signal of the residual protons of the 
deuterated solvent stated and chemical shifts δH are reported relative to tetramethylsilane. 
13C-NMR spectra were calibrated to the signal of the deuterated solvent indicated and 
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chemical shifts δC are reported relative to tetramethyl silane. 31P-NMR spectra were calibrated 
and chemical shifts δP were relative to an external standard of 85% phosphoric acid. All 
chemical shifts are reported in parts per million (ppm) and coupling constants (J) in Hertz (Hz). 
7.1.5 Mass spectrometry 
High resolution mass spectrometry was carried out on a Bruker maXis 3G or Micromass LCT 
Classic spectrometers, using positive or negative electrospray ionisation. 
7.1.6 UV-visible spectroscopy 
UV spectrophotometry was carried out on a Varian Cary® UV 100 spectrophotometer in 
stoppered quartz cuvettes of 2mm or 10mm path length. The standard assay temperature of 
25 °C was maintained using a Varian Peltier thermostat connected to the jacketed multi-cell 
holder. 
7.1.7 pH measurements  
The pH of buffers and other aqueous solutions was determined using a UB10 Ultrabasic 
benchtop pH meter from Denver Instrument Company or a Seven Compact S220 pH meter 
from Mettler Toledo. For samples of small volume, a micro glass body combination pH 
electrode was used. The sample pH was adjusted using aqueous hydrochloric acid (1M or 
10M) and sodium hydroxide (1M or 10M) solutions unless otherwise stated. 
7.1.8 Preparation of buffers and kinetic assay solutions 
All buffers and assay solutions were prepared using water from a Millipore Milli-Q system. This 
water is referred to as Milli-Q throughout this thesis. All buffers and assay solutions were 
filtered prior to use, after the addition and solvation of the last solid component.  
The buffers used contained:  
-Lysis Buffer: 
10mM 1,3-bis (tris (hydroxymethyl methylamino) propane (BTP) pH 7.3, 1 mM 
ethylenediamine tetraacetic acid (EDTA), 200 µM phosphoenol pyruvate (PEP) and 200 
mM potassium chloride (KCl). 
-Anion exchange (Source-Q) and Hydrophobic interaction (Source-Phe) binding buffer: 
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10mM BTP pH 7.3, 1 mM EDTA and 200 µM PEP. 
- Anion exchange (Source-Q) elution buffer: 
10mM BTP pH 7.3, 1 mM EDTA, 200 µM PEP and 1 M sodium chloride (NaCl. 
-Hydrophobic interaction (Source-Phe) elution buffer: 
10mM BTP pH 7.3, 1 mM EDTA, 200 µM PEP and 1 M ammonium sulphate. 
-Size exclusion chromatography (SEC) buffer: 
10mM BTP pH 7.3, 200 µM PEP and 100 mM KCl. 
-Assay buffer 
50mM BTP pH 6.8 
For the preparation of solutions used in kinetic assays, solid PEP monopotassium salt (Alfa 
Aesar and Sigma Aldrich) was dissolved in the appropriate volume of assay buffer to yield a 
10mM stock solution. Manganese (II) sulphate solutions and inhibitor solutions were prepared 
by dissolution of the solid in Milli-Q water. All kinetic assay solutions were filtered through a 
0.20 µM syringe filter before use. 
7.1.8.1  PREPA RATION OF E4P  
Solutions of erythrose 4-phosphate E4P for kinetic assays were prepared using a variation of 
previously described methods.152,153 Glucose 6-phosphate (G6P, 547 mg, 1.94 mmol, 
monosodium salt) was dissolved in 3 mL water and 350 mL glacial acetic acid added. This 
solution was placed in a three-necked round-bottom flask under a nitrogen stream and 
equipped with a stirrer bar and dropping funnel. Lead tetraacetate (1.50 g, 3.40 mmol, 1.75 
eq) was dissolved in 
glacial acetic acid (75 mL) and concentrated sulfuric acid (0.9 mL) added to this solution. The 
lead tetraacetate solution was added to the G6P solution dropwise over 4 h at room 
temperature. The presence of excess oxidant should be avoided and can be checked by 
moistened starchiodide paper. The addition is accompanied by the formation of a white lead 
sulphate precipitate. The resulting reaction mixture was stirred for another hour at room 
temperature, filtered through celite and the filter cake washed with water (200 mL). The 
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combined acetic acid and aqueous filtrates were concentrated to about 50 mL using a rotary 
evaporator under oil-pump vacuum and equipped with a dry-ice/acetone condenser. The 
solution was then diluted with water (100–200 mL) and concentrated again, and repeated 3–
5 times to remove acetic acid. Alternatively, removal of acetic acid was achieved using 
overnight continuous liquid-liquid extraction of the aqueous phase with ether. The resulting 
crude solution of E4P was purified using anion exchange chromatography on Source 15Q 
resin, eluting with a gradient of ammonium formate (0–2 M) in 0.2 M aqueous formic acid. 
E4P-containing fractions were identified by enzyme assay with NmeDAH7PS (see page 174) 
and pooled. The combined E4P-containing fractions were passed down a column packed 
with DOWEX 50WX8-100 resin (H+-form) and the eluate concentrated by rotary evaporation 
(see above) to yield the desired E4P-concentration (20–30 mM as determined by enzyme 
assay, see page 174). Solutions were aliquoted (500 μL), snap-frozen in liquid nitrogen and 
stored at −80 ºC. In order to allow for equilibration of monomeric, dimeric and oligomeric 
species of E4P, solutions were thawed the day before use, stored at 4 ºC overnight and 
equilibrated at room temperature for at least 1 hr before kinetic assays were carried out. 
 
7.1.8.2  LA NZE TTA  PH OSPHA TE A S SAY  
Lanzetta reagent154 was prepared fresh as required from the following components: 3 parts 
0.045% w/v malachite green in water, 1 part 4.2% w/v ammonium molybdate in 4 M HCl, 0.1 
parts 1.5% v/v Triton X-100 in water. The components were mixed in the dark and stirred for 
1 h before the solution was filtered through a 0.45 µm syringe filter. For the qualitative 
detection of phosphate-containing fractions after anion exchange chromatography, a 20 µL 
sample of each fraction was mixed with 250 µL of Lanzetta reagent and the colour change 
judged by optical inspection. For the quantitative determination of inhibitor concentration, 
300 µL of the inhibitor solutions were incubated with 10 µL calf alkaline phosphatase 
solution (5 units/mL in 4 mM MgCl2) for at least 2 h. To 100 µL of the digested sample was 
added 700 µL Lanzetta reagent and the absorbance at 630 nm determined after 20 minutes. 
A calibration curve for the determination of phosphate concentration was obtained from 
analogous analysis of solutions of appropriate concentrations (6-150 µM) of KH2PO4, which 
had been dried in high vacuum for at least 3 h before use. As a control, a glucose-6-
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phosphate solution of known concentration was also digested with calf alkaline phosphatase 
and analysed. 
 
7.1.9 Removal of metal ions from solution 
Divalent metal ions were removed from solutions by treatment with Chelex® 100 resin (Bio-
Rad). The resin was added to a solution and then stirred for at least 1 h before the resin was 
removed by filtration (0.2 μm). The resin invariably caused the pH of the solution to 
increase, sometimes necessitating adjustment to correct the pH of any resin-treated 
solution. 
 
7.1.10 Glycerol stocks 
All plasmid-containing strains of E. coli were stored frozen at −80 °C as glycerol stocks. 
Glycerol stocks were created by mixing 0.4 mL of 50% (v/v) glycerol with 0.6 mL of an 
overnight culture in either a 1.6mL micro-centrifuge or screw-top tube. 
 
7.1.11 Antibiotics  
The genes for NmeDAH7PS had previously been cloned into the pT7-7 vector, which carries 
resistance to ampicillin. Ampicillin was added to all growth media to a final concentration of 
0.1 mg/mL. Stock solutions of ampicillin at 100 mg/mL were created, filter sterilised and 
stored at −80 °C, and freeze-thawed a maximum of two times. 
 
7.1.12 Site-directed mutagenesis 
Mutagenesis was performed using  Phusion® High-Fidelity DNA Polymerase (Thermo Fisher 
Scientific). PCRs were performed in an Veriti® 96-well Thermal Cycler (Applied Biosystems) 
or an iCycler (Bio-Rad). Typically each PCR was 20 μL and used 50 ngµl-1 of plasmid template 
and 50 ngµl-1 of each primer. Cycling 
protocols were those recommended by each kit or polymerase. Primers for mutagenesis 
were synthesised by life technologies and resuspended in either TE buffer (10mM Tris-HCl, 
0.1mM EDTA) or sterilised Milli-Q water to a concentration of 100 μM. Template DNA 
(methylated) was digested by treatment with the restriction enzyme Dpn1 according to the 
protocols of the kit. 
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7.1.13 Plasmid extraction and purification 
Plasmids were extracted using a High Pure Plasmid Isolation Kit (Roche). Small cultures (5 
mL) of plasmid-containing cells were grown overnight with the appropriate antibiotic(s). The 
cultures were harvested the following morning and plasmids extracted and purified as per 
the kit instructions, with two variations. Firstly, as optionally specified in the kit instructions, 
the glass fibres were pre-equilibrated with binding buffer to increase plasmid yield, and 
secondly, plasmids were eluted from the fibres using 70 μL to 100 μL rather than 100 μL of 
elution buffer, to ensure a sufficient plasmid concentration for downstream uses. The 
concentration of purified plasmid was measured by absorption at 260nm using an 
appropriately blanked Nanodrop ND-1000 spectrophotometer. 
 
7.1.14 DNA Sequencing 
All DNA sequencing was performed at the Massey Genome Servive (MGS) using an Applied 
Biosystems 3130xl Genetic Analyzer with BigDye Terminator v3.1 (Applied Biosystems) 
sequencing chemistry.  Typically 400 ng to 500 ng of purified double-stranded plasmid and 4 
pM of primer were supplied for each sample. As all DAH7PS genes were in the pT7-7 vector 
the same forward and reverse primers were used for all sequencing. 
 
Forward: 5ʹ TAA TAC GAC TCA CTA TAG GGA GA 
Reverse: 5ʹ GTT TAC TCA TAT ATA CTT TAG AT 
 
7.1.15 Transformation 
Chemically competent cells (50 μL to 100 μL aliquots) were thawed on ice before addition of 
8 μL of either PCR product or purified plasmid. The mixture was left on ice for 20 min then 
placed in a 42 °C. water bath for 30 s to 45 s before being placed on ice again for 2 min to 3 
min. Cells were then outgrown for 1 h at 37 °C while shaking after addition of 250 μL super 
optimal broth (SOC) medium. A portion (50 μL to 200 μL) of the transformed cells was 
spread directly onto an LB-agar plate containing the appropriate antibiotic(s) and left to 
grow on the inverted medium overnight at 37 °C. 
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SOC medium: 2% (w/v) tryptone, 0.5% (w/v) yeast extract, 10mM NaCl, 2.5mM KCl, 10mM 
MgSO4, 20mM glucose. Filter sterilised in aliquots. 
 
7.1.16 Cell lines 
The cell lines used for plasmid propagation were either E. coli XL1-Blue or 
TOP10 (Invitrogen). For protein expression either E. coli BL21 (DE3) or BL21 (DE3) Star 
(Invitrogen) cell lines were used. 
7.1.17 Culture media 
LB-agar was prepared by dissolving either LB-agar (Miller’s) (37 gL−1) or LB (Lennox L) (20 
gL−1) and agar (15 gL−1) base in Milli-Q water and sterilised by autoclaving. The LB-agar 
solution was then heated in a microwave oven until boiling, and left to cool in a 60 °C oven. 
The LB-agar solution was then further cooled to 50 °C before antibiotic(s) were added 
immediately prior to pouring into round petri dishes.  
LB media for plasmid extraction, pre-cultures and protein expression cultures were prepared 
by dissolving 20 gL−1 LB (Lennox L) base in Milli-Q water and sterilised by autoclaving. 
Antibiotic(s) were added immediately prior to use. 
 
7.1.18 Protein expression cultures 
Cultures for protein expression were grown in 2 L baffled conical flasks in a shaking 
incubator at 180 rpm. Expression cultures were inoculated with an overnight culture ~ 1/40 
the volume and grown at 37 °C until induction of protein expression. 
Transcription of the DAH7PS genes were under the control of an inducible lac operon, 
therefore protein expression was induced by addition of IPTG to a final concentration of 1 
mM, when cultures were at a mid-logarithmic phase (OD600 of 0.4AU to 0.6AU). After 
induction, cultures were transferred to 23 °C and harvested the following morning. 
 
7.1.19 Cell harvesting 
Large cultures were harvested in 1 L bottles at 12 000 g for 15 min at 4 °C. The pellets were 
then re-suspended in a small volume of the supernatant liquid and transferred to 50mL 
centrifuge tubes and centrifuged at 6000 g for 10 min at 4 °C. The supernatant liquid was 
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removed and the cell pellet either immediately lysed, or flash frozen in liquid nitrogen and 
stored at −80 °C. 
Small volume cultures (≤ 5 mL) were progressively harvested in 1.6mL micro-centrifuge 
tubes at 16 000 g for 1 min. 
 
7.1.20 Cell lysis 
Cells were lysed by sonication. Sonication was performed with an Omni-Ruptor 4000 
Ultrasonic Homogenizer (Omni International). Cell pellets were resuspended in chilled lysis 
buffer (typically 25 mL) on ice, and sonicated in a beaker surrounded by packed ice. They 
were sonicated at 80% power and 5 multiples of 5 min with 40-50 percent pulsation. 
Cellular debris were removed by centrifugation either at 40 000 g for 30 min at 4 °C. 
 
7.1.21 Protein purification 
All proteins were purified by a three-step procedure composed of, in step order, anion-
exchange, hydrophobic interaction and size exclusion chromatography. The chromatography 
was performed on a GE Healthcare AKTA purifier™ 10 machines.  
Before use, all buffers were filtered (0.2 μm) under vacuum and degassed. Samples were all 
likewise filtered before being loaded to either a 10 mL,50 mL or 150 mL Superloop™ (GE 
Healthcare), or, for samples of volume less than 5 mL, into a static loop. The eluate was 
fractionated in 2mL fractions collected in 96-well plates. On A¨KTA purifier™ 10 machines, 
the eluate from injection of the sample onto the column (flow-through) was collected in 50 
mL centrifuge tubes. Elution from the columns was monitored principally at 280 nm, and 
depending on the machine being used, also at 260nm and 214 nm. When the fractions 
corresponding to DAH7PS could not be deduced from the chromatogram, suspected 
DAH7PS-containing fractions were analysed by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) and/or for DAH7PS activity. Fractions containing DAH7PS were 
then pooled and prepared for the next chromatographic step. 
 
7.1.21.1  ANION EXCH A NGE CH ROMA TOGRAPHY  
AEC was performed using SOURCE™ 15Q resin packed in a Tricorn 10/100 column (GE 
Healthcare), at 4 °C. The supernatant liquid (resulting from removal of the cellular debris by 
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centrifugation after cell lysis) was diluted four-fold with a no-salt buffer to reduce the 
concentration of anions. The no-salt buffer was 10mM BTP at pH 7.3 (NmeDAH7PS, pI = 
6.28), 200 µM PEP and 1mM EDTA. Elution from the column was performed using gradients 
of increasing NaCl concentration up to 1M at a flow rate of 1 mLmin−1 to 3 mLmin−1. 
For NmeDAH7PS and mutants thereof, the elution protocol involved a linear gradient to 0.4 
M NaCl over (0.8 x loaded volume). The gradient was then removed and 1 M NaCl was used 
to elute off any other bound protein. 
 
7.1.21.2  HYD ROPH OBIC  IN TE RAC TION CH ROMATOGR APHY  
The HIC was performed using SOURCE™15Phe resin packed also in a Tricorn 10/100 column 
(GE Healthcare). This purification step was performed at room temperature, as at 4 °C the 
hydrophobic interactions are weaker and the resin performance is degraded. Elution was 
performed at a flow rate of 1 mLmin−1 to 3mLmin−1.  
Crystalline (NH4)2SO4 was added to pooled AEC fractions to a concentration of 1M before the 
sample was filtered and loaded into a loop. The same buffers as used in anion exchange 
were used for HIC, except (NH4)2SO4 was substituted in place of NaCl. For all proteins, elution 
was by linear gradient from 1M to 0M (NH4)2SO4 over 50 mL. NmeDAH7PS and mutants 
eluted, depending on flow rates and column condition, between 0.75M and 0.25M 
(NH4)2SO4. 
 
7.1.21.3  S IZE  EXC LU SION CH ROMA TOGRA PHY  
Fractions containing NmeDAH7PS from HIC were pooled and loaded into a loop. SEC was 
performed using a HiLoad 26/60 Superdex™ 200 prep grade column (GE Healthcare), at 4., in 
the same no-salt buffer used in the both AEC and HIC. The elution flow rate was 1.0 mLmin−1. 
 
7.1.22 Polyacrylamide gel electrophoresis 
SDS-PAGE was performed using NuPAGE® 10% Bis-Tris Gel 1.0mm × 12-well pre-cast gels 
(life technologies) in NuPAGE® MOPS SDS Running Buffer (life technologies). Electrophoresis 
was performed using a XCell SureLock™ Electrophoresis Cell (life technologies), also at 165V 
for 45 min. Samples were mixed with NuPAGE® LDS Sample Buffer (4×) and a reducing agent 
(DTT). 
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Figure 7.1.22.1. Typical purification of NmeDAH7PS
WT
 and variants, indicating the three steps of purification 
and the purified protein from the SEC. 
 
7.1.23 Visualisation of protein bands 
All SDS-PAGE gels were stained in square petri dishes, mostly by coomassie brilliant blue R-
250, for at least 20 min before being destained to remove excess dye. Staining and 
destaining times were reduced by heating gel and solution in a microwave oven until almost 
boiling. Alternatively, some gels were stained using SimplyBlue™ Safe Stain (Invitrogen) 
instead of coomassie brilliant blue R-250. In the latter case, gels were first washed and also 
destained in water, and all steps were performed with heating until almost boiling in a 
microwave oven.  
Stain: 0.1% (w/v) coomassie brilliant blue R-250, 10% (v/v) acetic acid and 40% (v/v) 
methanol  
Destain: 10% (v/v) acetic acid and 40% (v/v) methanol 
Molecular weight standards (Novex® Sharp Pre-Stained Protein Standards [life technologies]) 
were run as the sample in one lane of each gel. Photographs of gels were taken on a white 
light transilluminator in a Molecular Imager® Gel Doc™ XR (Bio-Rad). 
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7.1.24 Concentration and buffer exchanging of protein solutions 
Protein solutions were concentrated using 10 000 Da molecular weight cut-off (MWCO) 
devices (Vivaspin 2 [GE Healthcare], Vivaspin 500 and Vivaspin 20 [Sartorius Stedim Biotech] 
and Amicon® Ultra-4 [Millipore]). All filtration units were rinsed before use with Milli-Q 
water. Protein solutions were buffer exchanged (e.g. into binding buffer for ITC) by 
repeatedly concentrating in a MWCO device and diluting with desired buffer. 
 
7.1.25 Enzyme Storage 
Purified protein was divided into aliquots in 0.2 µL thin-walled PCR tubes in 50 μL, flash-
frozen in liquid nitrogen, and stored at −80 °C. All protein samples were rapidly thawed 
immediately before use and kept on ice. Protein solutions were stored at 10 mg/mL. 
 
7.1.26 Protein concentration determination 
The concentration of all protein solutions were measured by  absorption at 280nm by an 
appropriately blanked Nanodrop ND-1000 spectrophotometer, using 2 μL samples of 
purified protein solution. The concentration was calculated from the absorption using molar 
extinction coefficient value for NmeDAH7PS is 31650 M−1cm−1. The coefficient values, 
calculated from protein sequences using the ProtParam tool on the ExPASy Proteomics 
Server,111 were the same for both NmeDAH7PSWT and variants. All measurements of protein 
concentration were performed as duplicates and averaged. 
 
7.1.27 Standard enzyme activity assay 
The standard assay for DAH7PS activity monitored the consumption of PEP by loss of 
absorbance at 232 nm, based on the method of Schoner and Herrmann57. All kinetic 
measurements were made using a Varian Cary 100 UV-visible spectrophotometer, stoppered 
1 cm pathlength quartz cuvettes and a total assay volume of 1 mL. Standard assays were 
carried out at 25 °C and all assay solutions were equilibrated to temperature and baseline 
absorbance before initialisation with either enzyme, metal ion, or E4P. Standard reaction 
mixtures contained 50mM BTP pH 6.8, a variable concentration of PEP, E4P and enzyme, and 
when appropriate 100 μM MnSO4. 
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Assay buffers were treated with Chelex® 100 resin (Bio-Rad) prior to use to remove metal 
ions, and Chelex-treated buffer solution was used to create concentrated stock solutions of 
PEP and A5P. Metal-ion solutions were created using either Chelex-treated buffer or Milli-Q 
water. 
Initial rates of reaction were measured as a least-squares fit of the initial rate data using Cary 
WinUV Kinetics Application (version 3.00, Varian). A unit of enzyme activity was defined as 
the loss of 1 μmol min−1 of PEP at 25 °C, and could be calculated from the measured loss of 
absorbance (at 232 nm) using Beer’s Law (ϵ is 2.8×103M−1 cm−1). The values of the kinetic 
parameters were determined by fitting data to the Michaelis-Menten equation using the 
software GraFit (version 5.0.13, Erithacus Software Limited).  
 
7.1.28 Determination of substrate concentrations 
The concentrations of substrate (e.g. PEP and E4P) solutions were determined using the 
standard assay system for DAH7PS activity. The concentration of the substrate not being 
measured was used in excess and the substrate for which the concentration was being 
measured was used at a limiting concentration. That the correct substrate was limiting was 
checked by addition of more of it after the reaction had reached completion. The change in 
absorbance, between that before initiation of the reaction and that at completion, was 
measured as ΔA1. A control reaction, absent in one of the substrates, was used to measure 
the change in absorbance due to the addition of enzyme to the cuvette at initiation of the 
reaction (ΔA2). The total change in absorbance (ΔA1 + ΔA2), was converted using Beer’s Law 
to a concentration of the limiting substrate in the cuvette, and the stock substrate 
concentration calculated. 
 
7.1.29 Isothermal titration calorimetry 
All ITC experiments were performed on a VP-ITC microcalorimeter (Microcal, GE Healthcare) 
operating at 298 K. All experiments consisted of 29 or 56 injections: one 2 μL injection and 
28 or 55 subsequent 10 or 5 μL injections (unless otherwise stated), using a reference power 
of 10 μCal s−1. For every experiment the ligand was in the syringe and protein in the cell. 
Before use, protein solutions were buffer exchanged into a binding buffer consisting of 
50mM BTP pH 7.0 and 0.5mM MnSO4 for all NmeDAH7PS and mutants. The protein 
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concentration was measured by UV absorption and all solutions were degassed in a vacuum 
immediately before use and both the cell and syringe were washed several times with 
binding buffer. 
 
The initial datum point was routinely deleted to allow for diffusion of ligand across the 
needle tip during the equilibration period. Heats of dilution experiments were measured 
independently and subtracted from the integrated data before curve fitting in Origin (version 
7.0, OriginLab®) with the standard one site or sequential binding site model supplied by 
MicroCal. 
 
7.1.30 Crystallisation of NmeDAH7PS and variants 
Crystallisation of NmeDAH7PS was achieved by concentrating the protein to approximately 10 
mg mL-1.1 µL of the buffer-exchanged enzyme solution (9–11 mg mL-1) was mixed with 1 µL of 
crystallisation buffer containing 0.1M Tris HCl (pH 7.2-7.5), 0.2 M trimethyl-amino-N-oxide 
(TMAO), 0.4 mM MnSO4 and 13–20% (w/v) PEG 2000MME. Crystals were grown by hanging-
drop vapour diffusion over 500 µL of crystallisation buffer and the crystallisation trays were 
incubated at 20 °C. Crystals began to form in 48 hrs and were fully formed within three-seven 
days. Crystals were flash frozen using liquid nitrogen in a cryo-protectant solution containing 
reservoir solution and 20% (v/v) PEG400. 
 
Figure 7.1.30.1 Typical crystals of NmeDAH7PS
WT
 used for soaking and seeding. 
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7.1.31 Seeding variant enzymes from NmeDAH7PSWT 
The growth of some variant enzymes was aided by the use of micro-seeding, if they would not 
grow in the conditions above. The use of fully grown crystals of NmeDAH7PSWT were used as 
seeds for the growth of some, more difficult to crystallise variants. In this process, several 
hanging drops containing 1 µL crystallisation condition and 1 µL enzyme were placed on a 
crystal tray coverslip and left for one day. After allowing time for equilibration a grown 
NmeDAH7PSWT crystal was crushed. This pool of microcrystalline NmeDAH7PSWT was 
transferred into a corresponding clear drop of variant enzyme in a dilution series across the 
several clear drops to initiate crystal growth. This was achieved using a seeding tool Hampton 
Research™.  
7.1.32 Co-crystallisation of active site inhibitors with NmeDAH7PS  
Co-crystallisation of ligand with NmeDAH7PS was achieved by preparing a solution containing 
approximately 5mM inhibitor dissolved in 10mM BTP (pH 7.3). 400 µL of this solution was 
added to the stock solution containing 50 µL of 10 mg/mL enzyme and was concentrated to 50 
µL using a 10 kDa molecular weight cut-off membrane (Vivaspin). The resulting solution was 
diluted again with 400 µL of inhibitor solution and concentrated by centrifugation. This process 
was repeated four times. The resulting protein solution was concentrated to approximately 10 
mg mL-1. 
7.1.33 Soaking of ligands into NmeDAH7PS  
Crystal soaking was achieved via two different methods. In the first method, crystals that 
were intended to be soaked in solutions containing ligands, multiple hanging droplets were 
prepared on the cover slide and equilibrated against reservoir solution in the same well. 
Droplets for crystallisation of NmeDAH7PS were setup using the method described above. 
The droplets for soaking were generated by mixing 1 μL of SEC buffer with 1 μL reservoir 
solution to which the desired concentration of the ligand/combination of ligands had been 
added. After crystals had formed and all droplets were deemed equilibrated against the 
reservoir solution (3-7 days), NmeDAH7PS crystals were transferred from the crystallisation 
drop to the soaking drop and left to soak for the time indicated.  
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In the other method, the crystallisation condition was brought to a ligand concentration of 
between 10 and 30mM. Upon formation of crystals, 1 µL of this solution was added to the 2 
µL that contained the crystals. This brought the concentration of ligand in the drop to 
between 3 and 10 mM. This was left to soak for the indicated time. 
 
7.1.34 Data collection, processing, structure determination and refinement 
X-ray diffraction datasets were collected at the Australian synchrotron using the MX1 and 
MX2 beamlines112. The datasets were integrated and processed using iMosflm, XDS, Aimless 
(CCP4 program suite).114113155156 The appropriate cut-off resolution was determined via CC½ 
≥ 0.5 while ensuring the data set was complete in the highest resolution shell.115 Matthews 
was run to determine number of chains present in the unit cell.157,158 To minimise bias, all 
ligands and waters were removed from the search model (PDB code 4HSN) before molecular 
replacement (Phaser MR (CCP4)) was carried out.116 Rigid body refinement in Refmac5 was 
used to generate the electron density maps for all structures and these were manually 
analysed to develop the structural model by means of COOT. 117,118 All datasets used the 
same sets of reflections for the calculation of Rfree as were allocated in the search model 
(PDB code: 4HSN). The quality of the model was optimised by consecutive model building in 
COOT and refinement with Refmac5. Water molecules and ligands other than the ligands of 
interest were added to the structure, apart from regions of the structure, which showed 
evidence for the ligands of interest were added manually via interpretation of the (2|Fo - 
Fc|) and (|Fo - Fc|) maps, with the requirement that putative water molecules had at least 
one hydrogen-bonding partner. Residues Met1-Asp9 were also absent from the model (PDB 
code 4HSN) used for molecular replacement. Molprobity and the validation tools of COOT 
were used to assess structure quality during refinement cycles.120 After the model and 
electron density was judged to be in good agreement in all regions apart from the ligand 
binding site(s) of interest, the electron density in the ligand binding site(s) was examined. If 
appropriate electron density was present, the ligand of interest, waters and potential other 
molecules were added to the model and the final rounds of refinement carried out. (2|Fo - 
Fc|) and (|Fo - Fc|) omit maps shown in figures were generated using the program FFT (CCP4 
program suite) before addition of the ligands to the model. 
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7.1.35 Protein structure figures 
Figures containing protein structures were generated using PyMOL (Version 1.7, Schrödinger 
LLC). 
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E X P E R I M E N T A L  F O R  C H A P T E R  2  
7.2.1 Synthesis 
(E)-Methyl 3-(diethoxyphosphonyl)-2-methylacrylate 
 
To a solution of tetraethyl methylene bisphosphonate (1.64 mL, 6.60 mmol) in THF (8 mL) at 
-78 °C under a stream of N2 was added a solution of sodium bis(trimethylsilyl)amide in THF 
(7.2 mL, 6.10 mmol), the mixture was stirred for 30 minutes and allowed to heat to -35 °C 
over this time. The cold bath was replaced with an ice bath and methyl pyruvate (580 µL, 6.2 
mmol) was added in a dropwise manner. The mixture was left to stir for 2.5 hours, and then 
quenched with saturated potassium dihydrogen phosphate (10 mL). The solution was 
concentrated in vacuo to remove the THF. The residue was extracted using EtOAc (5x10 ml). 
The combined organic layers were washed with brine and separated again. The washed 
organic layer was dried over MgSO4. Purification by flash chromatography (50% EtOAc/PET 
ether) gave (E)-methyl 3-(diethoxyphosphonyl)-2-methylacrylate 11 (330 mg, 23%) and (Z)-
methyl 3-(diethoxyphosphonyl)-2-methylacrylate (270 mg, 18.5%). NMR data were in 
accordance with literature values.23 
Rf (50% EA/Pet Ether): 0.22.  
1H NMR (400 MHz, CDCl3) δ ppm 6.66 (dq, J = 16.0, 1.2 Hz, 1H), 
4.09 (dq, J=7.8, 7.1 Hz, 4H), 3.79 (s, 3H), 2.25 (dd, J = 1.4, 3.3 Hz, 3H), 1.32 (t, J = 7.0 Hz, 6H).  
13C NMR (101 MHz, CDCl3) δ ppm 166.8 (d, J = 29.3 Hz, C1), 146.9 (d, J = 9.0 Hz, C2), 125.2 (d, J 
= 186 Hz, C3), 62.0 (d, J = 5.6 Hz, C3POCH2CH3), 52.6, 16.3 (d, J = 6.4 Hz, C3POCH2CH3), 15.8 (d, 
J = 6.4 Hz, C4). 
31P NMR (162 MHz, CDCl3, 
1H decoupled) δ ppm 15.0.  ESI-MS positive ion 
(MH+): Required 237.0886; found 237.0884. 
 
(E)-2-Methyl-3-phosphonatoacrylate (tripotassium salt) 
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To a solution of (E)-methyl 3-(diethoxyphosphonyl)-2-methylacrylate 11 (150 mg, 0.635 
mmol) in DCM (5 mL) under a stream of N2 was added trimethylsilyl bromide (600 µL, 4.5 
mmol). The mixture was stirred overnight and then evaporated. The residue was dissolved in 
10 % (w/v) aqueous KOH (2 mL), stirred for 5 minutes and then extracted with DCM (3x5 ml), 
and the organic phases discarded. The aqueous phase was treated with DOWEX-50X8 H+-
form resin, neutralised with 1M KOH and lyophilised to give a white powder. Analysis of the 
product by NMR showed only the presence of the desired (E)-2-methyl-3-
phosphonatoacrylate 6, and comparison of 31P NMR signal integrals indicated that the 
powder was 35 % pure, the impurity being presumably inorganic potassium salts and/or 
waters of hydration, indicating a yield for this step of 74 % and an overall yield of 17 %. NMR 
data were in accordance with literature values.23 
1H NMR (400 MHz, D2O) δ ppm 6.23 (dd, J = 15.6, 1.2 Hz, 1H), 1.95 (dd, J = 3.1, 1.2 Hz, 3H).
  
31P NMR (162 MHz, D2O, 
1H coupled) δ ppm 10.94. (dd, J = 17.2, 3.7 Hz).  13C NMR (101 MHz, 
D2O) δ ppm 176.4 (d, J = 24 Hz, C1), 147.9 (d, J = 5.3 Hz, C2), 126.3 (d, J = 173 Hz, C3), 16.2 (d, J 
= 6.9 Hz, C4). 
31P NMR (162 MHz, D2O, 
1H decoupled) δ ppm 10.96.  ESI-MS positive ion 
(MH+): Required 167.0104; found 167.0104. 
 
(S)-Methyl 2-(diethoxyphosphoryloxy)propanoate 
 
 
 
A solution of triethylphosphite (0.870 mL, 5.07 mmol) in DCM (12 mL) under nitrogen was 
cooled to 0 °C, and iodine (1.17 g, 4.61 mmol) was added. The solution was stirred until the 
characteristic brown iodine colour had been discharged, typically taking approx. 15 minutes. 
The resulting solution of diethylphosphoryl iodide was added drop-wise over 15 minutes to 
(S)-methyl lactate (367 µL, 3.843 mmol) in pyridine (2.5 mL) and DCM (60 mL) at 0 °C under 
nitrogen. Once addition was complete the mixture was stirred for 1 hour. The reaction was 
quenched with saturated aqueous sodium bicarbonate solution (20 mL), and stirred 
vigorously for 5 minutes. The organic phase was separated, and washed with 1 M aqueous 
hydrochloric acid (2 x 75 mL), saturated aqueous sodium bicarbonate solution (75 mL), and 
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brine (75 mL). The organic phase was dried over MgSO4 and concentrated in vacuo. Flash 
chromatography (50% EtOAc/PET ether) gave the (S)-methyl 2-
(diethoxyphosphoryloxy)propanoate 12 (640 mg, 70%). NMR data were in accordance with 
literature values.23 
Rf (50% ethylacetate/hexane): 0.32.  
1H NMR (400 MHz, CDCl3) δ ppm 4.92 (qd, J = 7.1 Hz, 
1H) 4.23 - 4.06 (m, 4H), 3.77 (s, 3H), 1.55 (d, J = 6.7 Hz, 3 H), 1.34 (dt, J = 3.1, 7.0 Hz, 6H).  13C 
NMR (101 MHz, CDCl3) δ = 171.0 (d, J = 5.2 Hz, C1), 71.6 (d, J = 5.2 Hz, C2), 64.2 (d, J = 6.0 Hz, 
POCH2CH3), 52.4 (d, J = 6.0 Hz, CO2Me), 19.2 (d, J = 5.4 Hz, C3), 16.0 (d, J = 5.4 Hz, POCH2CH3).
  
31P NMR (162 MHz, CDCl3) δ ppm -1.98.  ESI-MS positive ion matrix (H
+): Required 241.0836; 
found 241.0833. [α]D
20 = -18.3°. 
 
(S)-2-(Phosphoryl)propanoate (tripotassium salt) 
 
 
 
To a solution of (S)-phosphoester 12 (462 mg, 1.91 mmol) in DCM (15 mL) under nitrogen 
was added trimethylsilyl bromide (1.54 mL, 11.5 mmol), and the mixture was stirred 
overnight then evaporated. The residue was dissolved in 10 % (w/v) aqueous potassium 
hydroxide (5 mL), stirred for 1.5 hours minutes then extracted with DCM (3 x 4 mL) and the 
organic phases discarded. The aqueous phase was treated with Dowex-50X8 H+-form resin, 
neutralised with 1 M KOH and lyophilised to give a white powder, (1.03 g). Analysis of 
concentration via Lanzetta assay indicated that the (S)-phospholactate product 8 was 23 % 
pure containing ~20 % of lactate due to neighbouring group assisted hydrolysis. The 
remainder consisting of inorganic potassium salts and/or waters of hydration, giving a yield 
for this step of (237 mg, 75 %) and an overall yield of 52 % over two steps. NMR data were in 
accordance with literature values.23 
 
1H NMR (500 MHz, D2O) δ ppm 4.34 (m, 1H, lactate), 4.27 (q, J = 1.3, 7.0 Hz, 1H), 1.6 (d, J = 
7.0 Hz, 3H), 1.28 (d, J = 6.8 Hz, 3H, lactate). 13C NMR (126 MHz, D2O) δ ppm 180.5 (lactate), 
178.2 (d, J = 5.3 Hz, C1), 72.4 (d, J = 5.3 Hz, C2), 47.7 (lactate), 22.5 (lactate), 19.9 (d, J = 3.8 
Hz, C3). 
31P NMR (162 MHz, D2O) δ ppm 0.50 (80%); 0.10 (20%).  ESI-MS negative ion, 20% 
AcOH matrix): Required 168.9907; found 168.9904. 
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(R)-Methyl 2-(diethoxyphosphoryloxy)propanoate 
 
A solution of triethylphosphite (0.870 mL, 5.07 mmol) in dichloromethane (12 mL) under 
nitrogen was cooled to 0°C, and iodine (1.17 g, 4.61 mmol) was added. The solution was 
stirred until the characteristic brown iodine colour had been discharged, typically taking 
approx. 15 minutes. The resulting solution of diethylphosphoryl iodide was added drop-wise 
over 15 minutes to (R)-methyl lactate (367 µl, 3.843 mmol) in pyridine (2.5 mL) and 
dichloromethane (60 mL) at 0°C under nitrogen. Once addition was complete the mixture 
was stirred for 1 hour. The reaction was quenched with saturated aqueous sodium 
bicarbonate solution (20 mL), and stirred vigorously for 5 minutes. The organic phase was 
separated, and washed with 1 M aqueous hydrochloric acid (2 x 75 mL), saturated aqueous 
sodium bicarbonate solution (75 mL), and brine (75 mL). The organic phase was dried over 
MgSO4 and concentrated in vacuo. Flash chromatography (50% EtOAc/PET Ether) gave the 
phosphate ester 13 (380 mg, 42%). 
 
Rf- (50%EA/Pet Ether)-0.32. 
1H NMR (400 MHz CDCl3) δ ppm (qd, J = 7.1 Hz, 1H), 4.22 - 4.07 
(m, 4 H), 3.77 (s, 3 H), 1.55 (d, J = 7.0 Hz, 3 H), 1.34 (dt, J = 3.3, 7.1 Hz, 6 H).  13C NMR (101 
MHz, CDCl3) δ ppm 171.0 (d, J = 5.2 Hz, C1), 71.6 (d, J = 5.2 Hz, C2), 64.1 (d, J = 6.0 Hz, 
POCH2CH3), 52.4 (d, J = 6.0 Hz, CO2Me), 19.2 (d, J = 5.4 Hz, C3), 16.1 (d, J = 5.4 Hz, POCH2CH3).
  
31P NMR (162 MHz, CDCl3) δ ppm -1.98. ESI-MS positive ion matrix (H
+): Required 241.0836; 
found 241.0833. [α]D
20 = +18.5°. 
 
(R)-2-(phosphoryl)propanoate (tripotassium salt)  
 
 
 
To a solution of (R)-phosphoester 13 (242 mg, 1.00 mmol) in DCM (7.7 mL) under nitrogen 
was added trimethylsilyl bromide (1.2 mL, 8.96 mmol), and the mixture was stirred overnight 
then evaporated. The residue was dissolved in 10 % (w/v) aqueous potassium hydroxide (3 
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ml), stirred for 1.5 hours minutes then extracted with DCM (3x 4 mL) and the organic phases 
discarded. The aqueous phase was treated with Dowex-50X8 H+-form resin, neutralised with 
1M KOH and lyophilised to give a white powder (470mg). Analysis of concentration via 
Lanzetta assay indicated that the (R)-phospholactate product 7 was 17 % pure and contained 
~24 % lactate due to neighbouring group assisted hydrolysis. The remainder consisting of 
inorganic potassium salts and/or waters of hydration, giving a yield for this step of (80 mg, 
48 %) and an overall yield of 20 % over two steps. 
 
1H NMR (400 MH, D2O) δ ppm, 4.36 (m, 1H, lactate), 4.27 (d, J = 6.7 Hz, 1H), 1.62 (d, J = 7.0 
Hz, 3H), 1.25 (d, J = 6.8 Hz, 3H, lactate). 13C NMR (101 MHz, D2O) δ ppm 180.5 (lactate), 
178.2 (d, J = 5.3 Hz, C1), 72.4 (d, J = 5.3 Hz, C2), 47.7 (lactate), 22.5 (lactate), 19.9 (d, J = 3.8 
Hz, C3). 
31P NMR (162 MHz, D2O) δ ppm 1.55 (76%); 1.29 (24%). ESI-MS negative ion, 20% 
AcOH matrix): Required 168.9907; found 168.9913. 
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The research described in chapter 2 was the subject of a publication before submission of this 
thesis. The supplementary material for this publication reporting experimental details 
appended with the permission of the copyright owners and can be accessed at: 
SUPPLEMENTAL DATA 
 
Structural analysis of substrate-mimicking inhibitors in complex with Neisseria meningitidis 3-
deoxy-D-arabino-heptulosonate 7-phosphate synthase - The importance of accommodating 
the active site water. 
Logan C Heyes1, Sebastian Reichau1, Penelope J Cross1, Geoffrey B Jameson2 and Emily J 
Parker1 
1Biomolecular Interaction Centre and Department of Chemistry, University of Canterbury, 
Christchurch, New Zealand 
2Institute of Fundamental Sciences, Massey University, Palmerston North, New Zealand 
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Inhibition studies 
 
 
 
Figure S1. Inhibition of NmeDAH7PS., Top left. Inhibition with vinyl phosphonate 6 inhibitor using 19.9–79.6 
µM PEP, 18.9–151.2 µM vinyl phosphonate inhibitor 6.  Top right. Inhibition with (R)-phospholactate 7 using 
19.9–79.6 µM PEP, 202–1616 µM (R)-phospholactate 7. Bottom left. Inhibition with of (S)-phospholactate 8 
using 19.9–79.6 µM PEP, 268–2144 µM (S)-phospholactate 8. Enzyme activities were followed by monitoring 
the loss of PEP followed spectrophotometrically at 232 nm. Assay conditions used were 100 µM MnSO4, 115 
µM E4P.  Initial rates were obtained by linear least squares regression of the absorbance data and the data 
fit is using non-linear regression analysis providing a global fit using all data points to the equation for 
competitive inhibition using Grafit (Erathicus software).  
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Table S1: Comparison of global fits to types of reversible inhibition 
 Chi
2 
values of fits to models for reversible inhibition
a
 
Inhibitor Competitive Noncompetitive Mixed Uncompetitive 
  
0.00004 0.0004 0.0035 0.0009 
 
0.0002 0.0005 0.0042 0.001 
 
0.00007 0.0004 0.008 0.0009 
a
The data was fitted to each equation using non-linear regression using Grafit.  A graphical representation of 
the derived fits for competitive inhibition is proved in Figure S1. The following equations were used: 
v =
V max[PEP]
Km 1+[I ] Ki( )+[PEP]
     (Competitive) 
v =
V max/ 1+[I ] Ki]( )[PEP]
Km 1+[I] Ki]( )+[PEP]
     (Noncompetitive) 
v =
V max[PEP]
Km 1+[I ] Ki]( )+ 1+[I ] Ki '][PEP]( )
   (Mixed) 
v =
V max[PEP]
Km+[PEP] 1+[I ] Ki]( )
     (Uncompetitive) 
CO2
-
2-O3P
Vinyl phosphonate
6
OPO3
2-
CO2
-
(R)-Phospholactate
7
OPO3
2-
CO2
-
(S)-Phospholactate
8
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Figure S2. Stereoview of overlay of the three inhibitors and the natural substrate PEP. PEP 1 is shown in 
yellow, vinyl phosphonate 6 is shown in green, (R)-phospholactate 7 is shown in cyan and (S)-phospholactate 
8 is shown in magenta. Mn
2+
 is shown as a purple sphere.  The carbon atoms of the NmeDAH7PS residues and 
the key active site waters (WAT1-5) are shown in the same colours as the respective ligands. 
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Characterisation of Inhibitor Binding 
 
  
Figure S3. Omit maps of vinyl phosphonate 6 bound at the active site of NmeDAH7PS contoured at 3σ. The 
four chains of NmeDAH7PS are indicated. Top left: chain A, top right: chain B, bottom left: chain C and 
bottom right: chain D. 
 
 
 
 
A 
D C 
B 
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Figure S4. Interatomic distances of vinyl phosphonate 6 bound at the active site of NmeDAH7PS. The four 
chains of NmeDAH7PS are indicated. Top left: chain A, top right: chain B, bottom left: chain C and bottom 
right: chain D. Mn
2+
 is shown as a purple sphere in all panels. 
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Figure S5. Omit maps of (R)-phospholactate 7 bound at the active site of NmeDAH7PS contoured at 3σ. The 
four chains of NmeDAH7PS are indicated: top left: chain A, top right: chain B, bottom left: chain C and 
bottom right: chain D. 
 
 
 
A 
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B 
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Figure S6. Interatomic distances of (R)-phospholactate 7 bound at the active site of NmeDAH7PS. The four 
chains of NmeDAH7PS are indicated: top left: chain A, top right: chain B, bottom left: chain C and bottom 
right: chain D. Mn
2+
 is shown as a purple sphere in all panels. 
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Figure S7. Omit maps of (S)-phospholactate 8 bound at the active site of NmeDAH7PS contoured at 3σ. The 
four chains of NmeDAH7PS are indicated. Top left: chain A, top right: chain B, bottom left: chain C and 
bottom right: chain D. 
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Figure S8. Interatomic distances of (S)-phospholactate 8 bound at the active site of NmeDAH7PS. The four 
chains of NmeDAH7PS are indicated: top left: chain A, top right: chain B, bottom left: chain C and bottom 
right: chain D. Mn
2+
 is shown as a purple sphere in all panels.  
A 
D 
C 
B 
Mn2+ 
Mn2+ 
Mn2+ Mn2+ 
 - 188 - 
E X P E R I M E N T A L  F O R  C H A P T E R  3  
7.3.1 Inhibition Kinetics of three aromatic amino acids 
Standard assays were performed, which consisted of E4P (250 µM), PEP (100 µM), MnSO4 
(100 µM) and the amino acid; L-Phe, L-Tyr or L-Trp (50 µM – 1 mM) in 50 mM BTP, pH 6.8.  
Assays were carried out at 25 °C and were initiated by the addition of NmeDAH7PS. All  
Assays were performed in triplicate and averaged. 
7.3.2. Isothermal titration calorimetry 
Binding of Phe to NmeDAH7PS at pH 7 was measured by ITC using a VP-ITC unit operating at 
298 K (Microcal, GE Healthcare). Before use, the protein was buffer exchanged against 
binding buffer [0.5 mM MnSO4 in 50 mM BTP buffer (pH 7)] and all solutions were degassed 
in a vacuum. Protein concentration was measured by UV absorption immediately before 
titrations were started. The titrations were comprised of 28 injections, one 2 µL injection 
followed by 27 x 10 µL injections of Phe. The initial datum point was routinely deleted to 
allow for diffusion of ligand across the needle tip during the equilibration period. A heat of 
dilution experiment was measured independently and subtracted from the integrated data 
before curve fitting in Origin 7.0. For the binding of Phe to NmeDAH7PS, 16 µM of 
NmeDAH7PS was used and the syringe contained 1.2 mM Phe. The data were fitted with the 
two-site sequential-binding model supplied by Micro-Cal. 
Binding of Trp to NmeDAH7PS was completed using an ITC200 unit operating at 298 K 
(MicroCal; GE Healthcare) using the same sample preparation as described above however 
samples were not degassed in this case. The titrations comprised of one 0.5 μL injection 
followed by 19 injections of 2 μL. The initial datum point was routinely deleted to allow for 
diffusion of ligand across the needle tip during the equilibration period. For the binding of 
Trp to NmeDAH7PS, 30 µM of NmeDAH7PS was used and the syringe contained 20 mM Trp. 
The data could not be fitted using the models supplied by Micro-Cal. 
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7.3.3 Crystal soaking, co-crystallisation, structure determination and refinement 
Soaking of the aromatic amino acids into crystals of NmeDAH7PS was achieved using the 
established procedures outlined in (section 7.1.32). Tyr was difficult to dissolve at high 
concentrations and therefore required the addition of a small volume of base (sodium 
hydroxide) to the crystallisation condition before soaking. Co-crystallisation of ligands at both 
active and allosteric sites occurred making up the reported crystallisation condition with 
1.5mM Phe and 1 mM PEP. Several hanging drops were prepared using the previously 
established method (NmeDAH7PS ~10 mg/mL) per well and an already formed NmeDAH7PS 
crystal in the absence of these ligand concentrations was used to seed into these drops. A 
seeding dilution series was carried out across all drops until an appropriate crystal had formed 
using procedures outlined in (section 7.1.31). 
The X-ray diffraction data for the liganded structures were collected at the Australian 
Synchrotron on the Macro (MX1) and Micro Crystallography (MX2) beamlines. All four 
liganded structures (Phe, Trp, Tyr, Phe+PEP) crystallised like NmeDAH7PSWT in a monoclinic 
space group P 1211  and diffracted to 2.19 Å, 2.23 Å, 2.31 Å, and 2.05 Å, respectively. The 
results are summarised in Table 3.2.3.1, along with key structure refinement details. 
 
All structures were phased by molecular replacement using Phaser MR116, with the same 
Rfree reflection set. 
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E X P E R I M E N T A L  F O R  C H A P T E R  4  P A R T  I  
The research described in chapter 4 part I was the subject of a publication before submission 
of this thesis. The supplementary material for this publication reporting experimental details 
appended with the permission of the copyright owners and can be accessed at: 
SUPPLEMENTAL DATA 
 
The functional unit of Neisseria meningitidis 3-deoxy-d-arabino-heptulosonate 7-phosphate 
synthase is dimeric 
Logan C Heyes1*, Penelope J Cross1*, Shiwen Zhang, Ali Reza Nazmi1 and Emily J Parker1 
1Biomolecular Interaction Centre and Department of Chemistry, University of Canterbury, 
Christchurch, New Zealand 
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Figure S1. Differential scanning calorimetry showing thermal stability of NmeDAH7PS
WT
 and 
NmeDAH7PS
R126S
.  NmeDAH7PS
WT
 (brown) and NmeDAH7PS
R126S
 (blue). Dashed lines indicate the model that 
the data has been fit to. 
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Figure S2. Sedimentation velocity data collected at 20 ᵒ C and 50,000 rpm.  (A), (B) and (C) are the data from 
NmeDAH7PS
WT
 collected at 0.2, 0.4 and 1.2 mg.mL
-1
 and (D), (E) and (F) are the data from NmeDAH7PS
R126S
 
collected at 0.2, 0.4 and 1.2 mg.mL
-1
. The top panel in each section shows the sedimentation velocity data, 
the size-distribution best fit and residuals for the data fits. 
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Figure S3. Interface analysis alignment of, left, NmeDAH7PS
WT
 and right, NmeDAH7PS
R126S
. Green lines 
indicate hydrophobic interactions at the interface, red lines indicate hydrogen bonds at the interface and 
blue lines indicate salt-bridges at the interface. 
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E X P E R I M E N T A L  F O R  C H A P T E R  4  P A R T  I I  
7.4.1 Site-directed mutagenesis 
The constructs for the variant protein in this chapter were created by site-directed 
mutagenesis using NmeDAH7PSWT construct plasmids as the templates.  
NmeDAH7PS H219A 
For: 5ʹ TGG ACA ATG GCG GAA GCC CCG GCC TTG GTT AC 
Rev: 5ʹ GTA ACC AAG GCC GGG GCT TCC GCC ATT GTC CA 
The PCR products were transformed into Top10 cells.  Plasmids of the expected size, as 
determined by agarose gel, were DNA sequenced to identify those containing the successful 
mutation and transformed into BL21 StarTM (DE3) cells. 
Expression and purification were carried out as previously described for NmeDAH7PSWT. 
 
7.4.2 Kinetics and Inhibition 
Standard assays to determine kinetic parameters were carried out according to methods 
described in 7.1.27. The assays for determining the kinetic parameters kept the 
concentration of one substrate constant while varying that of the other and vice versa. 
Reactions were initiated with 2 µl of 1mg/mL NmeDAH7PSHis219Ala. To determine the KM (PEP) 
the E4P concentration was kept at 300 μM. The concentration of PEP was varied from 2.5-
160 μM. To determine KM (E4P), the PEP concentration was kept at 100 μM and the E4P 
concentration was varied from 5-180 μM. 
Inhibition assays were performed, which consisted of E4P (500 µM), PEP (100 µM), MnSO4 
(100 µM) and the amino acid Phe (50 µM – 1 mM) in 50 mM BTP, pH 6.8.  Assays were 
carried out at 25 °C and were initiated by the addition of NmeDAH7PS. All assays were 
performed in triplicate and averaged. 
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7.4.3 Isothermal titration calorimetry 
ITC was carried out using procedures described in (section 7.1.29). For NmeDAH7PSHis219Ala the 
protein concentration in the cell was 20 µM and the Phe concentration in the syringe was 
1.2 mM. A heat of dilution experiment was measured independently and subtracted from 
the integrated data before curve fitting in Origin 7.0. The data were fitted with the two-site 
sequential-binding model supplied by Micro-Cal. 
 
7.4.4 Analytical size exclusion chromatography 
To determine the quaternary structure of the NmeDAH7PSHis219Ala variant, it was applied to a 
WYATT© size exclusion chromatography column for multi-angle light scattering. Comparison 
was made to NmeDAH7PSWT as a void volume could not be obtained. 500 µl of 0.7 mg/mL was 
applied to the column. 
7.4.5 Crystallisation, structure determination and refinement 
Micro-seeding of NmeDAH7PSHis219Ala occurred using procedures outlined in (section 7.1.31). 
Soaking of the aromatic amino acids into crystals of NmeDAH7PS was achieved using the 
established procedures outlined in (section 7.1.32). The X-ray diffraction data for both the 
liganded and apo structures were collected at the Australian Synchrotron on the Macro 
(MX1) Crystallography beamlines. The liganded and apo structures crystallised like 
NmeDAH7PSWT protein in a monoclinic space group P 1211  and diffracted to 2.00 Å and 2.21 
Å, respectively. The results are summarised in Table 4.3.5.1, along with key structure 
refinement details. 
All structures were phased by molecular replacement using Phaser MR116, with the same 
Rfree reflection set. 
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E X P E R I M E N T A L  F O R  C H A P T E R  5  
7.5.1 Site-directed mutagenesis 
The constructs for the variant proteins in this chapter were created by site-directed 
mutagenesis using NmeDAH7PSWT construct plasmids as the templates.  
NmeDAH7PS E98A 
For: 5ʹ TCG TCC TCG GCT TCG CGA AAT AAA CGC GCA TCA           
Rev: 5ʹ TGA TGC GCG TTT ATT TCG CGA AGC CGA GGA CGA 
NmeDAH7PS K107A 
For: 5ʹ GGT CGT TAA TCA AAC CTG CCC AAC CCA CCG TCG TCC      
Rev: 5ʹ GGA CGA CGG TGG GTT GGG CAG GTT TGA TTA ACG ACC 
NmeDAH7PS Q172A 
For: 5ʹ GCG GAC GAC CGA AAG CGC AGT TCA CCG CCA ATT G                     
Rev: 5ʹ CAA TTC GCG GTG AAC TGC GCT TTC GGT CGT CCG C 
NmeDAH7PS E176A 
For: 5ʹ GCC AAG TTC ACC GCG CGT TGG CAA GCG GGC TG             
Rev: 5ʹ CAG CCC GCT TGC CAA CGC GCG GTG AAC TTG GC 
NmeDAH7PS E176Q 
For: 5ʹ AGC CAA GTT CAC CGC CAG TTG GCA AGC GGG CTG            
Rev: 5ʹ CAG CCC GCT TGC CAA CTG GCG TGT AAC TTG GCT 
NmeDAH7PS F211A 
For: 5ʹ CCT TGG TTA CAG ACA GGG CAT GAT GCG AAT GGC TCG CC   
Rev: 5ʹ GGC GAG CCA TTC GCA TCA TGC CCT GTC TGT AAC CAA GG 
NmeDAH7PS V223A 
For: 5ʹ GGC ATT CCG CCA TTG CCC ATA CCG GCG GCA A              
Rev: 5ʹ TTG CCG CCG GTA TGG GCA ATG GCG GAA TGC C 
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The PCR products were transformed into Top10 cells.  Plasmids of the expected size, as 
determined by agarose gel, were DNA sequenced to identify those containing the successful 
mutation and transformed into BL21 StarTM (DE3) cells. 
Expression and purification were carried out as previously described for NmeDAH7PSWT. 
7.5.2 Kinetics and Inhibition 
Standard assays to determine kinetic parameters were carried out according to methods 
described in 7.1.27. The assays for determining the kinetic parameters kept the 
concentration of one substrate constant while varying that of the other and vice versa. 
Reactions involving NmeDAH7PSPhe211Ala, NmeDAH7PSGlu98Ala and NmeDAH7PSGlu176Ala were 
initiated with 2 µl of 1 mg/mL. Reactions involving NmeDAH7PSGln172Ala, NmeDAH7PSGlu176Gln 
and NmeDAH7PSVal223Ala were initiated with 2 µl of 0.6 mg/mL. 
To determine the KM (PEP) the E4P concentration was kept at 300 μM for all variants except 
NmeDAH7PSGln172Ala, NmeDAH7PSGlu176Gln and NmeDAH7PSPhe211Ala for which the E4P 
concentration was 500 μM. The concentration of PEP was varied from 1-80 μM for 
NmeDAH7PSGlu98Ala, 4-128 μM for NmeDAH7PSGln172Ala and NmeDAH7PSGlu176Gln, 4-64 μM for 
NmeDAH7PSGlu176Ala, 2.5-80 μM for NmeDAH7PSPhe211Ala and 5-120 μM for 
NmeDAH7PSVal223Ala. To determine KM (E4P) for these mutants, the PEP concentration was kept 
at 100 μM and the E4P concentration was varied from 10-240 μM for NmeDAH7PSGlu98Ala, 10-
160 μM for NmeDAH7PSGlu176Ala and NmeDAH7PSVal223Ala, 6.25-250 μM for 
NmeDAH7PSPhe211Ala, 12-384 μM for NmeDAH7PSGlu176Gln, and 10-320 μM for 
NmeDAH7PSGln172Ala. 
 
Inhibition assays were performed, which consisted of E4P (500 µM), PEP (100 µM), MnSO4 
(100 µM) and the amino acid Phe (50 µM – 1 mM) in 50 mM BTP, pH 6.8.  Assays were 
carried out at 25 °C and were initiated by the addition of NmeDAH7PS. All assays were 
performed in triplicate and averaged. 
7.5.3 Isothermal titration calorimetry 
ITC was carried out using procedures described in (section 7.1.29). for NmeDAH7PSGln172Ala, 
NmeDAH7PSGlu176Gln and NmeDAH7PSPhe211Ala the protein concentration in the cell was 16 µM 
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and the Phe concentration in the syringe was 1.2 mM. For NmeDAH7PSGlu176Ala the protein 
concentration in the cell was 22 µM and the Phe concentration in the syringe was 0.2 mM. 
For NmeDAH7PSLys107Ala the protein concentration in the cell was 21 µM and the Phe 
concentration in the syringe was 0.1 mM. For NmeDAH7PSGlu98Ala the protein concentration 
in the cell was 18 µM and the Phe concentration in the syringe was 1.2 mM. For 
NmeDAH7PSVal223Ala the protein concentration in the cell was 20 µM and the Phe 
concentration in the syringe was 20 mM. A heat of dilution experiment was measured 
independently and subtracted from the integrated data before curve fitting in Origin 7.0. The 
data were fitted with a one-site or two-site sequential-binding model supplied by MicroCal. 
7.5.4 Analytical size exclusion chromatography 
To determine the quaternary structure of NmeDAH7PS variants, they were all applied to a 
WYATT© size exclusion chromatography column for multi-angle light scattering. Comparison 
was made to NmeDAH7PSWT as a void volume could not be obtained. 500 µl of 0.6-0.7 mg/mL 
of variant proteins was applied to the column. 
7.5.5 Crystallisation, structure determination and refinement 
Micro-seeding of all NmeDAH7PS variant crystals occurred using procedures outlined in 
(section 7.1.31). Soaking of Phe or PEP into crystals of NmeDAH7PS was achieved using the 
established procedures outlined in (section 7.1.32). The X-ray diffraction data for both the 
liganded, PEP and apo structures were collected at the Australian Synchrotron on the Macro 
(MX1) and micro (MX2) Crystallography beamlines. The Phe-bound NmeDAH7PSGlu176Ala 
structure crystallised like the NmeDAH7PSWT in a monoclinic space group P 1211, While the 
apo structure crystallised in an orthorhombic space group P 212121. The two structures were 
refined to 2.04 Å and 2.40 Å, respectively. The Phe+PEP-bound and PEP-bound 
NmeDAH7PSGlu98Ala structures crystallised like the NmeDAH7PSWT in a monoclinic space 
group P 1211 and were refined to 2.42 Å and 2.50 Å, respectively. The Phe-bound and PEP-
bound NmeDAH7PSGlu176Gln structures crystallised like the NmeDAH7PSWT in a monoclinic 
space group P 1211 and were refined to 2.70 Å and 1.87 Å, respectively. The Phe-bound and 
PEP-bound NmeDAH7PSGln172Ala structures crystallised like the NmeDAH7PSWT in a monoclinic 
space group P 1211 and were refined to 2.30 Å and 2.68 Å, respectively. The Phe+PEP-bound 
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NmeDAH7PSLys107Ala structure crystallised like the NmeDAH7PSWT in a monoclinic space group 
P 1211 and was refined to 1.75 Å. All results are summarised in table 5.3.4.1 and 5.3.4.2. 
The NmeDAH7PSPhe211Ala structure crystallised in an orthorhombic space group P 212121 and 
was refined to 2.35 Å. The Phe-bound NmeDAH7PSVal223Ala structure crystallised in an 
orthorhombic space group P 21221 and only contained the dimer in the unit cell, unlike any 
of the NmeDAH7PS structures collected to date. The PEP-bound NmeDAH7PSVal223Ala 
structure crystallised like the NmeDAH7PSWT in a monoclinic space group P 1211. The 
structures were refined to a resolution of 1.70 Å and 1.84 Å respectively. All results are 
summarised in table 5.3.3.1.  
All structures were phased by molecular replacement using Phaser MR116, with the same 
Rfree reflection set. 
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APPENDIX I 
General appendices 
  
Figure A.1.1 Michaelis-Menten plots of the NmeDAH7PS
WT
 for the KM of PEP and E4P. Plotted and fitted globally 
using Graphpad Prism© version 6  
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                                                           hhhhhhhhhhhhhhhhh  
EcoPhe          ---------------MNYQNDDLRIKEIKELLPPVALLEKFPATENAANTVAHARKAIHK 
NmePhe        1 -------------MTHHYPTDDIKIKEVKELLPPIAHLYELPISKEASGLVHRTRQEISD 47 
EcoTrp          ----------------MNRTDELRTARIESLVTPAELALRYPVTPGVATHVTDSRRRIEK 
SceTyr          MSESPMFAANGMPKVNQGAEEDVRILGYDPLASPALLQVQIPATPTSLETAKRGRREAID 
ScePhe          -----MFIKNDHAGDRK-RLEDWRIKGYDPLTPPDLLQHEFPISAKGEENIIKARDSVCD 
EcoTyr          --------------MQKDALNNVHITDEQVLMTPEQLKAAFPLSLQQEAQIADSRKSISD 
                                     
                hhh     sssss        hhhhhhhhhhhhhhhhhhsssssssslllllllllllll     
EcoPhe          ILKGNDDRLLVVIGPCSIHDPVAAKEYATRLLALREELKDELEIVMRVYFEKPRTTVGWK 
NmePhe       48 LVHGRDKRLLVIIGPCSIHDPKAALEYAERLLKLRKQYENELLIVMRVYFEKPRTTVGWK 107 
EcoTrp          ILNGEDKRLLVIIGPCSIHDLTAAMEYATRLQSLRNQYQSRLEIVMRTYFEKPRTVVGWK 
SceTyr          IITGKDDRVLVIVGPCSIHDLEAAQEYALRLKKLSDELKGDLSIIMRAYLEKPRTTVGWK 
ScePhe          ILNGKDDRLVIVIGPCSLHDPKAAYDYADRLAKISEKLSKDLLIIMRAYLEKPRTTVGWK 
EcoTyr          IIAGRDPRLLVVCGPCSIHDPETALEYARRFKALAAEVSDSLYLVMRVYFEKPRTTVGWK 
*        * 
                             hhhhhhhhhhhhhhhhhh   ssss    hhhhh hhh  sssslll 
EcoPhe          GLINDPHMDNSFQINDGLRIARKLLLDINDSGLPAAGEFLDMITPQYLADLMSWGAIGAR 
NmePhe      108 GLINDPHLDGTFDINFGLRQARSLLLSLNNMGMPASTEFLDMITPQYYADLISWGAIGAR 167 
EcoTrp          GLISDPDLNGSYRVNHGLELARKLLLQVNELGVPTATEFLDMVTGQFIADLISWGAIGAR 
SceTyr          GLINDPDVNNTFNINKGLQSARQLFVNLTNIGLPIGSEMLDTISPQYLADLVSFGAIGAR 
ScePhe          GLINDPDMNNSFQINKGLRISREMFIKLVEK-LPIAGEMLDTISPQFLSDCFSLGAIGAR 
EcoTyr          GLINDPHMDGSFDVEAGLQIARKLLLELVNMGLPLATEALDPNSPQYLGDLFSWSAIGAR 
                                  *                                      
                    hhhhhhhhh    ssss      hhhhhhhhhhhh  sssssss  ssssssssss 
EcoPhe          TTESQVHRELASGLSCPVGFKNGTDGTIKVAIDAINAAGAPHCFLSVTKWGHSAIVNTSG 
NmePhe      168 TTESQVHRELASGLSCPVGFKNGTDGNLKIAIDAIGAASHSHHFLSVTKAGHSAIVHTGG 227 
EcoTrp          TTESQIHREMASALSCPVGFKNGTDGNTRIAVDAIRAARASHMFLSPDKNGQMTIYQTSG 
SceTyr          TTESQLHRELASGLSFPVGFKNGTDGTLNVAVDACQAAAHSHHFMGVTKHGVAAITTTKG 
ScePhe          TTESQLHRELASGLSFPIGFKNGTDGGLQVAIDAMRAAAHEHYFLSVTKPGVTAIVGTEG 
EcoTyr          TTESQTHREMASGLSMPVGFKNGTDGSLATAINAMRAAAQPHRFVGINQAGQVALLQTQG 
                    *   *                                  *       *    * 
                   sssss          hhhhhhhhhhhhhh         ssss         hhhhhh 
EcoPhe          NGDCHIILRGGKE-PNYSAKHVAEVKEGLNKAGLP----AQVMIDFSHANSSKQFKKQMD 
NmePhe      228 NPDCHVILRGGKE-PNYDAEHVSEAAEQLRAAGVT----DKLMIDCSHANSRKDYTRQME 282 
EcoTrp          NPYGHIIMRGGKK-PNYHADDIAAACDTLHEFDLP----EHLVVDFSHGNCQKQHRRQLE 
SceTyr          NEHCFVILRGGKKGTNYDAKSVAEAKAQLPAG------SNGLMIDYSHGNSNKDFRNQPK 
ScePhe          NKDTFLILRGGKNGTNFDKESVQNTKKQLEKAGLTDDSQKRIMIDCSHGNSNKDFKNQPK 
EcoTyr          NPDGHVILRGGKA-PNYSPADVAQCEKEMEQAGLR----PSLMVDCSHGNSNKDYRRQPA 
                 
                hhhhhhhhhhh      ssssss                              hhhhhhh 
EcoPhe          VCADVCQQIAGGEKAIIGVMVESHLVEGNQSL---ESGEPLAYGKSITDACIGWEDTDAL 
NmePhe      283 VAQDIAAQLEQDGGNIMGVMVESHLVEGRQ-------DKPEVYGKSITDACIGWGATEEL 335 
EcoTrp          VCEDICQQIRNGSTAIAGIMAESFLREGTQKI---VGSQPLTYGQSITDPCLGWEDTERL 
SceTyr          VNDVVCEQIANGENAITGVMIESNINEGNQGIPAEG-KAGLKYGVSITDACIGWETTEDV 
ScePhe          VAKCIYDQLTEGENSLCGVMIESNINEGRQDIPKEGGREGLKYGCSVTDACIGWESTEQV 
EcoTyr          VAESVVAQIKDGNRSIIGLMIESNIHEGNQSS--EQPRSEMKYGVSVTDACISWEMTDAL 
                 
                hhhhhhhhhhhhhhhs 
EcoPhe          LRQLANAVKARRG---- 
NmePhe      336 LALLAGANKKRMARAS- 351 
EcoTrp          VEKLASAVDTRF----- 
SceTyr          LRKLAAAVRQRREVNKK 
ScePhe          LELLAEGVRNRRKALKK 
EcoTyr          LREIHQDLNGQLTARVA 
 
Figure A.1.2 ClustalW sequence alignment of the characterised type Iα DAH7PS isozymes from E. coli and S. 
cerevisiae in comparison to N. meningitidis DAH7PS. Annotated by NmeDAH7PS helix (red), sheet (yellow) and 
loop (green). Total conservation across all isozymes (green). Functional conservation across Phe sensitive type 
Iα DAH7PS isozymes (blue). Mutations involved in this thesis indicated with (*).  
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Chapter 3 
  
Figure A.3.1 Left. Raw data of the ITC experiments for the binding of Trp (20mM) to NmeDAH7PS
WT
 (100µM) 
using the ITC200 Microcal™.Right. Raw data of the ITC experiments for the binding of Phe (0.8mM) to 
NmeDAH7PS
WT
 (16µM) using the VP-ITC Microcal™ 
 
  
 - 216 - 
 
Chapter 4 
 
 
Figure A.4.1 Michaelis-Menten plots of the NmeDAH7PS
His219Ala
 for the KM of PEP and E4P. Plotted and fitted 
globally using Graphpad Prism© version 6 
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Figure A.5.1 Normalised average B-factors for all chains of the Phe-bound (blue) and PEP-bound (green) 
DAH7PS (PDB codes: 4UC5 and 4HSN). 
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Figure A.5.2 Michaelis-Menten plots of the NmeDAH7PS
Glu98Ala
, NmeDAH7PS
Gln172Ala
, NmeDAH7PS
Glu176Ala
 and 
NmeDAH7PS
Glu176Gln
 for the KM of PEP and E4P. Plotted and fitted globally using Graphpad Prism© version 6 
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Figure A.5.3 Michaelis-Menten plots of the NmeDAH7PS
Phe211Ala
and  NmeDAH7PS
Val223Ala
 for the KM of PEP and 
E4P. Plotted and fitted globally using Graphpad Prism© version 6 
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Figure A.5.4 Binding isotherms of Phe to NmeDAH7PS
Lys107Ala 
before and after 48 hours of dialysis. 
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ABSTRACT: Allosteric regulation of protein function, the process by which binding of an effector molecule provokes a 
functional response from a distal site, is critical for metabolic pathways. Yet, the way the allosteric signal is communicat-
ed remains elusive, especially in dynamic, entropically-driven regulation mechanisms for which no major conformational 
changes are observed. To identify these dynamic allosteric communication networks, we have developed an approach that 
monitors the pKa variations of ionizable residues over the course of molecular dynamics simulations performed in the 
presence and absence of an allosteric regulator. As the pKa of ionizable residues depends on their environment, it repre-
sents a simple metric to monitor changes in several complex factors induced by binding an allosteric effector. These fac-
tors include coulombic interactions, hydrogen bounding and solvation, as well as backbone motions and sidechain fluc-
tuations. The predictions that can be made with this method concerning the roles of ionizable residues for allosteric 
communication can then be easily tested experimentally by changing the working pH of the protein or performing single 
point mutations. To demonstrate the method’s validity, we have applied this approach to the subtle dynamic regulation 
mechanism observed for Neisseria meningitidis 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase, the first enzyme 
of aromatic biosynthesis. We were able to identify key communication pathways linking the allosteric binding site to the 
active site of the enzyme and to validate these findings experimentally by reestablishing the catalytic activity of allosteri-
cally inhibited enzyme via modulation of the working pH, without compromising the binding affinity of the allosteric 
regulator. 
INTRODUCTION 
Allosteric regulation of protein function is critical to 
cellular metabolic control. Allostery is the process by 
which the binding of a ligand provides a functional re-
sponse at a distant site, and is essential for cell signaling 
events and sophisticated metabolic control through the 
regulation of enzymatic catalysis. Traditional models of 
allostery described the allosteric response as being medi-
ated by large conformational changes that directly affect 
activity.1,2 However, using the formalism of statistical me-
chanics, Cooper and Dryden 3 proposed that allostery 
could exist even in the absence of conformational changes 
via a purely dynamic, entropically driven, mechanism. 
Recent advances in protein NMR, molecular dynamics 
(MD) simulations and isothermal titration calorimetry 
(ITC) have illustrated that subtle changes in dynamic 
fluctuations of proteins can govern the communication of 
allosteric information between distant sites without con-
formational change, and that even intrinsic disorder and 
local unfolding can play an important role in allosteric 
regulation, thereby confirming the role of dynamics in 
allostery (4 and references therein). 
 
This concept of dynamic allostery is receiving increas-
ing recent attention.4-6 However, understanding of how 
the allosteric signal is communicated at an atomic level 
between distant sites remains challenging, due to the sub-
tle, transient and complex changes in dynamics encoun-
tered during entropically driven allosteric regulation. It is 
now well accepted that the allosteric signal is propagated 
via multiple pathways through a network of physically 
and/or thermodynamically interconnected residues.7-9 
Allosteric ligand binding perturbs this communication 
network and results in a functional response by the pro-
tein.  
However, elucidating such communication networks 
remains elusive, as they cannot be readily recognized by 
large changes in residue interactions and may include 
entropic (hydrophobic interactions and changes in pro-
tein flexibility) as well as enthalpic (van der Waals, hy-
drogen bonding and coulombic interactions) effects. 
Hence, the most recent approaches take advantage of MD 
simulations and aim to identify and characterize these 
allosteric networks10 using correlation analysis of residue-
residue contacts,11 dynamical network models,12,13 force 
distribution analysis,14,15 degree of frustration,16 evolution-
ary covariance,17 or correlated motions using mutual in-
formation theory.18,19  These approaches provide compli-
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cated communication networks that often need to be 
coarse-grained for analysis, leading to the loss of atomic-
level details. This results in the omission of electrostatic 
effects during analysis despite their potential influence.10 
Moreover, experimental validation of these reconstructed 
networks is uncommon, due to their complexity.   
Here we propose and test an approach that relies on the 
analysis of pKa variations of ionizable residues during MD 
simulations as a means of capturing the allosteric com-
munication pathway. The pKa of ionizable residues are 
neither fixed nor constant in time, but rather depend on 
their local environment and dynamics.20 Therefore sub-
stantial change in the time-averaged pKa of a given resi-
due upon binding an allosteric ligand suggests that this 
particular residue or its neighbors may play a role in the 
allosteric regulation of the enzyme. This approach has the 
marked advantage of taking into account backbone mo-
tions, side-chain fluctuations, solvent exposure, hydrogen 
bonding and other electrostatic interactions, which are 
otherwise difficult to consider individually. The resulting 
global pKa metric can be easily deconvoluted to account 
for the contribution of individual components, and to pro-
vide a means to probe dynamic allostery. This approach 
leads to experimentally verifiable predictions due to the 
possibility of perturbing a communication pathway by 
either mutating an ionizable residue or changing the 
working pH.  
To demonstrate the benefits of such an approach, we 
have used this method to shed light on the allosteric 
communication pathway of 3-deoxy-D-arabino-
heptulosonate 7-phosphate synthase from the pathogen 
Neisseria meningitidis (NmeDAH7PS). This enzyme cata-
lyzes the first committed step of the shikimate pathway in 
bacteria, responsible for aromatic amino acid biosynthe-
sis, and is allosterically regulated by the pathway end-
product phenylalanine.21 Its mechanism of allosteric re-
sponse is particularly challenging to delineate as the en-
zyme does not experience any major conformational 
change in its regulated state. Instead, regulation appears 
to be mediated by subtle fluctuations in dynamics upon 
binding of the allosteric effector, phenylalanine (Phe). By 
tracking the pKa changes and fluctuations associated with 
this allosteric effector, our study illuminates a dynamic 
network of non-covalent interactions that affects primari-
ly the dynamics of the protein to ultimately regulate its 
catalytic activity.  
 
RESULTS 
Comparison of Phe-bound and Phe-free structures 
implicates a hydrogen-bonding network in the allo-
steric response. DAH7PS is a metalloenzyme that cata-
lyzes the condensation of erythrose 4-phosphate (E4P) 
and phosphoenolpyruvate (PEP) to form DAH7P.21 PEP 
binds deep within the active site, located at the C-
terminal ends of the beta strands of the (β/α)8 barrel, and 
E4P interacts principally with the residues of the β2α2 loop 
(Figure 1). NmeDAH7PS is homotetrameric, consisting of 
two pairs of active, regulated dimers22 that share an ex-
tensive interface. There is a single allosteric site per chain, 
located close to the dimer interface, and the pair of sites 
is separated by a distance of ~25 Å. The allosteric site is 
located ~24 Å from its nearest active site, which is on the 
same chain, and is ~30 Å across the dimer interface from 
the active site of the opposing chain. The allosteric site is 
formed in part by an N-terminal extension from the op-
posing chain, which closes over the allosteric ligand, Phe, 
and also by the β-hairpin (β6a and β6b) insertion into the 
56 loop that contributes to the dimer interface (Figure 
1A).  
 
 
Figure 1. A. Homotetrameric Phe-bound NmeDAH7PS, for 
each dimer, one chain is displayed in white while the adja-
cent chain is colored with the following scheme: main (β/α)8 
barrel in blue, allosteric decorations in purple and catalyti-
cally important β2α2 loop in red. Mn
2+
 is shown as an orange 
spheres and Phe as green sticks in each monomeric unit. B. 
Monomeric unit of Phe-bound NmeDAH7PS with using the 
same color scheme as describe above and with the name of 
the secondary structure elements displayed  C. Stereoview of 
the overlay of the dimer interface of chain A and B of 
NmeDAH7PS for the apo (green) and Phe-bound (blue) 
forms. Hydrogen bonds are colored with respect to the struc-
ture they originate; apo, green and regulated, blue. Maps 
showing electron density for bound Phe are shown in Figure 
S1. 
 
A crystal structure of NmeDAH7PS bound to allosteric 
inhibitor Phe was determined at 2.2 Å (PDB code 4UC5).  
Comparison of this structure with the unliganded struc-
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ture (PDB code 4HSN)21 gives a root-mean-square devia-
tion (RMSD) of 0.96 Å for the alignment of 1302 Cα atoms 
of the tetramer, and 0.583-0.752 Å for the alignment of 
639-641 Cα atoms from all dimer pairings. There is a ~2° 
twist of one dimer relative to the other in the presence of 
Phe accounting for the larger change observed when the 
tetramers are compared. Despite the overall similarity 
between Phe-free and Phe-bound structures, it is evident 
that areas of the protein are significantly displaced in the 
Phe-bound structure. In particular, the N-terminal exten-
sion (residues 1-10) becomes ordered around the bound 
Phe. Additionally, the β2α2 loop (residues 95-120) is repo-
sitioned, with an average Cα RMSD from the apo struc-
ture of 2.3 Å. This change is associated with some differ-
ences in hydrogen-bonding partners for residues of this 
loop. Hydrogen bonds between Lys107 and residues 
Glu176, His209, and the backbone carbonyl of His210 of 
the opposing chain are lost, whereas new hydrogen bonds 
are established between Lys107 and Glu98 and Gln172 of 
the opposing chain. Likewise, hydrogen bonds between 
Glu98 and residues Thr151, Tyr155 and the backbone of 
Asp148 are lost, as is the hydrogen bond that links the 
backbone carbonyl of the catalytic Lys9923 with Gln172 of 
the opposing chain.  
Allosteric regulation triggers local flexibility 
changes and leads to a loss of correlated motions. To 
study the dynamics of NmeDAH7PS in solution, molecu-
lar dynamics (MD) simulations of both the apo and Phe-
bound forms of the tetrameric enzyme were conducted in 
explicit water after modelling of the missing residues 
from both structures. For each system two simulation 
runs of 200 ns were performed starting from slightly dif-
ferent structures (see Methods). As it has recently been 
demonstrated that the dimer is the elementary biological 
unit of the enzyme, capable of both catalysis and regula-
tion,22 analysis of the trajectories has been carried out on 
the dimeric unit, leading to a combined total of 800 ns 
simulated for both the apo and Phe-bound dimers.  
The root-mean-square deviations (RMSD) of the alpha 
carbons along the trajectories indicate that the simula-
tions can be considered as fully equilibrated after about 
80 ns, therefore, the following analyses are conducted on 
the last 120 ns of each trajectory. The dimers in the pres-
ence and absence of Phe sample slightly different, non-
overlapping conformations but do not deviate from their 
respective crystal structure by more than 3.7 Å (Figure 
2A). Overall, the RMSD results indicate that although the 
active and inhibited forms present a slightly different dy-
namic profile, both do not undergo large conformational 
changes or domain motions within the period of analysis 
and the differences between the apo and Phe-bound 
states are subtle.  
The distribution of the distances between the center of 
mass of each monomeric unit composing the functional 
dimer is more narrow in the absence of Phe and has a 
lower average calculated distance, suggesting a slight in-
crease in dynamics for each chain with respect to the oth-
er and a looser association of subunits to form the dimer 
in the presence of Phe (Figure S2).  
Alpha carbon root-mean-square fluctuations (RMSF) 
averaged per chain and per run, reveal only limited differ-
ences in the flexibility of the apo and Phe-bound chains, 
confirming the absence of major conformational changes 
over the course of the simulation (Figure 2B). Unsurpris-
ingly, the flexibility of the N-terminal tail, which covers 
the allosteric site upon binding of Phe, is greater for the 
apo form. This is also the case for the α0α00 loop which 
comes in contact with the tip of the N-terminal tail in the 
presence of Phe. Apart from the N-terminal region, the 
greatest change in observed upon binding of Phe corre-
sponds to key catalytic β2α2 loop, which becomes signifi-
cantly more flexible in the presence of the allosteric lig-
and. In addition, binding of Phe leads to an increase in 
flexibility of the β3α3 loop, β-hairpin insertion and, the 
region between residues 150 and 180 (β4 to α4 region).  
Finally, the external helix α7 appears to experience greater 
fluctuation in the Phe-bound form while the β8α8 loop 
becomes more rigid. 
 
 
Figure 2. A. RMSD of the alpha carbons of the dimer along 
the last 120 ns of simulation of each MD runs in the presence 
(blue dots), absence (green dots) of allosteric Phe, calculated 
using the X-ray crystal structure of the apo (x coordinates) 
and Phe-bound (y coordinates) forms as references. B. Corre-
lations between alpha carbons of the dimer calculated using 
the Pearson coefficient. The upper left triangle corresponds 
to the apo form and the lower right triangle to the Phe-
bound form. Correlation values are represented by a color 
gradient of blue to red. Correlated motions with an absolute 
value below 0.25 are neglected. C. Cα root-mean-square fluc-
tuations (RMSF) of the apo (green) and Phe-bound (blue). 
Secondary structure of the monomeric unit is depicted with 
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orange and purple rectangles to identify β-strands and α-
helices respectively. The difference in RMSF between the 
Phe-bound and apo forms is displayed on the dimer struc-
ture. Regions which are more flexible in the presence of Phe 
are represented with an increased thickness and a blue color 
gradient while regions more flexible in the apo trajectory are 
represented with decreased tube diameter and a green color 
gradient.  
 
Overall, both intra- and inter-chain motions between 
residues are more correlated in the absence of allosteric 
inhibitor, as revealed by the normalized matrix of corre-
lated motions between residues obtained from covariance 
matrix of the alpha carbon atoms of each residue. This 
suggests that the changes associated with the binding of 
Phe perturb the network of non-bonding interactions, 
resulting in a lower degree of communication between 
residues and more random motions, consistent with an 
entropically-driven allosteric mechanism.  
pKa analysis identifies ionizable residues involved 
in the allosteric response. The calculated pKa values for 
the ionizable residues of each frame of the apo and Phe-
bound trajectories were determined using PROPKA3.1.24 
By taking into consideration all the conformations sam-
pled during the MD simulations, this approach provides a 
robust means to assess the average pKa value of a particu-
lar residue, how much it fluctuates around this average, 
and the factors (desolvation effects, hydrogen bonds and 
coulombic interactions) influencing this value. 
 
 
Figure 3. A. The average pKa values for the apo and Phe-
bound forms are represented with green and blue squares 
respectively (also presented in Figure S3), while the error 
bars correspond to ± one standard deviation around the av-
erage (also presented in Figure S4). The lowest (6.8) and 
highest (8.3) experimental pH used are represented with 
dotted purple lines. Ionizable residues that present a major 
pKa shift upon binding of Phe have their residue number 
indicated in red while the other ionizable residues appear 
faded in the background. B. Structure of the dimer (one 
chain is shown in blue, the other in white) with residues ex-
periencing major pKa shift represented in sticks. The alloster-
ic site is highlighted by the presence of Phe shown in green 
sticks, while the catalytic site is identified with the manga-
nese ions shown as orange spheres.  
The differences between the pKa of the ionizable resi-
dues of the apo and Phe-bound forms, averaged over the 
course of the MD simulations, enable a number of resi-
dues likely to be involved in the allosteric communication 
pathway to be identified.  Twelve residues were calculated 
to experience a significant pKa shift upon binding of Phe 
(Figure 3A). These residues are found to be at key posi-
tions or to have a specific role (Figure 3B): Lys216 is in-
volved in the binding of allosteric Phe and Lys99 is re-
sponsible for proton-transfer reaction within the active 
site as part of catalysis. Glu98 and Lys107 are found on the 
β2α2 loop and interact with Asp148, whereas Glu176 inter-
acts with Lys107 across the dimer interface in the apo 
form. As the backbones of residues Asp148, Tyr155 and 
Glu176 are relatively close to the allosteric binding sites, 
they are likely to be affected by the binding of Phe. Tyr26 
and His219 are positioned at the tetrameric interface. The 
predicted pKa shift of Tyr5 is likely to be due to the altera-
tion in the flexibility of the N-terminal tail. 
The standard deviation of the pKa values of each ioniz-
able residue over the course of the MD trajectories gives 
an indication of how much its pKa value is predicted to 
fluctuate in the presence or absence of Phe (Figure 3A). 
These fluctuations may be associated with changes in 
conformational dynamics for the residue itself or for its 
surrounding environment. It is also apparent that a shift 
in the predicted average pKa value upon binding of Phe is 
not necessarily associated with a change in calculated pKa 
fluctuation, with Glu98 being the best example of such 
behavior. This observation implies that although the envi-
ronment of the residue changes in the presence of Phe, 
this residue remains tightly bound and/or buried in both 
inhibited and active forms. The opposite behavior is more 
common; several residues experience a change in the fluc-
tuation of their pKa value upon binding of Phe, but do not 
experience any major pKa shift of their average value. On 
the other hand, Lys107 experiences a drop in pKa fluctua-
tions, as well as in pKa itself, on the binding of Phe. 
Interestingly, of the twelve residues for which a major 
pKa shift is predicted, Tyr5, Glu98, Lys107, Glu176 and 
His219 present (almost) no overlap between their values 
at ± one standard deviation (Figure 3A), supporting the 
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existence of a significant pKa difference between the apo 
and Phe-bound forms. On the other hand, changes in 
average desolvation are also predicted for Glu98, Lys99 
and Lys107 (Figure S5), which experience an increased 
solvent exposure in the presence of allosteric Phe and for 
Tyr155, as well as Asp8 and Arg42, which bind allosteric 
Phe and which become more buried in the presence of 
Phe. 
Inter- and intra-chain communication changes up-
on allosteric inhibitor binding. To identify changes  
in the hydrogen bonds and coulombic interactions be-
tween pairs of residues upon binding of Phe that are likely 
to affect the pKa of ionizable residues, a weighted map of 
interactions in which two nodes represent two interacting 
residues and the diameter of the edge linking two nodes 
accounts for the strength of the interaction was generat-
ed. By specifying the working pH, we can predict which 
residues are protonated and thus account for the favora-
ble, unfavorable or non-existent coulombic interactions 
depending on the charge borne by the residues (Figure 
4A).  
The hydrogen bonding and coulombic interaction maps 
reveal clearly that in the absence of allosteric inhibitor, 
the 
 
Figure 4. A. Hydrogen bonds and coulombic interactions that are only present or are stronger in the apo (top) or the Phe-bound 
(bottom) trajectories. Nodes represent interacting residues and the edges between nodes indicate the interactions, with the di-
ameter of the edge accounting for the strength of the interaction. For the apo form, favorable interactions are shown in green 
and unfavorable ones are in red, and in the Phe-bound form favorable interactions are in blue and unfavorable ones are in red. 
The contribution of each effect (side chain hydrogen-bond, backbone hydrogen-bond and coulombic interactions) is detailed in 
FigureS6. B. Distribution of the distances between key ionizable groups. Frequency distribution of the distances for the apo 
(green) and Phe-bound (blue) forms. The distances are calculated using the hydroxyl oxygen of Ser, Tyr, Thr the center of the 
two carboxyl oxygens of Glu and Asp, the nitrogen of the ε-amino group of Lys, the center of the guanidinium ion of Arg and the 
center of the two nitrogens of the imidazole ring of His.  
 
key predicted interactions are the favorable coulombic 
interactions between Glu176 and Lys107 across the dimer 
interface, and between Lys107 and Asp148; the unfavora-
ble ones are between Asp148 and Glu176 across the dimer 
interface, as well as the hydrogen bond between Asp148 
and protonated Glu98 (Figure 4A). These strong interac-
tions ensure close contact between the two chains of the 
core dimeric unit of the enzyme and provide a short and 
robust inter-chain communication pathway between the 
allosteric site of one chain and the active site of the adja-
cent chain in the absence of Phe. Upon binding of allo-
steric Phe all these strong interactions are lost, essentially 
leading to the disruption of the network of interactions 
between ionizable residues that exists across the two 
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chains (Figure 4A). This observation is confirmed by ex-
amining the calculated distance distributions between the 
ionizable groups of these residues over the course of the 
MD simulations (Figure 4B). The calculated distance of 
2.7 Å between Lys107 and Asp148 in the apo form is shift-
ed to 6 - 19 Å in the presence of Phe, whereas the distance 
between Glu98 and Asp148 changes from 3.7 Å in the apo 
form to around 5 Å. The distance between Glu176 and 
Lys107 across the tight dimer interface is mainly centered 
around 2.7 and 3.5 Å in the absence of ligand, but is not 
closer than 5 Å and is calculated to reach as much as 18 Å 
in the presence of the allosteric ligand. Finally the dis-
tance between the two negatively charged residues Glu176 
and Asp148 in the apo form across the interface remains 
centered around 4.6 Å (Figure 4B), whereas binding of 
Phe and protonation of Glu176 enables this distance to 
reduce to as little as 3.6 Å between the two ionizable 
groups, although the distances are mainly centered 
around 5.2 and 8 Å.  
Within a single chain of the unregulated enzyme, 
Tyr155, which is close to the allosteric site, interacts via a 
hydrogen bond with Thr144 (adjacent to catalytically im-
portant Glu145) and with Thr151, which in turn interacts 
with Glu98. These interactions, which are lost upon bind-
ing of Phe, may contribute to communicate the allosteric 
information within a single chain. In the presence of Phe, 
the distance between Glu98 and Thr151 increases, while 
the distance between Thr151 and Asp148 decreases with 
the pair interacting via a hydrogen bond (Figure 4B). 
Binding of Phe also leads to the formation of strong inter-
actions within and around the allosteric site, which tight-
en the upper part of the dimer.  
A number of important changes also occur within and 
around the active site. In the apo form, repulsive cou-
lombic interactions, exist between catalytically important 
residues Lys188, Lys99, both of which are involved in the 
proton-transfer mechanisms during catalysis, Arg94 
which binds the carboxylate of PEP, as well as Arg236 and 
Arg101 which bind the phosphate of PEP and E4P respec-
tively23. This network of repulsive interactions, which is 
only present in the absence of Phe, between positively 
charged residues is likely to maintain the correct relative 
distances between key residues, thereby maintaining the 
most catalytically active conformation. Additionally, 
Glu145 interacts more favorably with Lys99 and Arg94 in 
the absence of Phe. Binding of Phe reshuffles this interac-
tion network, whereby, Lys107 and Glu98 now interact via 
a hydrogen bond and move closer to one another with a 
distance of 3.4 Å, compared with 5 Å in the absence of 
ligand (Figure 4B). The negative charge on Glu98 has an 
unfavorable effect on Glu145 which interacts less with 
Arg94 and Lys99 with the functional groups of these two 
residues moving away from Glu145.  The slight balance of 
repulsive charge-charge interactions between catalytically 
important Lys99, Lys188 and Arg94 is also broken and the 
distances between the functional groups of these residues 
increase. Significant changes in the angle formed by the 
functional groups of these interacting residues also sup-
port a shift from an active to an inactive topology of the 
key catalytic residues upon binding of Phe (Figure S7). 
Finally a large number of existing interactions centered 
on the metal ion are significantly strengthened in the 
presence of Phe.  
The inhibitory effect of allosteric Phe is reduced at 
elevated pH. The pKa calculations of the regulated and 
apo forms of NmeDAH7PS exposed several residues that 
likely adopt significantly altered pKa values in the pres-
ence and absence of Phe (Figure 5). Of particular interest 
are Glu98 and Glu176, which both present unusually high 
pKa values for Glu and are predicted to have different pro-
tonation states at standard assay pH depending on the 
presence of Phe. At an assay pH of 6.8 Glu98 is predicted 
to be protonated in the apo enzyme and deprotonated in 
the Phe-bound form, whereas Glu176 is predicted to be 
deprotonated in the apo form, but protonated in the 
presence of Phe. As the pKa values of these residues may 
lie close to assay pH, changing their protonation state 
experimentally through variations in pH may mimic in 
part the allosteric response. In the absence of Phe, over 
the pH range 6.8 to 8.3 there is no significant change in 
the protonation state of these two residues and little ef-
fect of pH on activity is predicted or observed (Figure 5A).  
To investigate the pH dependence of the allosteric re-
sponse, assays were conducted between pH 6.8 and 8.3 in 
the presence of 300 M Phe, as enzyme activity decreases 
only slightly over this pH range (Figure 5A). In addition, 
outside this range, the protonation states of the sub-
strates and important catalytic residues may be affected. 
The only change in protonation state predicted from the 
pKa analysis with increasing pH over this range is that 
Glu176 becomes substantially protonated by pH 8.3 in the 
presence of Phe.  
 
 
Figure 5. A. The effect of pH on the activity and inhibition of 
NmeDAH7PS in the presence of 300 µM L-phenylalanine. 
Activity at varying pH compared to maximal activity seen at 
pH 6.8 (green line).  Activity at varying pH in the presence of 
300 µM Phe compared to uninhibited enzyme at pH 6.8 (blue 
line). Substrate concentrations were at least 5-fold higher 
than the Km values (assessed at the different pH values) of 
each substrate at each pH (substrate concentrations were 100 
µM PEP and 500 µM E4P). B. The entropic and enthalpic 
contributions to the binding isotherm of Phe to 
NmeDAH7PS at pH 7 (orange) and pH 7.8 (purple).  
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The specific activity was observed to decrease slightly 
between pH 6.8 and 7.8, with a sharper reduction at pH 
8.3 (to 90% maximal activity, Figure 5A). More important-
ly, in the presence of Phe the inhibitory response was ob-
served to be severely attenuated as the pH was raised (Fig 
5A.), consistent with the dependence of NmeDAH7PS 
allostery on the network of ionizable residues for signal 
transmission. Comparable KD values were measured for 
the binding of Phe at both pH 7 and pH 7.8 (the maxi-
mum pH for enzyme stability over the course of the ex-
periment), indicating that the binding of Phe is not com-
promised in this pH range. Moreover, the entropic and 
enthalpic contributions to the free energies of binding of 
Phe to each site in the sequential two-site binding model 
are very similar at both pH values (Figure 5B). 
 
DISCUSSION 
Evolution has favored the existence of subtle yet fun-
damental, dynamic networks of non-covalent interactions 
within proteins that are intimately related to function. 
These non-covalent interactions consist primarily of hy-
drogen bounds and coulombic interactions but also in-
volve hydrophobic interactions, water-mediated hydrogen 
bonding. As a protein samples its energy landscape, inter-
actions between residues that comprise the network are 
constantly changing. A method of altering the dynamics 
of a protein and therefore its function is to alter the exist-
ing network by favoring transient, non-covalent interac-
tions through the binding of an allosteric effector mole-
cule in order to reshape the conformational space sam-
pled by the protein. This altered state will manifest as the 
product of the interactions broken and formed in the 
network linking the two remote sites. In order for the 
information from a remote site to be conferred to the ac-
tive site, communication through these complex non-
covalent bonding networks is essential.  
Allosteric regulation of NmeDAH7PS relies on changes 
in the intricate network of interactions that connect allo-
steric and catalytic sites of the protein, both within a sin-
gle chain and across the dimer interface. This network 
undergoes a significant reorganization to evoke the allo-
steric regulatory response in the enzyme. For the apo en-
zyme this network enables the communication between 
the allosteric site and the catalytic site through the dimer 
interface in particular via strong coulombic forces among 
Glu98, Lys107, Asp148 and Glu176, but also within a single 
chain via hydrogen bonds involving Thr151, Tyr155, Glu145 
and Glu98. The presence of the allosteric effector mole-
cule Phe, leads to the loss of these two communication 
pathways between allosteric and active sites and an in-
crease of non-correlated motions within the enzyme. The 
catalytic activity of the enzyme appears to be considerably 
lowered mainly because of the increased flexibility of the 
β2α2 loop, providing an entropic penalty to substrate 
binding, and disruption of the optimal, finely tuned, rela-
tive position of key catalytic residues, providing a primari-
ly enthalpic penalty to substrate binding. 
Identification of the changes occurring in the reorgani-
zation of this network is revealed by monitoring the cal-
culated pKa variability between the active and regulated 
forms during the course of an MD simulation. Previous 
similar studies have, however, been made on a limited 
selection of structures generated from MD to depict pro-
tein flexibility25-32. Our studies show that the use of com-
prehensive sampling of conformational space leads to the 
complete recovery of the vast information pKa calcula-
tions can provide and enable the formulation of robust 
conclusions based on the observed variations.  
In principle, constant-pH molecular dynamics 
(CpHMD)33-35 should be the method of choice for studying 
pKa variations as a function of protein motions. However, 
such an approach cannot be applied as an analytical tool 
on existing trajectories and is usually associated with a 
computationally expensive replica-exchange method that 
cannot be applied to large multimeric proteins. Apart 
from CpHMD, the pKa of ionisable residues in a protein 
can be assessed using either methods that relies on the 
Poisson-Boltzmann36 or Generalized Born37 continuum 
models (which are for example implemented in MEAD,38 
MCCE,39 pkD,40 UHBD41 and H++42); or empirical methods 
such as implemented in PROPKA.24 PROPKA has been 
shown to outperform electrostatic based methods27 while 
reducing computational cost and is thus well suited for 
performing pKa analysis of complete, existing MD trajec-
tories. 
It should be emphasized that the key residues that are 
predicted to play an important role in the signal transmis-
sion are not readily identified by comparing the pKa or 
structural changes of the crystal structures. Indeed, not 
surprisingly such an approach is precluded by the inher-
ent static image of the interactions, which leads to a 
number of ‘false positives’ and to the oversight of key in-
teractions. Combining structural analysis, MD simula-
tions and pKa analysis of the MD trajectories therefore 
greatly improves the robustness of the results and enables 
to refine the interpretation of the findings to lead experi-
mentally verifiable results. 
Changes in the pKa of ionizable residues result from dis-
tinct changes in the non-covalent interaction network 
connecting the functional sites of NmeDAH7PS. We have 
shown that alteration of the protonation state of these 
crucial ionizable residues by altering the pH, limits the 
ability of the enzyme to effectively reorganize its interac-
tion network in the presence of Phe.  
The combination of MD and pKa calculations exposes 
the communication network between functionally im-
portant remote sites. The methodology described here to 
illustrate the complexities of ‘dynamic allostery’ can be 
transferred to any enzyme that is likely to rely on subtle 
short time-scale changes in dynamics and network of 
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non-covalent interactions between residues for activation, 
regulation and complex formation.  
 
CONCLUSION 
Allostery is the process by which binding of a ligand at 
one site of a protein leads to a functional response at a 
distant site. Despite its importance in enzymatic regula-
tion, little is known about how the allosteric signal is 
communicated from one site to the other, especially in 
the absence of large conformational changes in the pro-
tein. Here we have shown that monitoring the pKa varia-
tions of ionizable residues over the course of molecular 
dynamics simulations in the presence and absence of allo-
steric regulator can unravel the allosteric communication 
pathways in proteins. We have verified the predictions of 
this approach experimentally, by showing that subtle pH 
variations can mimic the allosteric control, by changing 
the protonation state of key residues without affecting the 
catalytic activity of the enzyme or its ability to bind an 
allosteric effector molecule.  
 
METHODS 
Crystallization of NmeDAH7PS. NmeDAH7PS was 
expressed and purified as previously described.21 The re-
sulting protein solution was concentrated to approxi-
mately 10 mg mL-1. 1 µL of enzyme solution (9–11 mg mL-1) 
was mixed with 1 µL of crystallization buffer containing 
0.1 M Tris HCl (pH 7.3), 0.2 M trimethyl-amino-N-oxide 
(TMAO), 600 µM MnSO4 and 15–20 % (w/v) PEG 
2000MME. Crystals were grown by hanging drop vapor 
diffusion over 500 µL of crystallization buffer and the 
crystallization trays were incubated at 20 ºC. Crystals be-
gan to form in 48 hours and were fully formed within sev-
en days. The grown crystals were added to another drop 
containing 50% SEC buffer containing 200 µM PEP, 100 
mM KCl and 10 mM BTP and 50% crystallization buffer 
also containing either 10 mM Phe and left to soak for 2-6 
hours. Crystals were flash frozen using liquid nitrogen in 
a cryoprotectant solution containing ligand present reser-
voir solution and 20 % (v/v) PEG400. 
Crystallography, Structure determination and re-
finement. An X-ray diffraction dataset was collected at 
the Australian synchrotron using the MX1 beamline.43 The 
datasets were integrated and processed using XDS and 
aimless.44,45 Appropriate cut-off resolution was deter-
mined via CC1/2≥0.5 ensuring the data was complete in the 
highest resolution shell.46 Space group and unit cell pa-
rameters for NmeDAH7PS with the soaked ligands were 
the same as those previously identified (PDB code 
4HSN)21 meaning that initial phases could be obtained via 
molecular replacement using the original structure as a 
search model in Phaser MR.47 All ligands and waters were 
removed from the search model (PDB code 4HSN) before 
molecular replacement was carried out. Refmac5 was used 
to generate the electron density map and this was manu-
ally analyzed and refined in COOT.48,49 The quality of the 
model was optimized by consecutive model building in 
COOT and refinement with Refmac5. Water molecules 
were added manually via interpretation of the │2Fo-
Fc│map ensuring that they had the ability to hydrogen 
bond to at least one acceptor or donor. Residues Met1-
Asp9 were absent from the model (PDB code 4HSN) used 
for refinement, however this region of the protein be-
comes ordered in the presence of Phe and only the first 3 
residues are unresolved. Molprobity was used to assess 
structure quality during refinement cycles and before 
deposition.50  
Isothermal titration calorimetry. Binding of 
NmeDAH7PS to L-phenylalanine at pH 7 and 7.8 was 
measured by ITC using a VP- ITC unit operating at 298 K 
(Microcal, GE Health-care). Before use, the protein was 
buffer exchanged against binding buffer [0.5 mM MnSO4 
in 50 mM BTP buffer (pH 7 and 7.8)] and all solutions 
were degassed in a vacuum. Protein concentration was 
measured by UV absorption immediately before titrations 
were started. The titrations were comprised of 28 injec-
tions, one 2 µL injection followed by 27 10 µL injections of 
L-phenylalanine. The initial datum point was routinely 
deleted to allow for diffusion of ligand across the needle 
tip during the equilibration period. A heat of dilution ex-
periment was measured independently and subtracted 
from the integrated data before curve fitting in Origin 7.0. 
For the binding of NmeDAH7PS to L-phenylalanine, 15 
µM of NmeDAH7PS was used and the syringe contained 
1.2 mM L-phenylalanine; and the data were fitted with the 
two-site sequential-binding model supplied by Micro-Cal. 
pH dependent kinetics. The assay system for 
NmeDAH7PS was a modified form of the assay used by 
Schoner and Herrmann as previously described.51 The 
assays to determine the optimum pH of NmeDAH7PS 
activity contained PEP (100 µM) and MnSO4 (100 µM) in 
50 mM BTP buffer, 10 µM ethylenediaminetetraacetic acid 
(EDTA) and E4P (500 µM) which were the correct pH 
(6.8, 7.3, 7.8 and 8.3) at 298K. Outside of this range, the 
enzyme dramatically lost activity. The buffer was made up 
in ultrapure water that had been treated with Chelex res-
in. After incubation at the required temperature for 5 
minutes, the reaction was initiated by the addition of en-
zyme (2 µL, 1.0 mg/mL). For the pH dependent inhibition 
kinetics, the buffer contained the same components as 
above, except 300 µM L-phenylalanine was added before 
incubation. All assay experiments were performed in trip-
licate. 
Confirmation that substrate binding was not se-
verely affected by pH range. For NmeDAH7PS at pH 
8.3, the reactions to determine Km
E4P used 100 µM PEP and 
32 µM to 375 µM E4P, and for Km
PEP used 500 µM E4P and 
3 µM to 100 µM PEP. For NmeDAH7PS at pH 6.8, the re-
actions to determine Km
E4P used 100 µM PEP and 12.5 µM 
to 250 µM E4P, and for Km
PEP used 500 µM E4P and 7.5 µM 
to 120 µM PEP. The buffers contained MnSO4 (100 µM) in 
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50 mM BTP buffer and 10 µM ethylenediaminetetraacetic 
acid (EDTA). They were initiated by the addition of 
NmeDAH7PS (2 µL, 1.0 mg/mL). 
System preparation for the MD simulations. The 
crystal structures of NmeDAH7PS in the absence (PDB ID: 
4HSN) and presence of allosteric Phe (PDB ID: 4UC5) 
were used as a starting point for the calculations. Missing 
residues and side chains were reconstructed with 
MODELLER.52 The top two tetrameric models generated 
for each structure, selected on the basis of the lowest 
MODELLER objective function value and the lowest glob-
al DOPE score, were chosen as starting point for the 
simulations (two simulations for each apo and Phe-bound 
forms). PROPKA3.124 was used to assess the pKa of ioniza-
ble residues and the value averaged by chain and model. 
The protonation state of these residues for the apo system 
and for the Phe-bound system was then selected based on 
these pKa to simulate a pH of 7.4. Proton position of his-
tidine residues was chosen with MCCE.39  
MD simulations. All MD simulations were carried out 
with NAMD53 using CHARMM all-atom parameter set 22 
with the CMAP correction.54,55 The simulations were run 
on 1048 cores of the IBM BlueGene/P part of the high per-
formance computing service facility at the University of 
Canterbury. The particle mesh Ewald (PME) method was 
used to calculate electrostatic interactions and Van der 
Waals cut-off was set up at 12 Å. Each system was solvated 
in an explicit TIP3P water box of 118 Å x 118 Å x 130 Å and 
the net charge neutralized with Na+ and Cl- ions added 
with a minimum distance of 5 Å from the enzyme and 
from each other.Using the conjugate gradient energy 
minimization method, each solvated protein was mini-
mized for a total of 100000 steps first by allowing only 
water molecules, ions and hydrogens atoms to move 
(20000 steps), then keeping only the backbone atoms 
fixed (30000 steps) and finally releasing all atoms (50000 
steps). Each system was then gradually headed from 0 K 
to 310 K over 124000 steps keeping a harmonic restraint of 
10 kcal/mol on backbone atoms. The Nosé-Hoover Lange-
vin piston pressure control was then used to simulate the 
NPT ensemble at 1 atm, 310 K. Each system was equili-
brated for 100000 steps with the restraint decreased to 5 
kcal/mol, for another 100000 steps with the restraint at 1 
kcal/mol, and finally for 1 ns without any restraints. The 
four equilibrated systems were then each subjected to 200 
ns of NPT molecular dynamics simulation at 1 atm and 310 
K with the trajectory saved every 10 ps.  
Trajectory analysis. The resulting trajectories were 
aligned to remove any undesired rotational and transla-
tional movements of the enzyme. The first 80 ns of each 
simulation were removed to allow for full equilibration of 
the systems. Since it has been shown that the dimeric unit 
is the smallest biological unit capable of both catalysis 
and allosteric regulation 22, so each dimer of the tetramer 
were considered as two different trajectories for the pur-
pose of position and distance analysis and combined to 
effectively lead to 480 ns of fully equilibrated trajectory 
for each system. After alignment of the resulting trajecto-
ries, root mean square deviations (RMSD) and root mean 
square fluctuations (RMSF) were calculated using 
Gromacs 4.5 56. Correlated motions based on Pearson co-
efficient were determined with Carma 57. Distance distri-
butions were calculated in VMD 58 using in-house Tcl 
scripts using the hydroxyl oxygen of Ser, Tyr, Thr, the 
center of the two carboxyl oxygens of Glu and Asp, the 
nitrogen of the ε-amino group of Lys, the center of the 
guanidinium ion of Arg  and the center of the two nitro-
gens of the imidazole ring of His. 
pKa analysis. For each frame of the tetramer trajecto-
ries, the coordinates of the protein without hydrogen at-
oms, in complex with its ligands (manganese ions and, 
should it be present, allosteric Phe) were saved as a PDB 
format. The resulting files were converted from 
CHARMM PDB format to a more standard PDB format. 
For each system, PROPKA3.1 was run on each of the 
24,000 structure files in parallel using asynchronous dy-
namic load balancing and the output files parsed in usa-
ble data. In order to take full advantages of the different 
conformational space sampled by each monomeric unit 
composing the tetramer, the values of interest (pKa, 
desolvation effect) and each type of interactions (cou-
lombic, side-chain hydrogen bonds and backbone hydro-
gen bonds) were analyzed in such way that averages value 
can be obtained (i.e. does not depends on the chain the 
ionizable residue belongs to). Parsing and analysis of the 
data were performed using dedicated python scripts. The 
method and the associated scripts can be easily be trans-
ferred to the analysis of other systems and is available 
upon request. 
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Table S1. Data Collection and refinement 
 NmeDAH7PS 
 L-Phenylalanine 
Data Collection  
Crystal system; space group Monoclinic, P1211 
Unit cell parameters   
a, b, c (Å) 73.61, 143.50, 75.18 
α, β, γ (º) 90, 96.18, 90 
Resolution range (Å) 47.82-2.19 (2.23-2.19) 
Measurements 301997 
Unique reflections 79522 
Redundancy 3.8 
Completeness (%) 99.9 (100.0) 
I/σ (I) 9.3 (1.2) 
Rmerge 0.084 
CC1/2 0.50 
Wilson B value (Å)
2
 39.81 
Matthews coefficient 2.60 
 
Refinement 
 
Rwork 0.1890 
Rfree 0.2357 
Chain length 351 
Observed number of residues 345 (All Chains) 
Water molecules 330 
Other (Mn
2+
, PEG, SO4
-
) 9 
Ligand 4 
Mean B (Å)
2
  
Protein 48.59 
Water 43.82 
Other 67.46 
Phe 37.13 
R.m.s.d from target values  
Bond lengths (Å) 0.0095 
Bond angles  1.2712 
Dihedral angles 0.0690 
Ramachandran  
Preferred (%) 97.69 
Allowed (%) 1.73 
Outliers (%)  0.58 
PDB Entry 4UC5 
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Table S2. Calculated Phe dissociation constant from ITC experiments 
  Site 1 Site 2 Model 
pH 7 3.3 ± 0.8 µM 11 ± 1.3 µM Sequential two site 
pH7.8 2.0 ± 0.7 µM 8.6 ± 1.2 µM Sequential two site 
 
 
 
Table S3. Substrate affinities at pH 6.8 and 8.3 
 
 pH 6.8 pH 8.3 
Km
E4P 
(µM) 36.7 ± 1.8 106 ± 15 
Km
PEP 
(µM) 15.4 ± 0.9 7.0 ± 0.6 
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Figure S1. |Fo-Fc| maps for L-phenylalanine bound at the allosteric site contoured at 3σ. The four chains of 
NmeDAH7PS are indicated. Top left: chain A, op right; chain B, bottom left: chain C and bottom right: chain D. 
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Figure S2. Distribution of the distance between the centre of mass (COM) of each monomer for the apo (green) 
and Phe-bound (blue) MD simulations.  
 
 
Figure S3. Calculated pKa difference of ionizable residues between apo and Phe-bound forms of NmeDAH7PS, 
averaged over the course of the MD simulations. The middle blue line represents the average difference in pKa 
between the apo and Phe-bound form and the top and bottom blue lines correspond to the average ± one 
standard deviation. Residues that present a major pKa shift and therefore might be involved in the allosteric 
communication pathway have been selected on the basis of their distance from the average ± one standard 
deviation. 
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Figure S4. Standard deviation of the pKa of the ionizable residues. Difference between the standard deviation of 
the pKa of the ionizable residues of the apo and Phe-bound forms, over the course of the MD simulations. The 
middle green line represent the average difference and the upper and lower green lines correspond to the average 
± one standard deviation. Residues that might be implied in the allosteric communication pathway have been 
selected on the basis of their distance from the average ± one standard deviation. 
 
 
Figure S5. Average desolvation values of ionizable residues. Difference between the desolvation values of the 
ionizable residues of the apo and Phe-bound forms, averaged over the course of the MD simulations. The 
desolvation is given in unit of pKa. The larger the value, the more buried the residue is. The middle orange line 
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represent the average difference and the two other orange lines correspond to the average ± one standard 
deviation.  
 
 
 
 
 
 
Figure S6. Detailed differential maps of interactions between the apo and Phe-bound forms. Details of the 
coulombic interactions, side chain H-bounds (between the ionizable group of a residue and the hydrogen donor 
or acceptor function present on the side chain of another residue) and backbone H-bonds (between the ionizable 
group of a residue and the backbone of another) that are only present or stronger in the apo (left column) or the 
Phe-bound (right columns) trajectories. Nodes represent interacting residues and the edges between nodes 
indicate the interactions, with the diameter of the edge accounting for the strength of the interaction. For the apo 
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form, favorable interactions are in blue and unfavorable ones are in orange, and for the Phe-bound form, 
favorable interactions are in red and unfavorable ones are in purple.  
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Figure S7. Distribution of the distances between ionizable groups of interest. Frequency distribution of the 
distances for the apo (green) and Phe-bound (blue) forms. The distances are calculated using the hydroxyl 
oxygen of Ser, Tyr, Thr the center of the two carboxyl oxygens of Glu and Asp, the nitrogen of the ε-amino 
group of Lys, the center of the guanidinium ion of Arg and the center of the two nitrogens of the imidazole ring 
of His. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
